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Abstract 
DEVELOPMENT OF A BAYESIAN JOINT LOGISTIC MODEL 
TO BETTER STUDY THE ASSOCIATION  
BETWEEN HAPLOTYPES AND DISEASE 
Publication No._________ 
Anthony M. D’Amelio Jr., B.S.E 
Supervisory Professor: Carol J. Etzel, PhD. 
In 2011, there will be an estimated 1,596,670 new cancer cases and 571,950 cancer-
related deaths in the US.  With the ever-increasing applications of cancer genetics in 
epidemiology, there is great potential to identify genetic risk factors that would help identify 
individuals with increased genetic susceptibility to cancer, which could be used to develop 
interventions or targeted therapies that could hopefully reduce cancer risk and mortality.   
In this dissertation, I propose to develop a new statistical method to evaluate the role of 
haplotypes in cancer susceptibility and development.  This model will be flexible enough to 
handle not only haplotypes of any size, but also a variety of covariates. I will then apply this 
method to three cancer-related data sets (Hodgkin Disease, Glioma, and Lung Cancer).  I 
hypothesize that there is substantial improvement in the estimation of association between 
haplotypes and disease, with the use of a Bayesian mathematical method to infer 
haplotypes that uses prior information from known genetics sources.   
Analysis based on haplotypes using information from publically available genetic sources 
generally show increased odds ratios and smaller p-values in both the Hodgkin, Glioma, and 
Lung data sets.  For instance, the Bayesian Joint Logistic Model (BJLM) inferred haplotype TC 
had a substantially higher estimated effect size (OR=12.16, 95% CI = 2.47-90.1 vs. 9.24, 95% CI 
vii 
 
= 1.81-47.2) and more significant p-value (0.00044 vs. 0.008) for Hodgkin Disease compared to 
a traditional logistic regression approach.  Also, the effect sizes of haplotypes modeled with 
recessive genetic effects were higher (and had more significant p-values) when analyzed with the 
BJLM.  Full genetic models with haplotype information developed with the BJLM resulted in 
significantly higher discriminatory power and a significantly higher Net Reclassification Index 
compared to those developed with haplo.stats for lung cancer. 
Future analysis for this work could be to incorporate the 1000 Genomes project, which 
offers a larger selection of SNPs can be incorporated into the information from known genetic 
sources as well.   Other future analysis include testing non-binary outcomes, like the levels of 
biomarkers that are present in lung cancer (NNK), and extending this analysis to full GWAS 
studies. 
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Chapter 1: Introduction 
The objective of this thesis is to develop valid risk models combining both genetic and 
non-genetic information to better model associations with disease, increase discriminatory 
power, and increase accuracy and clinical utility.  Discriminatory power is the ability of the 
model to correctly differentiate between case and control, and with improved risk modeling, 
discriminatory power will increase.  Clinical utility refers to the effectiveness of the model’s use 
in a clinical setting.  A more powerful model, in terms of discriminatory power, will identify 
more cases correctly labeled as affected compared to a true control incorrectly labeled affected.  
Genetic information in this thesis will consist of linked sets of single nucleotide polymorphisms 
(SNPs), which are specific locations within the genetic sequence of an individual where 
differences can arise from one person to another.  Linked sets of SNPs on the same chromosome 
are also called haplotypes. 
Haplotype analysis, defined as the study of a set of linked alleles occurring on the same 
chromosome has been used to discover sets of linked markers associated with specific diseases.  
With haplotype analysis, more power can be obtained in discovering a link between haplotypes 
and disease compared to the case of just examining the relationship between an individual SNP 
and disease.  After determining haplotypes in the data set, we can then determine the associations 
between haplotypes and disease, with the use of a logistic regression model.  Each haplotype is 
compared to the most frequent haplotype, as the most frequent haplotypes represent what would 
be more often seen in nature.  This is also called joint logistic analysis.   
Haplotypes have the potential to be viable markers for the early prediction of cancer 
development, and if not directly observed, can be inferred from sets of linked single nucleotide 
polymorphisms (SNPs) by either using frequentist mathematical methods or by using Bayesian 
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mathematical methods.  Bayesian mathematical methods for haplotype inference differ from 
frequentist methods because in Bayesian methods, priors (either informative or non-informative) 
can be used to determine the haplotype frequency.  Currently there these exist two prominent 
frequentist methods for risk model development with inferred haplotypes (Joint Logistic 
Analysis, Separate-Effects Model)
62,65
; however, no Bayesian method currently exists that not 
only infers haplotypes, but also can directly elucidate risk models that can be used to develop 
genetic risk profiles for disease. 
I propose to develop a new statistical method using Bayesian theory to evaluate the role 
of haplotypes in cancer susceptibility and development.  This model will be flexible enough to 
handle not only haplotypes of any size, but also a variety of covariates; whether they are binary, 
continuous, or categorical. I will then apply this method to cancer-related data sets to evaluate 
genetic susceptibility.  Haplotype analysis will be improved by directly incorporating previous 
published genetic information from HapMap, which is a large online collection of over 1 million 
SNPs from 11 different populations.  I hypothesize that there is substantial improvement in 
the association between haplotypes and disease, with the use of a Bayesian mathematical 
method to infer haplotypes using priors developed from publicly available genetics sources.  
In order to account for haplotypes in disease association studies and to maximize the full 
potential of haplotypes in such studies, I propose three specific aims: 1) to develop and test a 
novel Bayesian-based method, namely the Bayesian Joint Logistic Model (BJLM) to 
improve power to detect association between SNPs haplotypes constructed from single 
nucleotide polymorphisms (SNPs); 2) to incorporate the BJLM to develop risk models for a 
variety of diseases; 3) and, re-incorporate SNPs into risk models with the haplotypes 
inferred from the BJLM to maximize the effect of genetics. 
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All specific aims were accomplished with a Hodgkin data set from Dr. Randa El-Zein, a 
Glioma data set from Dr. Melissa Bondy, and a Lung Cancer GWAS set from Dr. Christopher 
Amos.  All three of these data sets were developed at M.D. Anderson Cancer Center.  The end 
result was a new Bayesian logistic model that evaluates the relationship between haplotypes and 
disease in the presence of possible covariates. 
 This thesis is innovative, and has five specific innovations for the scientific community.  
First, I expand genetic analysis to include possible associations for disease from haplotypes 
instead of just hits from individual SNPs.  Second, I develop and implement a forward-backward 
algorithm to infer haplotypes in the presence of missing SNP information (all or partial) by 
directly using the haplotypes that have been inferred with complete SNP data.  Third, I develop 
priors for Bayesian Analysis from HapMap data with the use of a Expectation Maximization 
Algorithm.  Fourth, I create the Bayesian Joint Logistic Method to allow for development of risk 
models with haplotypes.  Finally, I incorporate different sets of priors for different types of 
covariates (binary, categorical, continuous) in the development of risk models with haplotypes. 
 Before developing the BJLM, I will review some necessary background concepts such as 
risk modeling, genetic analysis and especially the use of haplotypes in genetic analysis. 
1.1. What is Risk Modeling in the Clinical Construct? 
1.1.1 Well-known Cardiovascular Risk Models 
Risk models have been used to estimate risk in a wide variety of complex diseases, from 
cardiovascular disease to lung cancer.  For instance, the Reynolds risk score
1
, is a cardiovascular 
disease risk model for women developed at Harvard University.  With this risk model, 24,558 
healthy women (with no immediate signs of cardiovascular disease) were followed for a median 
of 10.2 years for specific cardiovascular diseases such as coronary revascularization, myocardial 
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infarction, ischemic stroke, and cardiovascular death
1
.  Development of the Reynolds risk score 
involved use of two-thirds of the study population (n = 16,400) with validation occurring in the 
other third of the study population (n = 8158)
1
.  The Reynolds risk score contains the risk 
variables of age, systolic blood pressure, high sensitivity C-reactive protein, total cholesterol, 
high-density lipoprotein cholesterol, current smoking status, and family history of heart disease 
for those under the age of 60
1
.  The calculation of 10 year cardiovascular risk, according to this 
model, is
1
: 
                                       
where B is a factor that aggregates the effects of the risk variables listed above
1
.  In the next few 
paragraphs, I will discuss some prominent examples of risk modeling. 
The most well-known example of risk modeling for clinical purposes are the 
cardiovascular disease risk models developed from the Framingham Health Study
2
.  Initial 
enrollment for this study began in the time period between 1948 and 1950 with inclusion of 
5,127 men and women aged 30-62 with no coronary artery disease.  A second and third 
generation cohort was introduced in 1971 and 2002
2
.  The first risk model produced from the 
Framingham cohort data was published in 1998, and it calculated the 10-year probability of 
coronary heart disease
4
.  With the coronary heart disease model, both a simple model based on a 
point system for risks, and a much more complicated model based on relative risks, were 
developed to predict 10-year risk
3
.  Other risk models using the Framingham Heart Study data 
studied cardiovascular diseases like atria fibrillation
4
, congestive heart failure
5
, general 
cardiovascular disease
6
, hard coronary heart disease
7
, and stroke
8
.    
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1.1.2.  Risk Modeling in Cancer: An Overview    
Risk modeling has become an ever increasing tool in cancer epidemiology and cancer 
prevention.  The Gail model
 
for breast cancer was first introduced in 1989, and contains variables 
such as age (as defined as those before or older than 50 years old), age at menarche, previous 
breast biopsies, age for 1
st
 born child, and family history of breast cancer
9
.  The risk for breast 
cancer are calculated below in equation 1.2
9
, 
                       
                                           
                                                       
                                                       
where Agemen = Menarche age, Nbiops = Previous breast biopsies, Ageflb = age for 1
st
 born 
child, Numrel = family history of breast cancer, and Agecat = aged greater than 50.   
This model was validated in Caucasian females, and the Gail model performed well within 
specific risk factor strata and for individuals over the age of 60
10
.  With the Gail model, high-risk 
individuals for breast cancer were recommended for more extensive screening
11,12
.  Gail then 
created a new breast cancer model for African-Americans named CARE, based from the 
Women’s Contraceptive and Reproductive Experiences study, because of differences in risk 
profiles between Caucasian and African-American women
13
.  Then, in 2005, a variable that 
elucidates mammographic breast density was added to the Gail model by Jeffrey A. Tice’s 
group, and its discriminatory power increased modestly from 67% (95% CI = 0.65-0.68) to 68% 
(95% CI = 0.66-0.70) using data from the San Francisco Mammography Registry
14
.  With the 
success of the Gail model in estimating risk for breast cancer, risk models were created for other 
cancers, such as colorectal
15,16
, bladder
17
, ovarian
18
, and melanoma
19,20
. 
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1.1.3. Risk Modeling in Cancer:  Evolution of Lung Cancer Modeling 
 Lung cancer risk modeling has become a viable tool to study potential risk for lung 
cancer, and several models have been developed.  The first models for lung cancer were 
developed in 2000 by Dr. Graham Colditz at Harvard and it was based on different scores for an 
individual’s environment, smoking intensity, family history of smoking, occupational history, 
and diet
21
.  His research group included experts in the risk factors listed above, and they 
estimated risk for lung cancer based on consensus from experts in lung cancer oncology.  The 
point guide for all non-occupational risk factors is listed in Table 2 of Colditz et al.
21
. 
For each individual, the risk points for each applicable risk factor are added, added with 
risk points from occupational exposures, and then divided by the total US population risk point 
average to obtain a cancer risk score.  This result is then given a Surveillance, Epidemiology, and 
End Results (SEER)
22
 multiplier which represents the increase or decrease in potential risk 
compared to the “average” individual risk profile, and then that multiplier is multiplied by the 
average 10-year absolute risk for lung cancer in the United States at a specified age (as 
determined by SEER) to determine an individual’s 10-year lung cancer risk21.  For example, if a 
60-year old male individual has 50 risk points, and the US population risk point average is 20, 
they have a cancer risk score of 2.5.  This cancer risk score of 2.5 corresponds to a SEER 
multiplier of three
21
, and a 60-year old male has a 0.547% chance of obtaining lung cancer in the 
next ten years according to SEER
21
.  Therefore, this 60-year old male has a 1.641% chance of 
lung cancer in the next ten years according to the Colditz risk model. 
 The second lung cancer risk model was published by Peter Bach in 2003.  Unlike the 
previous lung cancer model developed by the Colditz group which was developed as a 
consensus, this model was developed based on the placebo arm of the Carotene and Retinol 
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Efficacy Trial cohort (CARET)
23
, which was a large randomized cohort in which 18172 
individuals who were heavy smokers and aged 50-75, were tested for effect of beta-carotene on 
lung cancer.  The CARET trial was stopped in July 1996 after an interim report showed that 
beta-carotene increased lung cancer risk in heavy smokers
24,25
.  The Bach model, created 1-year 
proportional hazard models for both incidence of lung cancer allowing for mortality from all 
causes other than lung cancer
25
.  These models allowed for competing causes, so absolute lung 
cancer risks were reduced according to the probability of non-lung cancer mortality.  Key 
variables in the Bach models included cigarettes per day, smoking duration, quitting time (in 
years), age, asbestos exposure, and sex
25
.  One advantage of the Bach model is the easy 
calculation of a multiple of absolute lung cancer risks as the one year models only have to be 
added for determination of multi-year lung cancer risk prediction.  Validation of the Bach model 
from Kronin et al. showed that the Bach model has moderate discriminatory power, varying from 
0.57 (95% CI = 0.49-0.67) for those aged 65-69 to 0.77 (95% CI = 0.70-0.84) for those aged 50-
54
26
.    
 The third lung cancer risk model developed to examine absolute risk of lung cancer 
incidence is the Spitz model, which was constructed from a matched case-control study of 1851 
cases and 2001 controls enrolled at MD Anderson Cancer Center from 1995-2006.  Cases and 
controls were matched on age (±5 years), sex, smoking status and race
27
.  The matching on 
smoking status restricted the model to be stratified for never, former, and current smokers.  
Below are the never, former, and current smoker, relative risk equations (equations 1.3 to 1.5), 
respectively, for Caucasian individuals, which were created for the Spitz lung cancer model
27
,                        
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Never Smokers: 
                                                            
Former Smokers: 
                    
                                                  
                                    
Current Smokers: 
                   
                                                   
                                                       
where Ets = environmental tobacco smoke, fh = two or more family members with cancer, Emph 
= self-reported emphysema, Dust = exposure to dust variables, quit1 = quit smoking between 
ages 42-53, quit2 = quit smoking at age 54 or older, sfh = one or more family members with a 
smoking related cancer, pk1 = pack-years between 28 and 42, pk2 = pack-years between 42 and 
57.5, pk3 = pack-years greater than 57.5, and asb = exposure to asbestos
27
.  
  After obtaining the relative risks, the absolute-risk of lung cancer are determined by using 
data from the Surveillance, Epidemiology, and End Results (SEER) on lung cancer incidence, 
and data from the National Center for Health Statistics (NCHS) for non-lung cancer mortality, 
combined with the relative risks results
22,28
.  The concordance statistic (measure of 
discriminatory power) for the Spitz model varies from 0.59 (95% CI = 0.51-0.67) in never 
smokers to 0.65 (95% CI = 0.60-0.69) for current smokers.  Later analysis led to the creation of 
lung cancer models for African-Americans and genetic extensions of the original Spitz 
model
29,30
.   
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 The Liverpool Lung Project (LLP) group in Liverpool, England developed the LLP 
model from a population-based case-control data set, with individuals aged 20-80, and matched 
by one case to two controls with both controls having the same gender and within 2 years of age 
with the case
31
.  Unlike the Spitz model, no matching exists for smoking, hence smoking 
intensity is the most dominant risk factor in the model, with four different risk classifications
31
.  
This model differentiates between early family history of lung cancer (family members obtaining 
lung cancer before age 60), and later family history of lung cancer (family members obtaining 
lung cancer after age 60)
31
.  Other risk factors include self-reported exposure to pneumonia, 
asbestos exposure, and previously having malignant tumors.  Age and sex are incorporated with 
the use of five-year Liverpool incidence rates for cancer.   These incidence rates allow for 
automatic calculation of a five-year absolute risk model for lung cancer, unlike the Bach and 
Spitz models, which can predict up to ten-year absolute risk calculations.  With the case-control 
data set for which the LLP model was derived, discriminatory power results were moderately 
good (AUC = 0.71), and these results were similar to those found in a 10-fold cross validation 
analysis (AUC = 0.70)
31
. 
 The most recent lung cancer model is the Prostate, Lung, Colorectal, and Ovarian 
(PLCO) model, which was developed from 70,962 subjects from the non-screening arm section 
of the PLCO trial, and was validated in the screening arm section of the PLCO trial (n = 
38,254)
32
.  The PLCO model consisted of the variables age, socioeconomic status, recent chest x-
ray, COPD, smoking status, smoking duration, pack-years smoked, body mass index, and family 
history of lung cancer.  Unlike previous lung cancer models, some of the variables, like pack-
years smoked and age, are modeled with restricted cubic splines (RCS).  RCS allows for 
variables to be separated into k breakpoints, with the variable being linear below and above the 
10 
 
maximum and minimum breakpoints, and also have k-2 cubic variables which are determined for 
all values above the breakpoints in between the maximum and minimum breakpoints
33,34
.  
Discriminatory power results were excellent in both the non-screening arm (AUC = 0.859, 95% 
CI = 0.848-0.871) and the screening arm (AUC = 0.841, 95% CI = 0.813-0.870)
32
.  Future 
analysis of this model will need to be conducted to see whether these results are validated in 
external datasets. 
These risk models need to be examined for their usefulness in a clinical setting.  
Typically, this is accomplished by determining discriminatory power, accuracy, calibration, and 
clinical utility.  First, the discriminatory power of a risk model is its ability to differentiate 
between a clinical case and a control.  Discriminatory power can be calculated by estimating the 
area under a curve (AUC) from a receiver operator curve (ROC) which is determined by 
comparing the sensitivity and 1-specificity at each calculated risk value
35
.  A good risk model 
will have discriminatory power values substantially higher than chance (50%).  Second, accuracy 
is determining by measuring the positive predictive value (PPV) and the negative predictive 
value (NPV) which are calculated in equations 1.6 and 1.7
36
,  
 
     
                                
                                                                
       
     
                                   
                                                               
       
 
Third, calibration examines whether the observed absolute risk for a disease calculated by the 
risk model is similar to the ratio between cases and total individuals for a defined set of risk 
groups.  Most calibrations are done with 10 fold cross-validations, or separating the cohort data 
into 10 groups based on observed absolute risk
37-39
.  Finally, clinical utility is the measurement 
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of the percentage of individuals correctly calculated as a case (based on a selected absolute risk 
cut-off value) compared to the percentage of individuals incorrectly selected by the model to be a 
case (even though the “case” is truly a control) at specific risk intervals. 
                
                                               
                                                   
       
1.2.  Genetic Analysis: Introduction to Haplotypes 
1.2.1.   Microsatellites to Single Nucleotide Polymorphisms (SNPs):  The Beginning 
of Statistical Genetic Analysis 
Differences in the genome among individuals have been explored extensively.  One of 
the first methods to explore these differences in the genome is the use of microsatellites.  
Microsatellites are also known as short tandem repeats, and typically involve many repeats of a 
small set of genetic information (1 to 6 base pairs)
40
.  They have mutation values higher than that 
of other sections of the genome; hence they have been used as markers for basic population 
analysis, and have been very popular in the studies of non-human animals
41
.  Below is a simple 
hyothetical example of a microsatellite on the two strands of DNA (Figure 1.1). 
 
Figure 1.1: Example of a microsatellite with four ACG repeats on DNA 
 
Figure 1.1:  A hypothetical section of 12 base pairs of DNA are examined.  The ovals show that 
these 12 base pairs consist of 4 ACG repeats on the forward strand of DNA.  The backward or 
second strand, of DNA, shows 4 repeats of TGC, which occurs when the forward strand of DNA 
has ACG repeats.   
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However, microsatellites can have varying amounts of amplification, so that many 
microsatellites appear to be homozygous, but instead are really heterozygous; which can lead to 
incorrect evaluations about disease associations.  
After the discovery of microsatellites, geneticists began to study specific base pairs on the 
genome to see whether a group of individual base pairs affect disease risk.  Locations on the 
genome where they are single nucleotide differences in alleles, which are variant forms of the 
same gene at a specific base-pair, between one person and another are called SNPs
42
.  SNP 
studies have become very popular because of their specificity and the sheer numbers of SNPs 
throughout the genome; currently, roughly 11 million SNPs have been identified
43
.  Below is an 
hypothetical example of SNPs on a set of chromosomes (Figure 1.2). 
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Figure 1.2: Single Nucleotide Polymorphisms from 12 areas on the chromosome 
 
Figure 1.2: Ten chromosomes have been listed in the above figure, and twelve areas on each 
chromosome are being examined.  Nine of these twelve areas have the same allele for all ten 
chromosomes, while three of these areas have at least two different alleles in the set of 10 
chromosomes.  These areas are marked by the red ovals, and since these areas have at least two 
different alleles, they are listed as SNPs. 
 
The two largest databases of SNPs currently available are from HapMap
44
 and the 1000 
genomes project
43
.  HapMap has SNP data from 11 populations from various locations around 
the world (Table 1.1) that can be used to develop a haplotype map (hence HapMap) of the human 
genome which could be used to potentially detect patterns of genetic variation.   
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Table 1.1:  Populations and List of populations available for analysis in HapMap:  
 
The 1
st
 column is the population identifier for each population from the HapMap Genome 
Browser release #29, the second column has the location of each population, and the final 
column contains the number of individuals available for analysis. 
 
Population Identifier Location of Population Number of Individuals 
Available for Analysis 
ASW African ancestry in Southwest United 
States 
83 
CEU European Ancestry from Utah Residents 174 
CHB Han Chinese from Beijing China 86 
CHD Chinese in Denver, Colorado 85 
GIH Gujarati Indians in Houston, Texas  88 
JPT Japanese in Tokyo, Japan 89 
LWK Luhya in Kenya 90 
MEX Mexican Ancestry from Los Angeles 77 
MKK Maasai in Kenya 171 
TSI Tuscan in Italy 88 
YRI Yourban individuals from Nigeria 176 
 
Also, the development of HapMap has been used to attempt to find tagSNPs, which are 
estimated at around 300,000-600,000 SNPs out of the roughly 11,000,000 SNP currently 
detected
44
.  With the 1000 Genome Project
43
, the goal is to attempt to find more common 
variants that have minor allele frequency of 1% by the process of gene sequencing.  Next 
generation sequencing is being conducted in which short segments are randomly amplified and 
sequenced, then realigned to a consensus of the underlying genomic sequence.  The depth of 
converge relates to the average number of sequences per individual per location. In the current 
available results from 1000 genomes project, sequencing has been conducted at four fold 
coverage depths.  Then, for 1000 specific regions of the genome, sequencing is conducted at a 
much higher rate (50x).  Since sequencing can be a very expensive process, not as many 
individuals are sequenced in the 1000 genomes project compared to HapMap per population 
listed in Table 1.1, but there are more SNPs available.  For instance, 174 individuals from the 
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CEU population are available for analysis in HapMap, but only 92 individuals are available from 
the 1000 genomes project from the same CEU population. 
It was theorized that with SNPs, scientists and genetics could find regions of the genome 
with substantial differences from one person to another, especially with disease research.  This 
hypothesis, known as the Common Disease, Common Variant (CDCV) hypothesis became the 
basis for genome wide association studies (GWAS), which have been successful at finding links 
between SNPs and disease.  For instance, three lung cancer studies showed some moderate links 
between SNPs on chromosome five or 15 and lung cancer
45-47
.  However, it was soon discovered 
that increases in discriminatory power were modest for most diseases
30
.  Also, these SNPs only 
had odds ratios between 1.2 and 1.4, so thousands of individuals were needed to power the 
analysis that found the modest increases in discriminatory power.  The search for greater power 
in population and disease studies will be a major theme of this thesis. 
1.2.2.  Introduction to Linkage Disequilibrium and Haplotypes  
 Throughout the genome, there are roughly 2.9 billion base pairs
48
 and 11 million SNPs
43
, 
and for substantial sections of the genome, these SNPs and base pairs are not completely 
independent.  For instance, the allele structure at SNP rs1801131 could be dependent on the 
allele structure of SNP rs1801133.  These SNPs are located within 2 kb of each other on the 
MTHFR gene, and can be a factor in modulating non-Hodgkin lymphoma risk
49,50
.   The 
dependency between rs1801131 and rs1801133 is referred to as linkage disequilibrium (LD), 
which is defined as having an association between different alleles
51
.  Statistically, LD is 
calculated with both the D’ and the r-squared statistic, and they are dependent on the allele 
frequency of both the individual SNPs and the possible combination of alleles.  Below are these 
equations
51
: 
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where                            are the frequency of the two alleles at each base pair 
respectively, and                                     are the probability of having this 
combination of alleles.  In cases of low LD, D’ and r2 are close to zero, but when LD is high, D’ 
and r
2
 are close to one.   
Areas of the genome with high levels of LD are commonly referred to as haplotype 
blocks, and can vary from two to many SNPs within a relatively short distance in the genome (< 
100 kb).  An illustrative example is shown on Figure 1.3. 
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Figure 1.3: Actual Haplotypes from five SNPs associated with lung cancer in the study at 
MD Anderson Cancer Center
45
 
 
rs8034191       rs3885951        rs2036534  rs6495306    rs680244  
Haplotype 1  A A A A G 
Haplotype 2 A A A A A 
Haplotype 3 G A A A G 
Haplotype 4  G G A A G 
 
Figure 1.3:  Four inferred haplotypes from the lung cancer GWAS conducted at MD Anderson 
are shown for five SNPs in strong LD with each SNP.  This set of haplotypes that begin with 
SNP rs8034191 (Chromosome 15 at base pair location 76593078) and end at SNP rs680244 
(Chromosome 15 at base pair location 76681394). 
 
Larger size haplotype blocks typically do not occur in nature due to the high level of allele 
recombination throughout the genome.   According to Greenwood et. Al
52
, by using haplotype 
block data collected by Gabriel’s group in 200253, and genome recombination rates54, there was a 
strong negative correlation between recombination rate and haplotype block size.  With sex-
averaged recombination rates of greater than 4 cM/Mb, the average haplotype block size 
decreased to nearly zero, while much small recombination rates lead to much larger haplotype 
block sizes.  Mathematically the relationship between distance and recombination rates can be 
expressed as: 
   
   
 
       
 
where   is the recombination rate, N is the Effective Diploid Population Size, c is the probability 
of recombination per generation between two consecutive markers or SNP, and d is the distance 
between two consecutive markers
55.  Gabriel’s group also had a strict definition for alleles to 
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form haplotypes, and the 95% CI of D’ must contain the value one.  This definition is built into 
the program Haploview
56
, and all haplotypes discussed in this thesis will use this definition. 
1.2.3.  Introduction for Haplotype Analysis  
As a predictive marker for disease, haplotypes can have higher power to detect genetic 
associations for disease over a single SNP 
57-59
.  The increase is power exists because haplotypes 
incorporate the linkage disequilibrium aspect of a genome section being studied.  Because of this 
proposed increased power, haplotypes have been increasingly used as a disease risk predictor.  
Studies based on haplotypes are known as haplotype analysis, which is defined as the study of a 
set of linked alleles occurring on the same chromosome
60
.  With haplotype analysis, a geneticist 
can examine if the same SNPs that could have some association with disease also contain 
haplotypes that associate with the outcome of interest.   
Some programs that infer haplotypes are PHASE
55,61
, Haploview
56
, and Haplo.stats
62,63
.  
These programs use different methods to infer haplotypes, from a Bayesian method (PHASE), to 
haplotypes linked directly by strong regions of linkage disequilibrium (Haploview), and finally 
using an Expectation Maximization method (haplo.stats).  With PHASE, haplotype frequencies 
for each individual are evaluated with the use of a Markov Chain Monte Carlo (MCMC) 
algorithm which incorporates the distance between each locus (in base pairs) along a 
chromosome.  According to Stephens and Scheet
55
, haplotypes tend to group together in clusters 
along a chromosome, so to obtain accurate estimates of haplotypes at a particular region, linkage 
disequilibrium must be taken into account, and that can be accomplished by stating the base pair 
location of each genetic location at which haplotypes could occur in nature.  With Haploview, an 
open source code program written completely in JAVA, a multitude of haplotype analyses, from 
examination of Linkage Disequilibrium (LD) within a set of genetic markers located on a 
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specific chromosome, to single-marker and multi-marker association tests can be conducted.  
Haploview uses either familial data sets (data sets containing members of the same family), or 
case-control sets like that of the Puerto Rican data set.  An example of Haploview output is 
shown on Figure 1.4. 
 
Figure 1.4: Using Haploview to determine a haplotype from Chromosome 1 on the genome 
 
Figure 1.4:  This sample haplotype is derived from a 20 kb set of SNPs in the HapMap database 
that begin at rs6667720 on chromosome 1 at base-pair location 11,754,202 and end at 
rs13306556 on chromosome 1 at base-pair location 11,774,697.  Sixteen of the 17 SNPs listed in 
this block are linked together as one single haplotype. 
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Haplo.stats is a program developed in the programming language R which uses a 
generalized linear model to first determine the frequency of haplotypes for each individual, and 
then determine which haplotypes show significant differences between cases and controls with 
the use of a haplotype-specific score
62
.  Haplo.stats also allows for the estimation of odds ratios 
to represent the association between either a haplotype or a covariate and disease with the use of 
a joint-effect linear model developed by the Lake group in which each haplotype is compared to 
the most frequent haplotype
62,63
.  With the assumption that the most frequent haplotype 
represents the “normal” haplotype status, one can examine whether variant haplotypes are 
associated with disease.  Another popular linear model incorporated into the Haplo.stats is the 
separate-effects linear model, in which each haplotype is compared to a combination of all other 
possible haplotype (all other haplotypes are pooled together to form the reference group)
64-66
.   
1.3.   Overview of Dissertation Thesis 
In this thesis, the ideas from risk modeling, haplotype analysis, and Bayesian inference, 
will be examined in the construction of a new Bayesian mathematical model, the Bayesian Joint 
Logistic Model (BJLM) that will be used to elucidate disease risk in three separate data sets.  In 
Chapter 2, I will conduct a calibration of the Spitz lung cancer risk model using data from the 
Nederlands-Leuvens Longkanker Screenings ONderzoek cohort (NELSON) or also known as the 
Dutch-Belgium randomized lung cancer screening trial.  This analysis expands on the original 
validation of the Spitz lung cancer risk model, which was conducted using patients and controls 
from a Harvard case-control study (PI: David Christiani)
 67
.  In Chapter 3, I will explore the 
value of including haplotypes to estimate genetic susceptibility to lung cancer and extend the 
Spitz model using an individual SNP approach.   Chapter 4 contains the development of the 
BJLM including a simulation experiment to test its effectiveness with inferring haplotypes.   
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Chapter 5 contains an application of the BJLM to a Hodgkin data set to develop a novel risk 
model for Hodgkin disease consisting of haplotypes inferred with the BJLM.  In Chapter 6, I use 
the BJLM to construct a haplotype-based extension of the Spitz model and show that this model 
has higher discriminatory power compared to previous model extensions (including the single 
SNP approach).  Finally, in Chapter 7, I also highlight a modification of the BJLM in which I re-
introduce SNPs as well as the inferred haplotypes from the BJLM to construct a genetics-only 
risk model for Glioma. I then conclude this thesis in Chapter 8 whereby I summarize the results 
observed within this thesis and pose possible research plans for the future. 
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Chapter 2: Validation and Calibration of the Spitz Lung Cancer Risk Model 
2.1.  Introduction to the NELSON data set 
2.1.1.  Relationship between NELSON and NLST  
Risk modeling has been shown to be important tool in early detection and prevention of 
disease.  In the past few years, there have been substantial developments in risk model 
development for cancer; especially for breast cancer with the Gail model
9
.  As stated in Chapter 
1, validation of this model has been conducted in Caucasian females, and the Gail model 
performed well within specific risk factor strata and with individuals over the age of 60
10
.    With 
the Gail model, high-risk individuals for breast cancer have been placed into screening trials for 
future analysis
11,12
.  Screening trials have been recently shown to decrease mortality in cancer, 
especially lung cancer.  In late 2010, the National Lung Screening Trial (NLST), which was 
established in 2002 to determine whether screening participants at high risk for lung cancer with 
spiral CT or X-ray would reduce lung cancer mortality rates, has recently observed a 20% 
increase in 5-year survival rates within the CT group compared to the standard x-ray group
68
. 
Colorectal risk models have been used as important indicators to develop more effective cost-
benefit screening trials for this disease
69-72
.      
Creating valid and reliable risk models for lung cancer becomes especially important 
when one considers that over 80% of lung cancer cases are directly related to smoking, but only 
an estimated 11% of female smokers and 17% of male smokers will be diagnosed with lung 
cancer in their lifetimes
73,74
.  To address this challenge in estimating lung cancer risk, absolute 
risk models have been developed to identify high-risk individuals for lung cancer, and refine 
selection of individuals for screening trials
67,75,76
.   
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2.1.2. Testing the Spitz Model with NELSON Data 
One risk model is the Spitz lung cancer risk prediction model
27,67
.  The Spitz model was 
developed from an ongoing case-control study at M.D. Anderson Cancer Center with data 
available from 1995 to 2006.  All cases had histological confirmed lung cancer
27
.  Controls were 
frequency matched by age (±5 years), gender, race, and smoking status and were recruited from 
the largest multispecialty physician practice in Houston.  To attempt to be as comprehensive as 
possible in lung cancer risk prediction, potential lung cancer risk factors including exposures, 
and co-morbidities such as hay fever and emphysema were included in the models.  Standard, 
well established risk factors in the Spitz model included family history of smoking, passive 
smoking, age at quitting smoking for former smokers, pack-years for current smoking, asbestos 
and dusts exposures.  Since the case-control study design included matching on smoking status, 
separate models were developed for never, former, and current smokers.  The Spitz model has 
comparable discriminatory power and clinical utility with other lung cancer risk models (Bach 
and Liverpool Lung Project (LLP)
77
 lung cancer models)
67
.  In particular, the Spitz model had 
excellent clinical utility, which is the ratio of correctly identified cases compared to incorrectly 
identified cases that are truly controls, at defined absolute risk values
67
.  Although the Spitz 
model has good discriminatory power and clinical utility, these measures have only been 
evaluated using case-control data, not cohort data, and model calibration has not been evaluated.  
The purpose of this study was to determine the calibration, discriminatory power, and 
clinical utility of the Spitz model using prospective data from the Dutch-Belgian randomized 
lung cancer screening trial, “Nederlands-Leuvens Longkanker Screenings ONderzoek” 
(NELSON)
78-83
. The NELSON trial is especially important since it will be useful in determining 
future screening policy for lung cancer, like the recently announced results of the NLST trial
68,84
.  
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In the NELSON trial, the lung cancer mortality of those who undergo computer tomography 
(CT-Scan) screening offered by the NELSON group (screening arm), are compared to those who 
do not undergo CT-screening by the NELSON group (control arm)
77
.  A previous study has 
shown that contamination, defined as lung cancer screening in the control arm, was limited
80
.  
Information on cancer status is currently known for the screening arm, but not for the control 
arm, of the NELSON trial.  So, the validation of the Spitz model will be conducted with the 
screening arm participants only. 
2.2. Methods for Conducting Spitz Model Validation with NELSON Data 
2.2.1.  NELSON Study Population 
The NELSON group distributed a questionnaire regarding health and smoking history to 
548,489 individuals residing in the Netherlands and Belgium between the ages of 50 and 75
80
.  
Those individuals who had smoked more than 15 cigarettes per day for > 25 years, or > 10 
cigarettes per day for > 30 years, and were still smoking or had quit for 10 years or less, were 
invited into the NELSON trial
80
.  Exclusion criteria for this study included: Those with self-
reported moderate or poor health status in combination with an inability to climb two sets of 
stairs, those with a recent history of lung cancer (<5 years), those with a reported chest CT-Scan 
in the year before study recruitment, a body weight of more than 308 pounds (140 kg), and those 
with a history of renal, melanoma, or breast cancer
80
.  After exclusion, 15822 individuals were 
selected for the NELSON trial, and there was a 1:1 random draw to determine those who would 
get CT-screening.  Seven thousand nine hundred and fifteen individuals were selected for CT-
screening, while 7907 individuals were selected for the control arm.  Out of 7915 individuals in 
the screening, there were 196 individuals with confirmed lung cancer at the end of Phase 3 of the 
NELSON trial.  One hundred eighty eight of these individuals had their lung cancer originally 
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detected by CT-Screening as part of the screening process, while an other eight individuals were 
discovered to have lung cancer by linking the screen population with the cancer registry. 
Those individuals with missing data from the set of risk factors associated with the Spitz 
model were excluded from analysis.  After this exclusion, 109 individuals with lung cancer, and 
4622 individuals without lung cancer, were included for validation analysis.  The NELSON trial 
was approved by the Ethical Boards of all participating centers.  The Minister of Health of the 
Netherlands approved the NELSON trial after positive advice from the Dutch Health Council 
according to the Dutch Screening Act. 
2.2.2. Determination of 5-year Absolute Risk for Lung Cancer 
Calculation of the 5-year absolute risk of lung cancer using the Spitz model was 
determined by first obtaining the relative risk profile of each individual in this analysis.  Exact 
risk calculations using the Spitz risk model have been outlined in detail in the original published 
manuscript for the Spitz model
27
,
 
in which separate risk models were developed for former and 
current smokers. The model for former smokers incorporated the following variables: Quitting 
age; physician-diagnosed emphysema; dust exposure, prior self-reported hay fever and family 
history of cancer in first degree relatives. The model for current smokers included the following 
variables: pack-years, physician-diagnosed emphysema, dusts exposure, prior self-reported hay 
fever, family history of a smoking related cancer and asbestos exposure.  The relative risk was 
then calculated by multiplying the log odds from the risk components of the logistic model for 
former or current smokers.  
Absolute risk calculations were determined by first obtaining the age- and gender-
specific incidence rates from the Netherlands cancer registry
85
, and all-cause mortality 
(excluding lung cancer ) rates from the Netherlands cancer registry
86
 (Appendix 1: Table 1). To 
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account for the fact that Spitz model is stratified by smoking status, and to adjust for the 
NELSON population containing ever smokers only in this analysis, an adjustment factor for the 
incidence rate was used (Appendix 1: Table 2)
27
.  The age and gender adjusted incidence rates 
were multiplied by this adjustment factor, in which the percentage of ever-smokers developing 
lung cancer (stratified for sex) was divided by the percentage of either former smokers or current 
smokers in the general Dutch population (stratified for sex)
87-89
.  For instance, for a 61 year-old 
male current smoker, the constant adjustment factor is derived from the ratio of the proportion of 
all lung cancer cases in ever-smoking men (0.964) divided by the proportion of male current 
smokers in the population at risk (0.322), i.e., ac13 = 0.964/0.322 = 2.99.  At age 61, the male 
incidence rate for cancer is 192.4 individuals per 100000.  Hence, this individual’s adjusted 
incidence rate is 2.99*192.4 per 100000, or 0.00575.  Finally, the relative risks, the incidence 
rates, and the mortality rates are combined by using the Dupont-Plummer equation for absolute 
risks
90
 (Equation 2.1). 
               
   
 
                   
   
 
           
where R = relative risk calculated by the Spitz model, a = current age, s = number of years to 
calculate absolute risk,       = annual age and sex specific incidence rate,      = annual age and 
sex specific mortality rates from all other causes then the disease being examined, and          
= s year absolute risk for disease 
For this validation, the variables hay fever, dusts exposure, and family history were not 
available in the NELSON trial database.  A list of all variables used to construct absolute risk is 
summarized in Table 2.1.  
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Table 2.1: Lifestyle Variables Used in Original Spitz Model and in Validation of Spitz 
Model with NELSON data 
 
Variables Original Spitz variables Validation variables 
Pack-Years Yes Yes 
Age Stopped Smoking Yes Yes 
Age Used for LC incidence rate 
and LC-free mortality rate 
Used for LC incidence rate 
and LC-free mortality rate 
Sex Used for LC-specific 
incidence rate and LC-free 
mortality rate 
Used for LC-specific 
incidence rate and LC-free 
mortality rate 
Family History  Yes No 
Asbestos Exposure Yes Yes 
Dusts Exposure Yes No
 
Emphysema Yes Yes 
Hay Fever Yes No 
LC Incidence Rate  Yes (SEER rate) Yes (Netherlands rate) 
LC-free Mortality Rate Yes (NCHS rate) Yes (Netherlands rate) 
 
Smokers were defined as those who had smoked at least 100 cigarettes in their lifetime, 
while former smokers were those who had quit smoking at least 1 year before filling out the 
initial questionnaire.  Age was defined at the 1
st
 questionnaire time point.  Asbestos exposure 
was determined by a separate questionnaire of 17 items relating to work in fields that have 
exposure to asbestos. If an individual answered positively to any of those items, and had worked 
in an asbestos-related industry, they were considered as having been exposed to asbestos.  Self-
reported physician-diagnosed emphysema at any time before entering the NELSON trial was 
listed as positive for an individual to have emphysema. 
2.2.3. Estimation of Calibration and Discriminatory Power for NELSON analysis 
Calibration of the Spitz model within the Nelson trial data was conducted by comparing 
the ratio of cases to total individuals, and the 95% Confidence interval of each level of absolute 
risk, which was defined at the mid-point for each of the ten possible risk levels. Good calibration 
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was evident if the ratio of cases to total individuals were within the 95% Confidence Interval for 
the observed absolute risk of lung cancer.  This analysis was similar to the analysis from Figure 2 
in Bach et al
31
.  With the absolute risk lung cancer calculation, we calculated discriminatory 
power by obtaining receiver operator characteristic (ROC) curves and estimating the area under 
the curve (AUC) (empirical method) with SPSS 17.0™ statistical software (SPSS, Kaysville, 
UT).  Discriminatory power was calculated for the entire NELSON data set, and also for the 
former and current smoker subsets of the NELSON data set. 
2.2.4. Estimation of clinical utility for NELSON analysis 
Clinical utility for the Spitz model in the Nelson data set for all individuals was evaluated 
using scaled rectangle diagrams as developed in the Search Partition Analysis (SPAN, Auckland, 
New Zealand) program
91,92
.  With scaled rectangle diagrams, a graphical presentation of model 
discrimination is obtained by displaying the risk for disease for a specific risk model and true 
disease status. With these diagrams, the white rectangle represents all individuals, the green 
rectangle represents all cases, and the blue, purple, and red rectangles represent individuals with 
three increasing levels of risk for lung cancer (1.0%, 2.0%, and 3.0%, respectively).  Better 
clinical utility is defined as having a large ratio of cases correctly inferred by the model and 
having fewer individuals incorrectly inferred as cases.  Clinical utility was also represented using 
a varying absolute risk rate of lung cancer from 1.0% to 5.0%, and this analysis was conducted 
with Matlab.   
2.3. NELSON Data Results 
The epidemiologic and lifestyle information for the 109 individuals with lung cancer and 
4622 controls are presented in Table 2.2.  
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Table 2.2: Demographic characteristics of the NELSON population   
 Cases (N = 109) Controls (N = 4622) P-Value 
Age (years): mean ± s.e. 61.7±5.5 58.1±5.4 < 0.001 
Sex: No. (%)  
Male 
Female 
 
107 (98.2%) 
2 (1.8%) 
 
4520 (97.8%) 
102 (2.2%) 
 
0.794 
Smoking Status: (%) 
Current  
Former 
 
76 (69.7%) 
33 (30.3%) 
 
2878 (62.3%) 
1744 (37.7%) 
 
0.133 
Current Smokers    
Pack-Years: mean ± s.e. 45.2±18.8 40.5±16.9 0.016 
Emphysema No. (%) 
Yes 
No 
 
6 (7.9%) 
70 (92.1%) 
 
85 (3.0%) 
2793 (97.0%) 
 
0.028 
Asbestos Exposure No. (%) 
Yes 
No 
 
14 (18.4%) 
62 (81.6%) 
 
506 (17.6%) 
2372 (82.4%) 
 
0.850 
Former Smokers    
Age Stopped Smoking: mean ± s.e. 55.1±9.9 52.5±8.4 0.078 
Emphysema No. (%) 
Yes 
No 
 
1 (3.0%) 
32 (97.0%) 
 
103 (5.9%) 
1641 (94.1%) 
 
0.718 
 
Cases (mean age, 61.7 years) were on average three and a half years older than controls 
(mean age, 58.1 years; P<0.001).  Almost all the cases and controls (98%) were male.  Higher 
percentages of controls (37.7%) were former smokers compared to cases (30.3%), and the 
reverse was true for current smokers (62.3% vs. 69.7%) but these results were not statistically 
significant (P=0.133).  Current smokers who were cases reported significantly higher pack-years 
(45.2) compared to controls (40.5) (P=0.016) and were more likely to report prior history of 
emphysema (P=0.028).  However, such a difference was not evident in former smokers 
(P=0.718).  For the other variables in the analysis, there were no significant differences in either 
former or current smokers. Calibration results are shown in Figure 2.1 with the defined risk 
levels listed in Table 2.3.  
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Table 2.3: Calibration Details for Each Risk Level:   
 
Ten levels of risk are developed to test calibraton and these levels are based on the calculated 5-
year absolute risk range.  For instance, level of risk 2 corresponds to those subjects in the 10 to 
20 percentile of absolute risks in the NELSON population. 
 
Levels of Risk Number of 
Individuals 
Absolute risk 
range (%) 
Median (%) 
1 474 0.46-0.75 0.67 
2 473 0.75-0.90 0.80 
3 473 0.90-1.05 1.00 
4 473 1.05-1.25 1.14 
5 473 1.25-1.50 1.36 
6 473 1.50-1.81 1.65 
7 473 1.81-2.17 1.97 
8 473 2.17-2.67 2.19 
9 473 2.68-3.62 3.09 
10 473 3.62-11.49 4.15 
 
 
Figure 2.1: Calibration Results with 95% CI’s for each median risk level 
 
 
 
 
 
Figure 2.1: Calibration results for the Spitz Model with NELSON data.  Blue diamonds 
represent the midpoint for each estimated absolute risk level.  Red squares represent the observed 
rates of disease, while the black lines are the 95% CI of the midpoint of the estimated absolute 
risks for each risk level. 
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As the level risk increased, the range of absolute risks within the risk level increased until 
the highest risk level, which had a much larger range of absolute lung cancer risks.  In all risk 
strata except for the three highest and the lowest, the observed ratio between cases and total 
individuals were well within the 95% CI of the calculated 5 yr risk.  Four of the ten risk levels 
had an almost exact match between the observed cases to the total individual ratio and the 
calculated absolute risk, while two of the ten risk levels had their observed cases to the total 
individual ratio in close proximity to the calculated absolute risk.  Only for the highest risk 
individuals, and the lowest risk individuals, did there appear to be some separation between 
observed lung cancer ratios and calculated absolute risks for lung cancer. 
We next tested the discriminatory power of the Spitz model in the NELSON data set.  
The discriminatory power of the Spitz model for ever smokers in the NELSON data set was 0.69 
(95% CI = 0.64-0.75).  When stratified by smoking status, the discriminatory power for current 
smokers was 0.74 (95% CI = 0.67-0.80), and for former smokers, the discriminatory power was 
0.61 (95% CI = 0.52-0.71). 
Clinical utility results are graphically shown on Figure 2.2 using SPAN at three specific 
absolute risk values: 1.0% (shaded in blue), 2.0% (shaded in purple), and 3.0% (shaded in red).  
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Figure 2.2: Clinical Utility Results in Graphical Form for the Spitz model 
 
 
Figure 2.2: Clinical utility of the Spitz models. Scaled rectangle diagrams for the Spitz Model at 
defined levels of lung cancer risk. For each color of the diagram: white equals all controls with < 
1.0% risk, and light green equals all cases. Blue represents all individuals with at least 1.0% risk, 
but less than 2.0% risk. Purple represents all individuals with at least 2.0% risk, but less than 
3.0% risk. Red represents all individuals with at least 3.0% risk.  All of the numbers represent 
the number of cases or controls within a specific risk level.  For example, there are 1157 controls 
with risk less than 1.0%. 
 
At these risk values, the percentage of cases correctly identified with increasing risk values listed 
above are 89.9%, 63.3%, and 38.5%, respectively, while the percentage of controls incorrectly 
identified as cases were 75.0%, 32.7%, and 15.1%. Next, the analysis was expanded to include 5-
year absolute risks from 1% to 5%, and this analysis is graphically shown in Figure 2.3.   
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Figure 2.3: Expanded Clinical Utility for 5-year Absolute Risks from 1% to 5%  
 
A) Correct % of Cases Identified  B) Incorrect % of Controls identified as Cases 
 
 
 
C)  Ratio of Correctly Identified Cases to Incorrectly Identified Controls 
 
 
 
 
Figure 2.3: Expanded Clinical utility of the Spitz model without dusts in the NELSON data set 
for a wide region of 5-year absolute risks.  Components of clinical utility, correctly identified % 
of cases, and incorrectly identified % of identified as cases by the model, are shown in Figures 
2.4A and Figures 2.4B, respectively.  Figure 2.4C shows the ratio of correct identified % of cases 
to incorrect % of controls identified as cases for 5-year absolute risk range from 1% to 5%.  
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In Figure 2.3A, we show that the percentage of cases drops from 89.9% with absolute 
risk 1% or greater to about 9.2% for those with 5% absolute risk or greater. In Figure 2.3B, we 
show that for percentages of incorrectly identified cases that are truly controls, this percentage 
dropped from about 75.0% with absolute risk 1% or greater to about 2.2% for those with 5% 
absolute risk or greater.  The ratio of correct cases to incorrect controls steadily increase from 1.2 
correct cases for every incorrectly labeled true control at 1% absolute risk to over 4 correct cases 
for every incorrectly labeled true control at 5% absolute risk (Figure 2.3C).  
2.4.  Discussion of NELSON Results 
The purpose of this analysis was to validate the Spitz model with data from NELSON, a 
lung cancer screening trial in the Netherlands and Belgium.  The analysis showed good 
calibration with the five year absolute risk calculations.  These calibration results are the first in 
the lung cancer literature to show that five year absolute risk models can be calibrated just as 
well as a ten year absolute risk model for lung cancer. 
Further analysis of the calibration results suggested that the 5 year absolute risk 
calculations only faltered slightly at the highest risk levels.  There could be two reasons for the 
discrepancy between observed risk for cancer measured by the total numbers of cases divided by 
the total number of individuals and the 95% CI of the calculated 5 year absolute risk for lung 
cancer.  First, more stringent methods to measure some of the effects of the non-smoking 
variables, especially emphysema, may be needed.  Emphysema has been shown in numerous 
studies to be a statistically significant factor for lung cancer
27,93-95
, so if the risk of emphysema is 
being understated, if patient self-reported emphysema is not clinically validated, or if the 
discriminatory effect of emphysema is low within a data set, absolute risk values may be biased 
toward the null for these individuals, leading to less accurate validity results.  Also, the matching 
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of smoking status within the Spitz model could result in lower absolute risks, and hence, the full 
effect of smoking on lung cancer may not be measured for those with higher lung cancer risks 
despite the use of adjustment factors to account for smoking status.    
Discriminatory power from this analysis matches up well with the overall results from 
that we previously reported using Harvard case-control data
67,96-99
.  We show that the Spitz 
models currently have about a 69% discriminatory power to separate cases and controls.  
However, differences do exist between former and current smokers in the two studies.  For 
former smokers, discriminatory power was higher with the Harvard data set (70%) compared to 
the NELSON data set (61%), while for current smokers; discriminatory power was higher for the 
NELSON data set (73%) compared to the Harvard data set (68%)
67
.  These differences, 
especially in former smokers, can be explained by the lack of family history information and the 
fact that emphysema, in the NELSON data set did not differ between cases and controls.  
Emphysema is the most significant factor in the Spitz model for former smokers, and this was 
especially true in the Harvard dataset.  In the Harvard dataset, there were some suggestions that 
the presence of emphysema (a self-reported variable) could lead to recall bias, but because of the 
structure of the Harvard study, recall bias was limited, and there was a possibility that the AUC 
results were conservative
67,99-101
.  The lack of information about emphysema with NELSON data 
drove its discriminatory power towards the null, so therefore it is possible that for both studies, 
the discriminatory power of the Spitz model was actually conservative. 
The discriminatory power results does compare favorably to models developed for 
melanoma (0.62) and breast cancer (0.58-0.77)
14,16,102-105
.  However, models for colorectal cancer 
have higher discriminatory power (0.84-0.86) compared to the Spitz model
19
.   A future goal 
could be to improve the Spitz model such that discriminatory power increases to 0.75, which is 
36 
 
what is suggested for screening those with increased disease risk
107, 108
.  One approach to 
improving the discriminatory power could be to expand the model by incorporating risk 
biomarkers, especially SNPs identified from genome-wide association studies. Unfortunately, 
strong discriminatory factors that can increase overall discriminatory power do not currently 
exist.  Others have shown that adding one or more top hit SNP’s from GWAS does not 
substantially increased discriminatory ability of the models
108,109
.   
The clinical utility of the Spitz model’s performance improved from a ratio of roughly 
one correctly labeled case per misclassified case at lower absolute risk values to a ratio of four 
correctly labeled cases for every misclassified case, at higher absolute risk values.  These clinical 
utility results were similar to the Harvard study, as both studies had absolute risk values in which 
four times as many cases were labeled correctly compared to misclassifieds
67
.  However, the 
Scaled rectangle diagram shows that work still needs to be done in developing models for lung 
cancer risk prediction as all of the risk boxes only include some of the cases in the NELSON 
trial.  
One explanation for the lower detection of actual cancers is the very low ratio of cases to 
controls in this study.  For instance, at the 2.5% 5-year absolute risk listed in this analysis, there 
were 1148 individuals with at least a 2.5% absolute risk or greater for ever smokers, and 591 and 
557 individuals, for current and former smokers respectively.  For those with 2.5% or more 
absolute risk, there were only 59 individuals overall, with 16 being former smokers, and 43 
current smokers, who had a diagnosis of lung cancer.  For diseases with lower prevalence, or for 
studies with a preponderance of controls, these results are not that unusual. Systemic lupus 
erythematosus has a prevalence of only 33 in 100000 individuals worldwide, and when an 
antinuclear antibody test was designed for this disease, it had a sensitivity of 94% and a 
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specificity of 97%
110-112
.  However, when this test was applied to the entire population to test its 
accuracy, NPV values were close to 100% and PPV values were around 1%, which were due to 
having many more true negative and false positive results compared to false negative and true 
positive results, respectively
110
.   
This validation study of the Spitz model had some limitations.  First, there was no 
information in the NELSON data set for hay fever, dusts exposure, and family history of cancer 
(both smoking related and non-smoking related).  So, it is possible that the true discriminatory 
power and the clinical utility could have been understated.  However, after creating a dusts 
variable based on an asbestos questionnaire that was given to all accepted members of the 
NELSON trial to determine asbestos exposure, there were decreases in both discriminatory 
power and clinical utility (data not shown).  The dusts variable was created using the same 
questionnaire that was used for the creation of the asbestos variable, so since the asbestos 
variable did not show strong discrimination, the dusts variable also showed very weak 
discrimination, and hence, lower discriminatory power and clinical utility.  Second, there were 
few lung cancer cases relative to controls, and the cohort trial is still ongoing, so this 
discriminatory power, clinical utility and calibration values could change as more members of 
the NELSON study are diagnosed with lung cancer.   
Despite these limitations, the Spitz model had respectable discriminatory power, clinical 
utility, and calibration, results in a completely independent, longitudinal cohort.  Since 1.35 
millon individuals are diagnosed with lung cancer every-year worldwide and about 30% of all 
lung cancers occur despite reducing the prevalence of the major risk factors, it is essential that a 
risk model can differentiate between lung cancer patients and controls
113-114
.  These promising 
results show that no matter if the study population is a random draw of individuals of heavy 
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smokers from the general populations of Belgium and the Netherlands, or a case-control study 
with hospital-based participants
67
, the Spitz model is a useful model for predicting risk.     
Recently, the NLST trial showed an improved 5-year survival rates among high-risk 
smokers screened via CT versus standard x-ray.  The NLST defined high risk smokers as those 
aged 55-74 with smoking intensity of thirty or more pack-years, and are either current smokers 
or former smokers who have quit within the past 15 years
88
. Well-calibrated and validated lung 
cancer risk prediction models, such as the Spitz model, can be used in conjunction with NLST-
like screening trials as a cost-effective way to better identify those high-risk individuals who 
would most benefit from screening and hence decrease mortality rates as well as increase 
screening efficiency.  Such risk models can also be used to educate smokers to their personalized 
risk, which have been shown in preliminary studies to show promise in improving smoking 
cessation
115-117
.  Now, the Spitz lung risk model will be extended using genetic factors in the next 
chapter as an attempt to improve its discriminatory power. 
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Chapter 3: Expansion of Existing Risk Models Using Genetic Factors 
 In the previous chapter, the Spitz model has been validated and calibrated with the 
NELSON data set originating from Erasmus MC, which was an extension of the validation 
conducted with the Harvard lung cancer data set.  These validations determined the applicability 
of models consisting of non-genetic risk factors like self-reported health co-morbidities like hay-
fever and emphysema, pack-years, family history of cancer, and also occupation-related 
exposures like asbestos and dusts.   Discriminatory power results varied from 0.61 in former 
smokers with the NELSON data set, to 0.74 in current smokers.  In this chapter, I begin to 
explore the applicability of SNPs as risk factors that can better discriminate between cases and 
controls.   
3.1. Incorporating SNPs into Cancer Risk Models: A Primer 
With the development of genome-wide association studies, specific areas on the genome 
have been shown to be linked to increased risks of a number of diseases.  Specifically, in recent 
genome-wide association studies, the objective has been to find SNPs, or genes with variant base 
pairs, that show increased risk for disease
118
.  However, when SNPs are added to already existing 
models for cancer, the increase in the models ability to discriminate between cases and controls 
may be modest at best
119,120
.  For instance, when seven SNPs that were associated with an 
increased risk of breast cancer were found in two separate genome-wide association studies
121,122
 
were added to the National Cancer Institute’s Breast Cancer Risk Assessment Tool (BCRAT), 
they increased the discriminatory power less than just the addition of mammographic density to 
the BCRAT
119
.   
Even more recent studies have suggested that the increase for breast cancer is 
questionable.  A recent simulation study based on a meta-analysis of the breast cancer literature 
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suggested that 41 SNPs that showed significant associations for breast cancer can lead to a risk 
model with discriminatory power of 0.67
123
.  Addition of 50 additional variants with varying 
odds ratios of 1.2 to 1.5 will lead to discriminatory power between 0.70-0.80
123
.  However, in a 
commentary titled, “Predicting the Future of Genetic Risk Prediction”, there are concerns that 
these results may be too generous
124.  According to Chatterjee’s group, 27.9% of the known 
heritability of breast cancer would need to be discovered to obtain a discriminatory power of 
0.67
125
, but the 18 SNPs found in GWAS associated with the meta-analysis only found 7.9% of 
known heritability
124
.  Do the same concerns about the effectiveness of SNPs in breast cancer 
translate to lung cancer? 
In 2007, Dr. Margaret Spitz and her colleagues at the Department of Epidemiology at 
M.D. Anderson Cancer Center proposed a lung cancer risk prediction model
27
.  This model has 
been extended for former and current smokers to include biomarkers of DNA repair capacity and 
mutagen sensitivity
126
.  Obtaining these biomarkers is time-consuming and requires some level 
of technical expertise.  Therefore while feasible in a controlled academic setting, they are not 
applicable for widespread population-based implementation.  For this analysis, the original Spitz 
model will be expanded by incorporating four SNPs; two from chromosome 5 (rs2736100, and 
rs401681), and two from chromosome 15 (rs1051730 and rs8034191); that have been found to 
be associated with lung cancer risk
45-47,127-129
.  This will be an expansion of the results published 
previously in which SNPs rs1051730, rs8034191 and rs401681 added to the original Spitz 
model, led to a modest increase in discriminatory power of 0.012, from 0.661 to 0.673
30
.  
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3.2. Materials and Methods to add SNPs to Risk Models 
3.2.1. Study Population for MD Anderson Lung Cancer Study 
A total of 3852 lung cancer patients and controls were accrued for this study.  Lung 
cancer patients (N=1851) were enrolled from the Thoracic Center at the University of Texas MD 
Anderson Cancer Center starting in July of 1995 and ending in May 2006
27
.  All lung cancers 
were histologically confirmed, were newly diagnosed, and had no treatment (chemo or radiation) 
for lung cancer
27
.  Controls (N=2001) were recruited from the Kelsey-Seybold clinics, and these 
individuals were lung cancer-free individuals with no prior history of cancer (except for 
nonmelanoma skin cancer).  These controls were frequency matched by age (±5 years), sex, 
ethnicity, and smoking status
27
.  The risk factors in the original Spitz study are listed in Table 
2.1 in Chapter 2 on page 27.  Only ever smokers (individuals that have only smoked > 100 
cigarettes in their lifetimes) are included in this analysis. 
3.2.2.   Incorporating Genetic Information into Risk Modeling 
 To test whether top hits from GWAS do indeed increase discriminatory power in lung 
cancer risk modeling, I will develop and examine three risk models with the addition of top 
SNPs from the Texas lung cancer GWAS conducted by Dr. Christopher Amos’s group at the 
University of Texas MD Anderson Cancer Center
45
, and from epidemiological data extracted 
from the Original Spitz lung cancer risk study.  First, I will add the top SNP from the lung cancer 
GWAS, rs8034191, which is located on chromosome 15.  Second, I will add three top SNPs, 
with two top SNPs from chromosome 5 (rs2736100 and rs401681), and a third SNP which is in 
strong linkage disequilibrium (LD) with SNP rs8034191 (rs1051730).  Finally, I will develop 
risk modeling using haplotypes based on the SNPs in LD that were top hits in the GWAS study 
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from chromosome 5 (rs2736100 and rs401681) and chromosome 15 (rs1051730 and rs8034191), 
and genotype information will be available for 2291 individuals (1154 cases and 1137 controls). 
 For the development of the risk model with haplotypes, all haplotypes were inferred with 
Haplo.stats
62-63
, and all haplotypes were compared to the most frequent haplotype for both 
chromosome 15 and chromosome 5.  After inferring of haplotypes, the risk of the non-common 
haplotypes in chromosomes 15 and 5 will be determined with the rest of the covariates from the 
Spitz model. 
 All risk models will have its discriminatory power calculated.  These models will be 
compared to each other, and to the original Spitz model.  Discriminatory power results will be 
calculated for all individuals, and former and current smokers, separately.  Also, risk models, 
including the original Spitz model, will be compared to each other by using the Net 
Reclassification Index (NRI)
130
 which quantifies the improvement of classification due to 
changes in the predictive value of the extended model compared to the original model.  NRI 
results will be calculated overall and separately for cases and controls.   
3.3.   Risk Model Results for Adding Genetic Information to Spitz models 
3.3.1.   Results: 1
st
 Model: Top SNP + Spitz Original Model 
 The first model to be examined includes all variables in the original Spitz model plus 
SNP rs8034191.  The risks for each variable in this model are listed in Table 3.1.  
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Table 3.1: Multivariate analysis of Spitz Lung Cancer Model Risk Factors plus SNP 
rs8034191   
New risk models incorporating all relevant Spitz risk factors
27
 for Former and Current Smokers 
plus SNP rs8034191 are developed using multivariate logistic regression 
 
Risk Factor Former Smokers 
(584 cases / 654 controls) 
Current Smokers 
(533 cases / 481 controls) 
 Regression 
Coefficient 
OR (95% CI) Regression 
Coefficient 
OR (95% CI) 
Constant -1.202 N/A -1.204 N/A 
Emphysema  0.933 2.543 (1.786-3.620) 0.982 2.669 (1.839-3.875) 
Dust Exposure  0.470 1.600 (1.254-2.040) 0.189 1.208 (0.919-1.589) 
Family history ( ≥ 2) 0.485 1.625 (1.263-2.091) N/A N/A 
Age Stopped Smoking 
42-53 years  
0.081 
 
1.084 (0.804-1.461) N/A N/A 
Age Stopped Smoking 
≥ 54 years  
0.414 1.513 (1.127-2.031) N/A N/A 
Hay Fever (No vs. Yes) 0.375 1.455 (1.079-1.963) 0.391 1.478 (1.048-2.084) 
Asbestos Exposure N/A N/A 0.503 1.654 (1.117-2.451) 
Smoking Family 
History (≥ 1) 
N/A N/A 0.546 1.726 (1.279-2.328) 
Pack-Years (28-41.9) N/A N/A 0.226 1.254 (0.836-1.881) 
Pack-Years (42-57.4) N/A N/A 0.321 1.378 (0.927-2.048) 
Pack-Years (≥ 57.5) N/A N/A 0.653 1.922 (1.311-2.818) 
rs8034191 (G vs. A) 0.210 1.234 (1.039-1.464) 0.227 1.254 (1.037-1.518) 
 
With this extended model, the discriminatory power increases slightly from 0.660 (95% CI = 
0.637-0.681) in the original Spitz model to 0.668 (95% CI = 0.646-0.690), and this increase is 
significant (p = 0.019).  Also, the new model has superior ability to classify case/control status in 
all individuals compared to the original Spitz model according to the NRI value, (0.182, p-value 
= < 0.001).  This NRI increase is more prevalent with true cases (NRI = 0.348, p-value = < 
0.001), compared to cases (NRI = -0.167, p-value = < 0.001). 
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3.3.2.   Results: 2
nd
 Model: SNPs from Chromosomes 15, 5, and 6 + Spitz Original 
Model 
The second model to be examined includes all variables in the original Spitz model plus 
SNPs rs2736100, rs401681, and rs1051730.  The risks for each variable in this model are listed 
in Table 3.2. 
 
Table 3.2:  Multivariate analysis of Spitz Lung Cancer Model Risk Factors plus three 
SNPs: rs2736100, rs401681, and rs1051730   
New risk models incorporating all relevant Spitz risk factors
27
 for Former and Current Smokers 
plus SNPs rs2736100, rs401681, and rs1051730 are developed using multivariate logistic 
regression 
 
Risk Factor Former Smokers 
(583 cases / 654 controls) 
Current Smokers 
(534 cases / 481 controls) 
 Regression 
Coefficient 
OR (95% CI) Regression 
Coefficient 
OR (95% CI) 
Constant -1.475 N/A -1.752 N/A 
Emphysema  0.930 2.534 (1.777-3.611) 0.992 2.695 (1.851-3.926) 
Dust Exposure 0.468 1.596 (1.251-2.037) 0.198 1.218 (0.924-1.606) 
Family history ( ≥ 2) 0.486 1.625 (1.262-2.093) N/A N/A 
Age Stopped Smoking 
42-53 years  
0.074 1.077 (0.798-1.452) N/A N/A 
Age Stopped Smoking 
≥ 54 years 
0.417 1.518 (1.130-2.039) N/A N/A 
Hay Fever (No vs.Yes) 0.386 1.472 (1.089-1.988) 0.388 1.474 (1.042-2.085) 
Asbestos Exposure N/A N/A 0.532 1.702 (1.145-2.530) 
Smoking Family 
History (≥ 1) 
N/A N/A 0.571 1.770 (1.307-2.395) 
Pack-Years (28-41.9) N/A N/A 0.285 1.330 (0.883-2.004) 
Pack-Years (42-57.4) N/A N/A 0.368 1.445 (0.969-2.155) 
Pack-Years (≥ 57.5) N/A N/A 0.679 1.973 (1.341-2.901) 
rs2736100 (C vs. A) 0.143 1.154 (0.975-1.365) 0.303 1.354 (1.118-1.641) 
rs1051730 (A vs. G) 0.229 1.257 (1.060-1.491) 0.239 1.270 (1.048-1.540) 
rs401681  (C vs. T) 0.091 1.095 (0.919-1.304) 0.106 1.173 (0.967-1.423) 
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With this extended model, the discriminatory power increases slightly from 0.659 (95% CI = 
0.636-0.681) in the original Spitz model to 0.674 (95% CI = 0.652-0.696), and this increase is 
significant (p = 0.004).  Also, the new model has much better ability to classify case/control 
status in all individuals compared to the original Spitz model according to the NRI value, (0.268, 
p-value = < 0.001).  This NRI increase is more prevalent with true cases (NRI = 0.357, p-value = 
< 0.001), compared to controls (NRI = -0.089, p-value = 0.003). 
3.3.3.   Results: 3
rd
 Model: Haplotypes from Chromosome 5 and 15 + Original Spitz 
Model 
The third model to be examined includes all variables in the original Spitz model plus 
haplotypes from chromosome 15 (rs8034191 and rs1051730) and chromosome 5 (rs2736100 and 
rs401681).  The haplotypes and their frequencies are listed on Table 3.3. 
 
Table 3.3: Haplotype Frequencies for Top SNPs in GWAS that are in High Linkage 
Disequilibrium with Each Other According to Texas lung GWAS Study
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Chromosome 15 Haplotypes 
SNPs bp Haplotypes Frequencies 
 
rs8034191 
rs1051730 
 
76,593,078 
76,681,394 
AG 0.62096 
AA 0.01150 
GG 0.01281 
GA 0.35472 
Chromosome 5 Haplotypes 
 
rs2736100 
rs401681 
 
1,339,516 
1,375,087 
AT 0.24978 
AC 0.23538 
CT 0.17601 
CC 0.33883 
 
From the haplotype frequency results, this model will be constructed from the AA, GG, 
and GA haplotypes from chromosome 15, and the AT, AC, and CT haplotypes from 
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chromosome 5.  Also, all of the variables from the Spitz model will be included in this model.  
The risks for each variable are listed in Table 3.4. 
 
Table 3.4: Multivariate analysis of Spitz Lung Cancer Model Risk Factors plus haplotypes 
from Chromosome 15 and Chromosome 5   
New risk models incorporating all relevant Spitz risk factors
27
 for Former and Current Smokers 
plus the haplotypes from Chromosomes 5 and 15. 
 
Risk Factor Former Smokers 
(584 cases / 654 controls) 
Current Smokers 
(534 cases / 481 controls) 
 Regression 
Coefficient 
OR (95% CI) Regression 
Coefficient 
OR (95% CI) 
Constant -1.000 N/A -0.862 N/A 
Emphysema  0.927 2.526 (1.771-3.604) 0.996 2.707 (1.857-3.945) 
Dust Exposure  0.471 1.601 (1.254-2.044) 0.201 1.223 (0.927-1.613) 
Family history  
( ≥ 2) 
0.491 1.635 (1.269-2.106) N/A N/A 
Age Stopped Smoking 
42-53 years 
0.073 1.076 (0.798-1.452) N/A 
 
N/A 
 
Age Stopped Smoking 
≥ 54 years 
0.422 1.525 (1.135-2.048 N/A N/A 
Hay Fever(No vs. Yes) 0.377 1.459 (1.080-1.970) 0.385 1.469 (1.039-2.078) 
Asbestos Exposure N/A N/A 0.529 1.697 (1.141-2.524) 
Smoking Family 
History (≥ 1) 
N/A N/A 0.571 1.769 (1.306-2.397) 
Pack-Years (28-41.9)  N/A N/A 0.280 1.323 (0.877-1.994) 
Pack-Years (42-57.4)  N/A N/A 0.369 1.446 (0.970-2.157) 
Pack-Years (≥ 57.5) N/A N/A 0.679 1.972 (1.340-2.902) 
Chromosome 15 
Haplotype  
AA vs. AG 
GG vs. AG 
GA vs. AG 
 
 
0.328 
-0.001 
0.224 
 
 
1.388 (0.631-3.054) 
0.999 (0.458-2.181) 
1.251 (1.052-1.488) 
 
 
-0.068 
-0.219 
0.239 
 
 
0.934 (0.402-2.170) 
0.803 (0.357-1.806) 
1.270 (1.044-1.544) 
Chromosome 5 
Haplotype: 
AT vs. CC 
AC vs. CC 
CT vs. CC 
 
 
-0.236 
-0.145 
-0.087 
 
 
0.790 (0.630-0.990) 
0.865 (0.661-1.131) 
0.916 (0.674-1.246) 
 
 
-0.469 
-0.238 
-0.088 
 
 
0.625 (0.489-0.800) 
0.788 (0.581-1.069) 
0.916 (0.655-1.279) 
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With this new model, the discriminatory power increases slightly from 0.659 (95% CI = 0.636-
0.681) in the original Spitz model to 0.675 (95% CI = 0.653-0.697), and this increase is 
significant (p = 0.003).  Also, the new model has much better ability to classify case/control 
status in all individuals compared to the original Spitz model according to the NRI value, (0.254, 
p-value = < 0.001).  This NRI increase is greater with true cases (NRI = 0.349, p-value = < 
0.001), compared to controls (NRI = -0.094, p-value = 0.001). 
3.3.4.   Results: Comparison of three genetic model extensions  
 When comparing these three models created in sections 3.3.1 through 3.3.3 and the 
original Spitz model, the discriminatory power (with the AUC) and the NRI were calculated.  
Discriminatory power results between each model (and the 95% CI’s) are listed in Table 3.5. 
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Table 3.5: Discriminatory power for the three genetic models and the Original Spitz Model   
 
All discriminatory power calculations are based on relative risk calculations, and P-values were 
determined with NCSS/PASS software.  For the p-value columns:  
(1) = Comparing the Original Spitz lung cancer risk models to the three new risk models defined 
in this chapter;  
(2) = Comparing the Spitz models with one SNP added to the other two genetic models; and  
(3) = Comparing the Spitz models with 3 SNPs to the Spitz models with Haplotypes  
 
Discriminatory Power in All Individuals (1116 cases and 1135 controls) 
Model AUC (95% CI) p-value 
 (1) (2) (3) 
Original Spitz 0.659 (0.636-0.681) --- --- --- 
Original Spitz + rs8034191 0.668 (0.646-0.690) 0.0183 --- --- 
Original Spitz +  3 SNPs 0.675 (0.652-0.696) 0.0036 0.103 --- 
Original Spitz + Haplotypes 0.676 (0.653-0.697) 0.0024 0.075 0.383 
Discriminatory Power for Former Smokers (583 cases and 654 controls) 
Original Spitz 0.641 (0.609-0.671) --- --- --- 
Original Spitz + rs8034191 0.650 (0.619-0.680) 0.073 --- --- 
Original Spitz + 3 SNPs 0.655 (0.623-0.684) 0.036 0.290 --- 
Original Spitz + Haplotypes 0.655 (0.623-0.684) 0.039 0.324 0.842 
Discriminatory Power for Current Smokers (533 cases and 481 controls) 
Original Spitz 0.673 (0.639-0.705) --- --- --- 
Original Spitz + rs8034191 0.683 (0.649-0.714) 0.106 --- --- 
Original Spitz + 3 SNPs 0.692 (0.658-0.722) 0.034 0.208 --- 
Original Spitz + Haplotypes 0.693 (0.660-0.724) 0.020 0.131 0.276 
 
With these results, for all individuals and current smokers, the models with either three SNPs or 
two haplotypes are significantly superior to the Original Spitz models.  However, there are no 
significant differences (at the 5% level) among the genetic models.  To test the ability of the 
genetic models to improve the risk profiles of each individual compared to the original Spitz 
Model, the NRI was calculated for each genetic model compared to the Spitz model, and for each 
genetic model against each other (Table 3.6). 
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Table 3.6:  Net Reclassification Index results for comparing the three extensions of the 
Spitz risk models with the Original Spitz Model   
All Net Reclassification Index results (NRI) and P-values were determined with MATLAB.  For 
the p-value columns:  
(1) = Comparing the Original Spitz lung cancer risk models to the three new risk models defined 
in this chapter;  
(2) = Comparing the Spitz models with one SNP added to the other two genetic models; and  
(3) = Comparing the Spitz models with 3 SNPs to the Spitz models with Haplotypes  
 
NRI for All Individuals 
Model (1) (2) (3) 
 NRI p-value NRI p-value NRI p-value 
Original Spitz --- --- --- --- --- --- 
Original Spitz + rs8034191 0.183 < 0.001 --- --- --- --- 
Original Spitz + 3 SNPs 0.269 < 0.001 0.167 < 0.001 --- --- 
Original Spitz + Haplotypes 0.255 < 0.001 0.159 < 0.001 0.099 0.018 
NRI for Cases 
Original Spitz --- --- --- --- --- --- 
Original Spitz + rs8034191 0.350 < 0.001 --- --- --- --- 
Original Spitz + 3 SNPs 0.358 < 0.001 0.005 0.858 --- --- 
Original Spitz + Haplotypes 0.349 < 0.001 -0.020 0.510 0.201 < 0.001 
NRI for Controls 
Original Spitz --- --- --- --- --- --- 
Original Spitz + rs8034191 -0.167 < 0.001 --- --- --- --- 
Original Spitz + 3 SNPs -0.089 0.003 0.161 < 0.001 --- --- 
Original Spitz + Haplotypes -0.094 0.001 0.179 < 0.001 -0.103 < 0.001 
  
For the NRI results, the genetic models with SNPs from the GWAS and the genetic 
model with haplotypes improve the risk profile results for both cases and controls with the 3 SNP 
model having significant superior values in NRI for all individuals (NRI = 0.269, p-value = < 
0.001) and cases (NRI = 0.358, p-value = < 0.001) compared to the original Spitz model.  
Interestingly, not one genetic model improves discrimination in controls as all of them are 
significantly worse than the original Spitz model.  The genetic model with haplotypes does 
worse in discrimination with controls compared to the model with three SNPs (NRI = -0.103, p-
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value = < 0.001), but the haplotype model measures discrimination in cases better than the three 
SNP genetic model (NRI = 0.201, p- value = < 0.001).   
3.4.  Discussion:  Adding Haplotypes and SNPs to the Spitz Lung Cancer Risk Model 
 These results show that adding SNPs or haplotypes can increase the 
discriminatory power compared to the original Spitz model.  The largest increases in 
discriminatory power occur when the two haplotypes on chromosomes 15 and 5 are added to the 
original Spitz model.   However, the NRI gives contradictory evidence that the haplotype model 
outperforms the three SNP model.  When compared directly to each other, there is significant 
improvement for the haplotype model in terms of NRI for all individuals, but the three SNP 
model improves discrimination between cases and controls the most compared to the original 
Spitz model.  Also, for all individuals, former smokers, and current smokers, there are no 
significant differences in AUC between the haplotype model and the three SNP model. 
A potential reason for the non-significant increase in discriminatory power with the 
haplotype model compared to the model with 3 SNPs is that the haplotypes may not be generally 
true haplotypes.  Even though they are listed as areas of strong LD in the Texas lung GWAS 
manuscript
45
, data from HapMap in the Caucasian (CEU) population uploaded into Haploview 
suggest quite the opposite for the Chromosome 5 haplotype containing SNPs rs2736100 and 
rs401681 (Figure 3.1) 
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Figure 3.1:  Gold Plot from Haploview for the SNPs in HapMap between rs2736100 and 
rs401681.   
 
Figure 3.1:  This figure highlights three haplotype blocks inferred via the Gabriel et. al 
method
53
.  SNP rs401681 is located within one haplotype block, while SNP rs2773160 is not 
located within the same haplotype block.  Also, and of higher importance, the LD between SNPs 
rs2773160 and rs401681 is weak, as expressed by the white diamond with the value 8 in the 
middle at the bottom of the plot.  That value represents the D’ for these two SNPs (0.08), and the 
95% CI of D’ for these two SNPs are from 0.00 to 0.23. 
 
With the weak LD between these two SNPs, it could be argued that these SNPs should have been 
modeled separately instead of a haplotype.  In this case, modeling these SNPs as a haplotype 
may have lead to weaker modeling, and a non-significant increase in discriminatory power 
compared to the model with 3 SNPs and no haplotypes.  If haplotypes in stronger LD are found 
in the full Texas lung GWAS dataset, there is a possibility that these haplotypes can lead to 
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model development with higher discriminatory power compared to models with either weak LD 
haplotypes or with SNPs only.  
3.5. Why we need the BJLM 
 In the previous three chapters, risk modeling and haplotype analysis have been 
introduced.  Chapter 2 showed that risk models with basic epidemiological factors like smoking 
status, self-reported health co-morbidities, and family history for disease can moderately 
discriminate between cases and controls, and occasionally show good clinical utility.   The 
highest discriminatory power recorded was 0.74 from the current smoker set of the NELSON 
trial, but ever smokers recorded a discriminatory power of only 0.69 in both of the validation 
data sets.  Excellent risk models have discriminatory power of 0.80, while good and very good 
risk models generally have discriminatory power values of 0.70 and 0.75, respectively
131
.   
In an attempt to increase the discriminatory power of the Spitz lung cancer model, three 
new models were created with 1 SNP, 3 SNPs, and 2 haplotypes added to the original Spitz lung 
cancer model in Chapter 3.  These models showed a general increase in discriminatory power, 
but this increase was small and non-significant when trying to add haplotypes to the original 
Spitz model compared to adding SNPs to the original Spitz model.  According to numerous 
manuscripts, haplotypes are supposed to have greater power compared to individual SNPs, but 
the results from this analysis may suggest otherwise.  Can modeling and selection of haplotypes 
be improved such that increased discriminatory power will be achieved in risk models that could 
be use to select individuals for screening trials or to identify individuals at high-risk for 
incidence of disease?  This will be attempted in the next chapter with the introduction of the 
BJLM. 
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Chapter 4: Development of the Bayesian Joint Logistic Method 
4.1. Relationship between the BJLM and Haplotype Analysis 
To attempt to improve the effectiveness of using haplotypes into risk modeling, I will 
develop the Bayesian Joint Logistic Method (BJLM).  This chapter will contain the full 
development of the BJLM with both simulation results for development of haplotypes and also 
results from constructing a risk model for the Hodgkin dataset.  Haplotype analysis is the study 
of a pattern of descent of a set of linked alleles occurring on the same chromosome
60
, and this 
analysis has been used to discover sets of linked markers associated with specific diseases.  With 
haplotype analysis, more power can be obtained in discovering a link between haplotypes and 
disease compared to the case of just examining the relationship between a SNP and disease
132
.  
Haplotype analysis has been used to discover new genetic risk factors in a wide variety of 
cancers, including breast, pancreatic, and Hodgkin lymphoma
133-135
.   
Some programs that infer haplotypes for haplotype analysis are PHASE
55
, Haploview
56
, 
and Haplo.stats
62
, with Haplo.stats having the ability to construct frequentist models of haplotype 
data.  Haplo.stats allows for the estimation of odds ratios to represent the association between 
either a haplotype or a covariate and disease with the use of either a joint-effect linear model or a 
separate-effect linear model.  Currently there these exist two prominent frequentist methods for 
risk model development with inferred haplotypes (Joint Logistic Analysis, Separate-Effects 
Model)
62,65
; however, no Bayesian method currently exists that not only infers haplotypes, but 
also can directly elucidate risk models that can be used to develop genetic risk profiles for 
disease. 
Linkage disequilibrium (LD) studies have accelerated in recent years with the 
development and implementation of a haplotype map of the human genome (HapMap) beginning 
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in 2003, and with the newest version, HapMap 3, fully updated in May 2010
136-139
. Currently, 
there are over 1,000,000 QC+ SNPs genotyped and non-redundant from 11 different populations 
throughout the world.  Extracting this information could be very useful with inferring haplotypes 
more accurately which could lead to stronger associations with disease. 
I hypothesize that there could be substantial improvement in the association 
between haplotypes and disease, with the use of a Bayesian mathematical method to infer 
haplotypes that uses priors developed from known genetics sources (HapMap).  The 
development of this model, the Bayesian Joint Logistic Model (BJLM), will be completed in four 
stages; 1) extraction of the haplotypes and their counts from HapMap data 2) the framework, in 
this case a Hidden Markov Chain Monte Carlo (MCMC) model with mixing, with associated 
Dirichlet prior from HapMap data to begin the estimation of haplotype frequencies, 3) a method 
to infer haplotypes that contains missing SNP data, and 4) the logistic model to estimate the risk 
for each haplotype reconstructed by the BJLM.  The complete developmental flow-chart for the 
BJLM is shown below in Figure 4.1. 
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Figure 4.1: Flow-Chart of the BJLM from the 1
st
 step: HapMap to the Final Step:  
Creation of a Bayesian Logistic Model 
 
Figure 4.1:  In this flow chart, the 1
st
 section is to extract the SNP data from HapMap and infer 
haplotypes using a frequentist method in which the haplotype frequencies of all haplotypes in a 
haplotype block are updated until the likelihood stays within 0.001 of the previous iteriation.  
Then, this information is used as prior information to determine the haplotypes with full SNP 
data for each haplotype block.  Then missing haplotypes (those with partial SNP data) are 
inferred using a forward-backward algorithm to determine all haplotypes for all individuals.  
Finally, this haplotype information is added to the covariate information, and a Bayesian logistic 
risk model is created in WinBugs.  Full details are expressed in the next section.  
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4.2. Development of the framework for the BJLM 
4.2.1. Extracting information from HapMap for BJLM use 
Programs like Haploview
56
 have been created to read HapMap data in order to generate 
LD statistics, develop Haplotype blocks
53
, determine Hardy-Weinberg equilibrium
140
 and 
determine which SNPs are tagSNPs
141
.  Unfortunately, the newest version of HapMap has 
formatting which is not fully compatible with SNP data from the non-CEU (or Caucasians 
currently living in UTAH) population (version 4.2).  It is also imperative a standalone program 
exist in order to extract the newest HapMap data.  I created a MatLab-based program called 
HapExtract that accepts HapMap dumped genotype data from the Human HapMap website 
(http://www.hapmap.org), and the program is flexible enough to accept genotype data from each 
of the 11 populations in HapMap3.  Downloaded genotype data from HapMap is bounded by the 
base-pair information of the SNPs at each end of the portion of the genome to be examined.  For 
example, the input chr1:11777000..11778970 for the HapMap website will extract all genotypes 
from that region of the chromosome.  With these data from HapMap, all of the genotypes can be 
converted into more user-friendly data, or a list of SNPs can be inputted into HapExtract that will 
only extract the HapMap data from the inputted SNP list.   
A portion of the HapMap genotype dump file is shown below in Figure 4.2. 
 
 
 
 
 
 
57 
 
Figure 4.2:  Sample section from HapMap genotype data dump 
 
Figure 4.2:  The first three lines are the standard printout for any HapMap genotype dump, 
regardless of the population dataset being extracted.  The data between the blue lines list the 
components of the file, and the ids of all individuals that have genotype data.  All data below the 
blue lines are the genotypes and rs numbers which are collected by the program, and all other 
information between the genotypes and the rs numbers are discarded.  Finally, the bolded SNPs 
represent the information that the user wants saved in the HapMap file for future analysis. 
 
After selecting the SNPs used for future analysis, the genotype information for each 
individual in the HapMap data set in allele form (A, T, C, G).  Upon obtaining the HapMap data 
set in allele form, HapExtract converts the information into a Haploview ready format with two 
files; the first file contains the marker name and the base-pair information, and the second file 
contains the allele information for each marker in Haploview format (A=1,C=2,G=3,T=4).  Next, 
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the user can translate the allele information to a haplo.stats ready format if appliciable.  Then, the 
allele information can be translated into the number of variant alleles for each SNP.   This format 
could be used for haplotype analysis with the program HapReg
142
, or for future haplotype 
analysis in the form of calculating haplotype frequencies from the HapMap data.   
Within each HapMap population, there are some pockets of missing SNP data, which is 
represented by the allele NN, and this information is removed from future use.  Output examples 
from the HapMap extraction program are shown in Figure 4.3. 
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Figure 4.3: Output Example with both Missing SNP Data and without Missing SNP Data 
  A) HapMap Format            B) Variant Allele Format  
 
Figure 4.3:  Figure 4.3.A is the formatted HapMap genotype data from HapMap for all 174 
individuals in the CEU population, and figure 4.3.B. contains the number of variant alleles for 
each CEU individual in the SNPs rs1801131 and rs1801133.  In this population, CEU individual 
5 has missing genotype data, coded by NN in figure 4.3A.  For determining the set of haplotypes 
that will serve as prior data for inferring haplotypes, this individual will be removed from the 
analysis. 
 
 After obtaining the number of variant alleles for each individual, the haplotypes from 
HapMap are inferred by using a simple algorithm that continues until the likelihood changes by 
less than 0.001 (Figure 4.4).  Below is the calculation for the likelihood 
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where i = 1,2…, M and M = number of haplotypes in the HapMap sample,     = haplotype 
frequency for each haplotype in the HapMap sample, and        = initial set of haplotype 
frequencies.  For the initial set of haplotype frequencies, these frequencies represent an equal 
percentage for each possible haplotype. 
 
Figure 4.4:  Algorithm that determines the Haplotypes inferred from HapMap individuals 
that is used for the BJLM 
 
Figure 4.4:  All potential haplotypes are inferred at an equal frequency for the 1
st
 step.  Then, 
with these frequencies and the possible haplotypes for every individual in the HapMap dataset 
according to the available variant allele data, new haplotype frequencies for each potential 
haplotypes are calculated.  These frequencies are inserted into equation 4.1, and the likelihood is 
calculated.  Steps B and C are conducted until the change in haplotype from one iteration to 
another are less than 0.001.  Finally, once this algorithm is completed, and the set of haplotypes 
and their counts determined, they are passed onto the BJLM for analysis with the dataset to be 
examined. 
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4.2.2. Determining Haplotypes from Full Data Using Information from HapMap 
In the previous section, haplotypes inferred from HapMap SNP data was inferred using a 
likelihood algorithm as expressed in Figure 4.4.  In this section, the second component of the 
BJLM includes the framework for the determination of haplotypes from a disease dataset to be 
examined, which will be a Hidden MCMC model.  MCMC models can be used to extract 
information for haplotypes because of their ability to sample quickly through genotypes to 
produce haplotypes without making unnecessary assumptions like phase determination
61
.  In the 
literature, some of the more well-known examples of using Bayesian MCMC models to infer 
haplotypes are from Xing et. al
143
, Stephens et. al.
55,61
, Niu et.al
144
, and Bansal et. al
145
.  Gibbs 
sampling
146
 will be used to sample out the haplotypes in question.  With Gibbs sampling, one can 
extrapolate unknown haplotypes, if one can determine the frequencies of alleles for each loci, the 
genotypes for each individual, and the prior distribution in question, g            
147
.   
The prior to be used for the BJLM will be previous haplotype data extracted from 
HapMap, and the procedure for this was discussed in section 4.2.1.  With this prior, haplotype 
information can be examined from a known, verified source, and incorporated into the analysis 
for all individuals with complete SNP data.  For calculation of the haplotypes with complete SNP 
data from the disease dataset, the haplotypes from HapMap will be modeled from a Dirchlet 
distribution.  This distribution made sense to use as the prior distribution because the haplotype 
frequencies estimated from HapMap equaled one, and the computation simplicity of the Dirichlet 
distribution.   The Dirchlet distribution is the conjugate prior for multinomial distribution, and 
that is how the genotypic counts are modeled, hence the computational simplicity of this 
distribution for Bayesian haplotype analysis (Equation 4.2). 
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where    is the haplotype frequency, and    is the hyper parameter value for the haplotype based 
on the racial composition of the group. 
With the prior information from HapMap, one can determine the probability of a 
previously unknown haplotype with the associated genotypes and haplotype frequencies 
         according to144: 
              
 
   
       
    
     
 
   
 
with Y is the genotypes, Z is the haplotypes, Θ is the set of population haplotype frequencies, 
    is the frequency for assigned haplotypes, n is the number of individuals, M is the number of 
possible haplotypes,   
    
is the maximum likelihood estimate at each haplotype (g) according 
to the parameters of the Dirichlet distribution ( )144.  
The iterations of the above parameters, can update the haplotype frequencies given the 
genotypes and haplotypes, hence constituting a Gibbs sampling algorithm
144
.  Eleven hundred 
iterations are conducted to determine haplotype frequency, and this occurs in three separate 
processes.  The first 100 iterations to determine haplotype frequency will assume no prior 
information to remove non compatible haplotypes between HapMap data and the dataset to be 
analyzed.  The second set of 100 iterations incorporate the HapMap prior information into the 
haplotype draw, and are used as a burn-in set for which the chain of frequency values for each 
haplotype will become stable again.  Finally, 900 iterations will be conducted that will determine 
the haplotype draws for each individual, the mean frequency for each haplotype, and the 95% 
credible interval for each haplotype.  The haplotype information for the dataset with all SNP 
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information will be used to then determine the missing haplotypes for those with incomplete 
SNP information (if applicable) with the forward-backward algorithm for the 3
rd
 part of the 
BJLM. 
4.2.3. Using a Modified Forward-Backward Algorithm to Infer Haplotypes for 
Individuals with Missing SNP Data 
Since real data sets sometimes contain missing genotype data, whether due to genotypic 
error or human error, the third step in the Bayesian framework is to impute the missing haplotype 
pair, if applicable.  Estimation of missing data will occur in cases and controls separately since 
the frequency of haplotypes will be different in cases and controls.  This will be accomplished 
with the use of a forward-backward algorithm, which can estimate the missing haplotype pair by 
taking into account the probability of haplotypes as determined in section 4.2.2 both before and 
after the individual with missing SNP data
148-150
.    A flowchart for the modified forward-
backward algorithm and its application to missing haplotype data is shown in Figure 4.5.  
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Figure 4.5: Determining Missing Haplotype Pair from individuals with missing SNP data 
with the Forward-Backward Algorithm 
 
Figure 4.5:  First, the forward-backward algorithm will be conducted by separating the 
haplotype pair so that two sets exists which contain the 1
st
 haplotype and the 2
nd
 haplotype for 
each missing individual separately.  Second, haplotype frequencies from the whole dataset will 
be calculated for both haplotype sets.  Third, the state transition probabilities      will be 
calculated by multiplying the haplotype frequencies calculated in the previous step (Equation 
4.4). 
 
                                 
where    and    = haplotypes that exist in the haplotype sets, i and j = 1,….,N, where N = 
number of haplotypes available for each haplotype set, and    = actual haplotype at individual t. 
Fourth, for each individual, the haplotype frequencies for each individual      based on the 900 
iterations of the BJLM conducted in section 4.2.2. is calculated (Equation 4.5). 
    
          
    
     
    
      
Fifth, the probability distribution of a haplotype based for each individual        is 
calculated by using the mnrnd function in Matlab, which selects random values from a 
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multinomial distributions for as many times as the user desires given a set of multinomial 
probabilities.  In this case, the mnrnd function incorporates the haplotype probabilities for all 
possible haplotypes and conducts a random haplotype draw for every individual for as many 
times as the user desires.  This probability distribution assumes that no information on the actual 
haplotypes for each individual with missing SNP data is known, and that the probability is just 
based on the haplotype frequencies for the dataset with full SNP information.   In this case, the 
number of random draws equal the number of cases or controls in the study (depending on 
whether the program is determining haplotypes for missing cases or controls) (Equation 4.6). 
       
           
                   
     
                  
       
where    = random draw of haplotype i at individual t. 
Sixth and seventh, the individuals with missing SNP data are selected, and then the 
potential haplotype pairs for those with missing data are determined by the haplotypes inferred 
with the full data set.  This ensures that the only haplotypes that can be selected for an individual 
will match the haplotypes already in the sample. 
The next step of the forward-backward algorithm involves the calculation of the forward 
and backward variables.  For the forward portion of the algorithm, the forward variable is 
initially estimated at the 1
st
 individual in the data set by determining the probability that the state 
of Markov chain equals the actual state (probability that the haplotype exists for the individual) 
for the 1
st
 individual times the probability distribution of an observation at the 1
st
 individual 
(which is the probability of the haplotype in each part of the pair based on the full dataset)
 149
.  
Then, the forward variable is updated by taking into account all of the probabilities for each 
haplotype based on the full dataset, and also the probability of a haplotype at the next individual.  
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This continues until the individual is reached with the missing haplotype.  The equations for the 
forward portion of the algorithm are
148
: 
                           
              
 
   
                                 
where t = individual up to missing individual (T), t = 1,2,…,T-1,         = probability 
distribution of a haplotype based on the full dataset at individual t, N = number of haplotypes in 
the full SNP dataset,   = actual haplotype at individual t, where    and    = haplotypes that exist 
in the haplotype sets, i and j = 1,….,N,     = set of transition probabilities from one haplotype to 
another, and       = forward variable used in calculation of the missing haplotype
149
. 
The backward portion of the algorithm begins at either the individual before the next 
missing individual, or the end of the disease dataset if no more missing individuals exist.  This 
portion is initialized with the backward variable equaling one at the first individual, and then 
inducted by taking into account the backward variable value at individual t, probability of 
haplotype at individual t, and probability of change from one haplotype to another while the 
program heads backward toward the individual with the  missing haplotypes.  The equations for 
the backward portion of the algorithm are
148
: 
                     
                  
 
   
                                
where Q = next missing individual (or end of disease dataset if no more missing individuals 
exist),      = backward variable at individual t. 
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After determining the estimates of the forward and backward variables, we can then determine 
the probability of each haplotype at the individual with missing haplotype data,      . 
       
          
             
 
   
                
We then determine the missing haplotype pair by multiplying the probabilities of the haplotypes 
for each separate haplotype pair and conducting a random draw to select the haplotype pair for 
each missing individual.  This random draw is conducted for each iteriation of the BJLM that 
was used to determine the initial haplotypes and their frequencies in section 4.2.2.  Finally, the 
haplotypes frequencies are calculated once again with the 95% credible intervals, and the full 
haplotype pairs for all individuals are passed onto the modeling section of the BJLM.  
4.2.4. Development of the Bayesian Logistic Model for Haplotype Association 
The third component of the BJLM model is the incorporation of a Bayesian binary 
logistic model to link the case-control status of a disease (dependent variable) and the haplotypes 
constructed in the earlier components of the BJLM (independent variables).  Logistic models 
have been used extensively throughout epidemiology, especially in developing models to 
estimate probability for a range of cancers
27,30,31,151,152
. With the BJLM model, the intention is to 
introduce the use of a Bayesian binary logistic model for haplotype analysis to both estimate 
associations between haplotypes and disease and also to increase the power to detect the 
association, when compared to classical logistic models.  Bayesian logistic models incorporate 
the logistic model with a prior multiplied to the exposure as shown in equations 4.12 and 4.13
153
.   
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where   is the vector of Gaussian priors for each individual t (  ),    is the vector of value of 
exposed risks (i) to each individual (t)     .    is the logistic risk function,    is the variance of 
  , and d is the number of individuals in analysis. When construction of the Bayesian logistic 
model is complete, the BJLM model can begin to be used for preliminary analysis of data with 
the use of an MCMC method
154-156
.  
To conclude the construction of the BJLM model for covariates, methods to incorporate 
binary, categorical, and continuous covariates must be taken into account.  For any binary 
covariates, the same procedure used to incorporate haplotypes into the BJLM (see eqs. 4.12 and 
4.13) will be used to incorporate binary covariates into the model. 
However, for categorical and continuous covariates, more complicated Bayesian methods 
must be used.  Categorical or polychotomous variables have been incorporated into Bayesian 
analysis previously
157-159
, and the approach that will be used for the BJLM model will be to 
separate the categorical variables into m-1 separate binary variables, where m is the number of 
categories for each categorical variable.  Then, the same procedure to incorporate haplotypes into 
the BJLM can be used to incorporate the m-1 separate binary variables for each categorical 
variable.   
Continuous covariates can be included into the Bayesian logistic model framework by 
incorporating smoothing priors to estimate these covariates nonparametrically
160
.  An example of 
a smoothing prior is a second-order Gaussian random walk prior, which allows for both 
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flexibility, but also lessens the impact of extreme values for the covariate
156
.  An example of 
such a prior is given by
156
: 
      
        
  
 
 
                
 
 
   
        
where       
   is the prior function,   
  is the variance for the continuous covariate in the 
sample, T is the number of individuals in the sample, and f is the entire continuous covariate 
value set ranked from smallest      to largest      .  With this smoothing prior that can be used 
to estimate the contribution of the continuous covariates, the BJLM can now incorporate all 
continuous variables without concern of variables with extreme values
156
. 
All modeling discussed in section 4.2.4. will be done using WINBUGS.  For the non-
informative Gaussian priors discussed earlier, all priors will have means of zero and variances of 
100 so that the beta(s) are both non-informative and WINBUGS can run without any trap issues.  
Trap issues can occur when a prior beta value is selected that cannot be resolved by the 
WINBUGS program during an iteriation.  For each haplotype and covariate, an empirical Bayes 
p-value will be constructed that calculates the frequency that a beta goes above and below zero 
during the non-burn in iteriations.  Below is that equation
161
: 
Empirical Bayesian P-Value =                               (4.15) 
Generally, in Bayesian analysis, p-values are not generally used as a method to determine 
whether variables should or should not be in a model, but in this case, the Empirical Bayesian p-
value will allow for a direct comparison between models eludicated using frequntist techniques, 
and models eludicated using Bayesian techniques.  WINBUGS can calculate Bayesian “p-
values” with the use of step functions161. 
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4.3. Haplotype Simulations to Test Ability of BJLM to infer Haplotypes 
 4.3.1.  Procedure for Haplotype Simulations  
To conduct simulations of the BJLM and its ability to infer haplotypes, genotypes from 
Chromosome 1 from HapMap between base pair values 11754200 and 11774700 with the CEU 
population as a “control” population, and the TSI population as the “case” population were 
extracted with the BJLM using HapExtract in section 4.2.1.  Then, using Haploview, both 
populations were examined to test whether the SNPs in the base pair range stated above 
contained haplotypes inferred from the same SNPs in both populations.  After discovering that a 
haplotype of 12 SNPs did exist for both populations, and these 12 SNPs were exactly the same, 
the genotypes for these 12 SNPs were extracted from HapExtract (Table 4.1). 
 
Table 4.1: Marker Information for the 12 SNPs in the Simulation Analysis:   
For these 12 SNPs extracted from the CEU and TSI populations, the rs number, chromosome, 
base-pair, and major/minor allele data is listed. 
 
rs Number Major/Minor Allele Chromosome  Base-pair 
rs6667720 T/C 1 11754202 
rs6540999 G/A 1 11755953 
rs11121828 A/G 1 11757041 
rs6696752 C/T 1 11758522 
rs6699881 C/T 1 11759215 
rs7538516 T/C 1 11759269 
rs6541001 C/T 1 11759954 
rs10779765 C/T 1 11760598 
rs4846048 A/G 1 11768839 
rs2184226 T/C 1 11770023 
rs1537516 G/A 1 11770448 
   rs13306556  C/T 1 11774697 
 
  Full haplotype analysis was conducted in accordance with section 4.2.1 of the BJLM, 
so that the haplotypes for the CEU and TSI populations were extracted. 
71 
 
 For both populations, 500 haplotypes will be simulated based on the extracted haplotypes 
from the HapMap datasets with HapSim, which is a haplotype simulator program in the R 
language
162
.  HapSim expands on previous simulation methods
163,164 
by including the patterns of 
linkage disequilibrium
 
and pre-specified allele frequencies to simulate large numbers of 
haplotypes effectively and quickly.  The functions haplodata and haplosim in the HapSim 
program extract the basic information from the haplotype files created with the BJLM, and then 
simulate the haplotypes for future analysis.  Since each individual has two possible haplotypes, 
the two haplotypes are combined so that the numbers of variant alleles per individual are 
determined, and in this format, the BJLM can determine both haplotypes and haplotype 
frequency.   
 Since HapSim creates haplotypes with no missing data, the 1
st
 run of the program will 
include information for all individuals.  To determine the effectiveness of the forward-backward 
algorithm, missing data is randomly added to each SNP in the haplotype with defined 
frequencies of 1%, 2%, 3%, 4%, or 5%.  The final cutoff for missing SNP data was selected at 
5% because I assumed that SNPs would not be included in genetic analysis if the call rate was 
less than 95%.  Then the forward-backward algorithm is applied to the missing data using the 
frequencies calculated from the full haplotype set in the 1
st
 run of the program.  One hundred 
replicates of missing data are conducted to ensure that a full spectrum of haplotype results is 
obtained from this analysis.  Simulations will be conducted with haplotypes varying from 2 to 12 
SNPs, so there will be 11 sets of analysis.  In this chapter, haplotype simulations with 2, 3, and 
12 SNPs will be analyzed.  Appendix 2 contains the results for haplotype simulations including 
4-11 SNPs.  
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4.3.2.  Haplotype (2 SNP) Simulation Results  
The two SNP haplotype simulation results are presented in Table 4.2 and Figure 4.6.  
Results are shown for the full set of haplotypes with frequency > 5 %. 
 
 
Table 4.2: Haplotype Simulation results for 2 SNP haplotypes.   
 
The haplotype index number is listed in the far left column, with the associated haplotype in the 
next column to the right.  The haplotype frequency assuming no missing data is listed in the 3
rd
 
column from the left, and the average frequency for each haplotype from the 100 replicates are 
listed in the column next to the no missing data column.  Finally, the 95% credible interval (CI) 
for these frequencies from the 100 replicates is listed in the final two columns. 
   
Haplotype # Haplotype No Missing 
Data 
Median 
Frequency 
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TG 0.564 0.568  0.540 0.590 
4 CA 0.263 0.262 0.241 0.286 
2 TA 0.124 0.123 0.105 0.141 
2 % Missing SNP Data 
1 TG 0.564 0.565  0.534 0.590 
4 CA 0.263 0.266 0.238 0.290 
2 TA 0.124 0.121 0.100 0.140 
3% Missing SNP Data 
1 TG 0.564 0.569  0.541 0.590 
4 CA 0.263 0.267 0.244 0.287 
2 TA 0.124 0.121 0.105 0.138 
4% Missing SNP Data 
1 TG 0.564 0.571  0.554 0.595 
4 CA 0.263 0.271 0.241 0.289 
2 TA 0.124 0.118 0.097 0.137 
5% Missing SNP Data 
1 TG 0.564 0.571  0.544 0.592 
4 CA 0.263 0.271 0.249 0.297 
2 TA 0.124 0.118 0.100 0.137 
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Figure 4.6: Graphical representations of the haplotype frequency for simulations of 2 SNP 
Haplotypes 
A) 1% Missing Data    B)  2% Missing Data 
                
C) 3% Missing Data  D) 4% Missing Data E) 5% Missing Data 
 
Figure 4.6:  The X axis is the simulation run number, and the Y axis is the haplotype frequency.  
The lines are as follows:  Blue Line = Haplotype TG, Red Line = Haplotype CA, and Green Line 
= Haplotype TA.   
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With these results, the missing data results are similar to the results with no missing data, as none 
of the haplotypes have more than a 1% difference in frequency between those with and without 
missing data.  Also, as the percentage of missing data increases, the 95% CI only increases 
slightly in length. This suggests that the BJLM is very stable for 2 SNP haplotypes when missing 
data is 5% or less. 
 4.3.3.  Haplotype (3 SNP) Simulation Results 
The three SNP haplotype simulation results are presented in Tables 4.3 and Figures 4.7.  
Results are shown for the full set of haplotypes with frequency > 5 %. 
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Table 4.3: Summary of Simulated haplotypes of 3 SNP length.   
 
The haplotype index number is listed in the far left column, with the associated haplotype in the 
next column to the right.  The haplotype frequency assuming no missing data is listed in the 3
rd
 
column from the left, and the average frequency for each haplotype from the 100 replicates are 
listed in the column next to the no missing data column.  Finally, the 95% credible interval (CI) 
for these frequencies from the 100 replicates is listed in the final two columns.    
 
Haplotype # Haplotype No Missing 
Data 
Median 
Frequency 
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGA 0.322 0.323  0.294 0.351 
2 TGG 0.242 0.246 0.219 0.275 
7 CAA 0.171 0.177 0.154 0.198 
8 CAG 0.092 0.084 0.069 0.099 
3 TAA 0.073 0.073 0.057 0.089 
4 TAG 0.051 0.051 0.038 0.064 
2 % Missing SNP Data 
1 TGA 0.322 0.322 0.296 0.352 
2 TGG 0.242 0.243  0.216 0.270 
7 CAA 0.171 0.180 0.155 0.204 
8 CAG 0.092 0.086  0.067 0.104 
3 TAA 0.073 0.074  0.055 0.091 
4 TAG 0.051 0.049  0.036 0.065 
3% Missing SNP Data 
1 TGA 0.322 0.324  0.290 0.348 
2 TGG 0.242 0.245 0.218 0.265 
7 CAA 0.171 0.180 0.157 0.197 
8 CAG 0.092 0.087  0.071 0.104 
3 TAA 0.073 0.073  0.059 0.088 
4 TAG 0.051 0.049  0.035 0.064 
4% Missing SNP Data 
1 TGA 0.322 0.322  0.294 0.350 
2 TGG 0.242 0.249 0.227 0.271 
7 CAA 0.171 0.181  0.159 0.204 
8 CAG 0.092 0.088  0.068 0.112 
3 TAA 0.073 0.074 0.058 0.091 
4 TAG 0.051 0.046  0.035 0.062 
5% Missing SNP Data 
1 TGA 0.322 0.327  0.303 0.358 
2 TGG 0.242 0.243 0.215 0.272 
7 CAA 0.171 0.184 0.161 0.213 
8 CAG 0.092 0.090 0.072 0.106 
3 TAA 0.073 0.074 0.057 0.091 
4 TAG 0.051 0.041 0.030 0.056 
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Figure 4.7: Graphical representations of the haplotype frequency for simulations of 3 SNP 
Haplotypes 
A) 1% Missing Data    B) 2% Missing Data 
        
C) 3% Missing Data  D) 4% Missing Data E) 5% Missing Data 
 
Figure 4.7:  The X axis is the simulation run number, and the Y axis is the haplotype frequency.  
The lines are as follows:  Blue Line = Haplotype TGA, Red Line = Haplotype TGG, Green Line 
= Haplotype CAA, Purple Line = Haplotype CAG, Light Blue Line = Haplotype TAA, and the 
Orange Line = TAG. 
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With these results, the missing data results are similar to the results with no missing data for four 
of the six haplotypes.  Haplotypes CAA and TAG do have differences of at least 1% in haplotype 
frequency when they are examined with three and five percent missing data compared to the 
situation where no missing data exists.  As the percentage of missing data increases, the 95% CI 
only increases slightly in length.  This suggests the BJLM is stable for 3 SNP haplotypes when 
missing data is 5% or less. 
4.3.4.  Haplotype (12 SNP) Simulation Results 
The 12 SNP haplotype simulation results are presented in Tables 4.4 and Figures 4.8.  
Results are shown for the full set of haplotypes with frequency > 5 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Table 4.4: Summary of Simulated haplotypes of 12 SNP length.   
 
The haplotype index number is listed in the far left column, with the associated haplotype in the 
next column to the right.  The haplotype frequency assuming no missing data is listed in the 3
rd
 
column from the left, and the average frequency for each haplotype from the 100 replicates are 
listed in the column next to the no missing data column.  Finally, the 95% credible interval (CI) 
for these frequencies from the 100 replicates is listed in the final two columns.     
 
Haplotype # Haplotype No Missing 
Data 
Median 
Frequency 
2.5% 97.5% 
1% Missing SNP Data 
1 TGACCTCCATGC 0.271 0.276 0.244 0.305 
14 TGGTTTCTGTGC 0.117 0.109 0.086 0.128 
33 CAACCCCCATGC 0.069 0.078 0.059 0.096 
46 CAGTTCCTGTGC 0.067 0.068 0.050 0.087 
9 TGGCCTCCATGC 0.057 0.059 0.042 0.075 
17 TAACCCCCATGC 0.056 0.057 0.042 0.074 
2 % Missing SNP Data 
1 TGACCTCCATGC 0.271 0.267 0.239 0.295 
14 TGGTTTCTGTGC 0.117 0.112 0.095 0.129 
33 CAACCCCCATGC 0.069 0.079 0.061 0.101 
46 CAGTTCCTGTGC 0.067 0.071 0.056 0.087 
9 TGGCCTCCATGC 0.057 0.058 0.040 0.073 
17 TAACCCCCATGC 0.056 0.056 0.042 0.073 
3% Missing SNP Data 
1 TGACCTCCATGC 0.271 0.267 0.239 0.293 
14 TGGTTTCTGTGC 0.117 0.115 0.091 0.136 
33 CAACCCCCATGC 0.069 0.078 0.059 0.096 
46 CAGTTCCTGTGC 0.067 0.069 0.050 0.087 
17 TAACCCCCATGC 0.057 0.059 0.041 0.072 
9 TGGCCTCCATGC 0.056 0.056 0.043 0.074 
4% Missing SNP Data 
1 TGACCTCCATGC 0.271 0.274 0.250 0.301 
14 TGGTTTCTGTGC 0.117 0.114 0.091 0.140 
33 CAACCCCCATGC 0.069 0.080 0.065 0.100 
46 CAGTTCCTGTGC 0.067 0.067 0.051 0.091 
9 TGGCCTCCATGC 0.057 0.054 0.038 0.067 
17 TAACCCCCATGC 0.056 0.051 0.033 0.067 
5% Missing SNP Data 
1 TGACCTCCATGC 0.271 0.271 0.247 0.299 
14 TGGTTTCTGTGC 0.117 0.116 0.094 0.139 
33 CAACCCCCATGC 0.069 0.082 0.064 0.101 
46 CAGTTCCTGTGC 0.067 0.062 0.045 0.078 
9 TGGCCTCCATGC 0.057 0.055 0.039 0.071 
17 TAACCCCCATGC 0.056 0.053 0.039 0.074 
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Figure 4.8: Graphical representations of the haplotype frequency for simulations of 12 SNP 
Haplotypes 
A) 1% Missing Data     B) 2% Missing Data 
         
C) 3% Missing Data  D) 4% Missing Data E) 5% Missing Data 
 
Figure 4.8:  The X axis is the simulation run number, and the Y axis is the haplotype frequency.  
The lines are as follows:  Blue Line = Haplotype TGACCTCCATGC, Red Line = Haplotype 
TGGTTTCTGTGC, Green Line = Haplotype CAACCCCCATGC, Purple Line = Haplotype 
TGGCCTCCATGC, Light Blue Line = Haplotype CAGTTCCTGTGC, and the Orange Line = 
Haplotype TAACCCCCATGC. 
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With these results, the missing data results are similar to the results with no missing data for five 
of the six haplotypes.  Haplotype CAACCCCCATGC did have differences between% 0.9 and 
1.3% when missing data existed compared to no missing data.  As the percentage of missing data 
increases, the 95% CI only increases slightly in length.  This suggests the BJLM is stable for 12 
SNP haplotypes when missing data is 5% or less. 
4.4. BJLM Creation Conclusion and Application to Real-World Data Sets 
With the BJLM, a program which can simultaneously infer haplotypes with or without 
missing data, I can process HapMap information into many other formats used for haplotype 
analysis, and can setup haplotypes for risk model analysis has been created.  The modified 
forward-backward algorithm allows for stable estimation of haplotypes from 2 to 12 SNPs, with 
missing data up to 5%.  Therefore, assuming that the call rate of all SNPs used to infer 
haplotypes in the analysis are at least 95%, stable estimation of haplotype from 2 to 12 SNPs 
occur with the BJLM.   
In the next three chapters, the BJLM will be applied to three separate data sets.  First, the 
BJLM will be tested in a Hodgkin data set with 200 cases and 220 controls that include 62 SNPs 
derived from a candidate gene analysis
133
.  A risk model including potential haplotypes from 
these 62 SNPs and covariate information including sex, age, and smoking status will be created 
using the BJLM for the Caucasian population in the Hodgkin dataset (n = 358, 163 cases and 195 
controls).  Second, an updated Spitz lung cancer risk model will be created that will include non-
genetic risk variables from the original Spitz lung cancer risk model plus inferred haplotypes that 
include the top SNPs listed in a meta-analysis of 10 lung cancer GWAS
165
.  Finally, for the first 
time, a Glioma risk model will be created that include the top haplotypes from an inflammation 
81 
 
pathway analysis plus top SNPs from the inflammation pathway that are not in LD with any of 
the top haplotypes in the inflammation pathway. 
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Chapter 5: Application One of the BJLM:  Using Haplotype Analysis to Elucidate 
Significant Associations between Genes and Hodgkin Disease 
With increasing number of genes available for study through high throughput platforms, 
more opportunities are available to discover key associations between genetic factors and 
disease.  Candidate gene studies have successfully determined genetic associations for risk in 
diseases and possible therapeutic targets, thus highlighting the continuing importance of 
candidate gene analysis.  In this study, the association between the inferred haplotypes in the 
inflammation (IL1B, IL4, IL4R, IL10), DNA repair (MGMT, XPC) and folate (MTHFR) 
pathways and overall risk of Hodgkin lymphoma were estimated.  Genetic and epidemiological 
data was obtained from a Hodgkin lymphoma cohort conducted at The University of Texas MD 
Anderson Cancer Center between 1987 and 1992 consisting of 200 cases and 220 controls 
matched by age, gender, and race/ethnicity.  
5.1.  Introduction to Hodgkin Disease 
In 2010, approximately 8,490 individuals were diagnosed in the United States (US) with 
Hodgkin lymphoma (HL) with about 1320 deaths
166
. Incidence of HL increases to 4 cases per 
100,000 in individuals between the ages of 20 and 30, decreases slightly through ages 40 and 60, 
and then increases again to 4 cases per 100,000 individuals between the ages of 70 and 80
167,168
.  
Evidence suggests that genetic factors could be responsible for both the peak in incidence for 
young adults and also the peak in older adults
133,169,170
.   
Epidemiological studies have shown associations between genetic polymorphisms in 
genes and cancer risk
171-174
, and hundreds of single nucleotide polymorphisms (SNPs) in 
multiple pathways have been identified.  Several studies have suggested that many of these 
polymorphisms result
 
in amino acid substitutions which may alter wild-type protein function and 
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lead to substantial changes in protein levels, thereby contributing to cancer susceptibility.  This is 
especially true with modifications in the DNA repair, folate, and inflammation pathways
49,50,175-
183,
. However, the single-SNP based strategy, in which each SNP is analyzed individually, may 
be insufficient to explain the risk of developing cancer, as complex diseases most likely result 
from genetic variants in multiple genes in different pathways. Recently, in accordance with this 
hypothesis, several studies have shown that epistatic interactions of multiple SNPs are necessary 
to contribute to cancer susceptibility
184-187
. 
Haplotype analysis is the study of a pattern of descent of a set of linked alleles occurring 
on the same chromosome. Several programs that infer haplotypes are Haploview
56
, PHASE
55,61
, 
and Haplo.stats
62
.  Haplo.stats also uses a joint-effects logistic model to estimate an odds ratio 
for the association between either a haplotype or a covariate with disease.  In a joint-effects 
model, each haplotype is compared to the most frequent haplotype under the assumption that the 
most frequent haplotype represents the “normal” haplotype status61.  In two previous studies, it 
has been shown using logistic regression analysis that variants among SNPs and combinations of 
haplotypes containing two SNPs can modulate HL risk
133,188,189
.  For this study, it is 
hypothesized that gene-gene interactions between candidate SNPs in
 
the DNA repair (MGMT, 
XPC), folate pathways (MTHFR), and inflammation (IL1B, IL4, IL4R, IL10) may contribute to 
HL susceptibility.  To test this hypothesis, haplotype analysis was used to discover sets of linked 
SNPs that could potentially elucidate the association of multiple polymorphisms in these three 
pathways and the risk of HL.  Also, the BJLM from Chapter 4 was incorporated to develop an 
experimental risk model from the non-Hispanic Caucasian section of the Hodgkin dataset. 
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5.2.  Materials and Methods in Hodgkin Disease Study 
5.2.1. Study Population for Hodgkin Disease Study 
Details of the study population were published elsewhere
133
.  Briefly, the study included 
200 histological confirmed adult cases registered at the University of Texas MD Anderson 
Cancer Center and 220 frequency matched controls with respect to age- (± 5 years), sex-, and 
race/ethnicity. Interviews were conducted by trained interviewers and demographic and clinical 
characteristics included: age at diagnosis, sex, race/ethnicity, family history of cancer, HL 
histological subtypes, disease stage and presence of B symptoms. Demographic analysis showed 
that controls were on average two years older than cases, and the majority of the participants 
were male (54.8%), and the vast majority of participants (85.2%) were non-Hispanic whites
133
.  
For non-Hispanic whites, 163 out of the 358 individuals were cases (45.5%), while for those who 
were not non-Hispanic whites, 37 out of the 62 individuals were cases (59.7%).  Fifty two 
percent (52%) of the cases (N=103) were diagnosed with stage II HL and 14% of the cases 
(N=27) were diagnosed with Stage IV HL
133
. The institutional review board at the University of 
Texas MD Anderson Cancer Center approved the study. 
5.2.2. SNP Selection for Hodgkin Disease Study 
Sixty-two SNPs in DNA repair, inflammation, and folate pathway genes were genotyped 
using Taq-Man-based methods as detailed elsewhere
133
.  The location (chromosome and base-
pair information), and the reference SNP (rs) number for each SNP in this study is listed in Table 
16.  For quality control and to ensure proper genotyping of samples, 5% of all samples were 
selected randomly for repeat analysis. 
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Table 5.1: Location and rs number for each Single Nucleotide Polymorphism.   
 
This table contains the genetic information of all 62 SNPs in this study 
 
Gene Rs 
number 
Chm. Base pair 
location 
Gene Rs number Chm. Base pair 
location 
MTHFR rs1801131 1 11788742 IL6 rs1800796 7 22539486 
MTHFR rs1801133 1 11790644 IL6 rs1800795 7 22539885 
COX2 rs20417 1 183381978 PolB rs3136794 8 42345711 
IL10 rs1800872 1 203334802 NBN rs1805794 8 91059655 
IL10 rs1800871 1 203335029 TLR4 rs2737191 9 117542269 
IL10 rs1800896 1 203335292 TLR4 rs12377632 9 117552284 
PARP1 rs1136410 1 222862037 TLR4 rs1554973 9 117560366 
MTR rs1805087 1 233374541 MGMT rs12917 10 131396273 
IL1B rs1143634 2 113306621 MGMT rs2308321 10 131455054 
IL1B rs1143627 2 113310618 MGMT rs2308327 10 131455160 
IL1B rs16944 2 113311098 MS4A2 rs535630 11 59618108 
OGG1 rs1052133 3 9773773 MS4A2 rs569108 11 59619680 
PPARG rs1801282 3 12368125 IL18 rs187238 11 111540198 
XPC rs2228001 3 14162450 XPG rs17655 13 102326003 
XPC rs2228000 3 14174889 APEX1 rs3136819 14 19994929 
IL8 rs4073 4 74971059 XRCC1 rs861539 14 103235506 
NFKB1 rs1020759 4 103867704 IL4R rs1805011 16 27281373 
IL2 rs2069762 4 123735585 IL4R rs1805012 16 27281465 
TLR3 rs3775291 4 187379223 IL4R rs1805015 16 27281691 
MTRR rs1801394 5 7923973 IL4R rs1801275 16 27281901 
CCNH rs2266690 5 86731030 IL4R rs1805016 16 27282428 
IL13 rs1800925 5 132020708 XRCC3 rs25487 19 48747566 
IL13 rs20541 5 132023863 XRCC1 rs1799782 19 48749414 
IL4 rs2243250 5 132037053 XPD rs13181 19 50546759 
IL4 rs2070874 5 132037609 XPD rs238406 19 50560149 
TNF rs1799964 6 31650287 ERCC1 rs3212986 19 50604576 
TNF rs1800630 6 31650455 LIG1 rs20580 19 53346365 
TNF rs1799724 6 31650461 LIG1 rs20579 19 53360642 
TNF rs1800629 6 31651010 TLR rs179008 23 12663316 
TNF rs361525 6 31651080 TLR8 rs5744077 23 12696844 
IL6 rs1800797 7 22539461 TLR4 rs2179356 23 141783842 
 
5.2.3. Haplotype Analysis for Hodgkin Disease Study 
 Inferred haplotype construction was completed using Haploview
56
.  Gold plots were 
constructed based on the SNPs for each gene and those SNPs with strong linkage disequilibrium 
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(LD), as determined by the confidence interval method. This method states that a block of SNPs 
are significant if 95% of all informative comparisons of the SNPs in questions show strong LD
53
.  
The PHASE package was used to compare frequencies of inferred haplotypes between cases and 
controls with significance determined by the method of Li and Stephens
190
.   
To determine whether the haplotypes inferred from each linked gene showed significant 
association for HL, these haplotypes were modeled accounting for age, sex, race/ethnicity, and 
smoking status with the Haplo.stats program incorporated into the software environment R
62,63
.  
The haplotype analyses were based on the regression-based method for binary (case-control) 
responses as described by Schaid et al. 2002
62
 and Lake et al. 2003
63
.  Haplotypes larger than a 
frequency of 0.05 were included in the analyses.  For each chromosome and linked gene, the 
joint-effects model was developed in which each haplotype is compared to the most frequent 
haplotype (which was used as the reference group)
62,63
. Analyses were conducted on these linked 
genes assuming both additive and genetic effects. 
5.2.4. Developing an Experimental Risk Model with the BJLM 
As a parallel analysis to the haplotype analysis conducted in section 5.2.3, haplotype 
models were developed to determine the effectiveness of combining the significant haplotypes 
from section 5.2.3 into multivariate logistic models.  Haplotypes were inferred using both the 
BJLM and haplo.stats, and the effectiveness of these genetic models created with haplotypes 
from these two programs will be compared to each other.  For haplo.stats, the haplotype results 
are collected from the program, and a risk model is created using multivariate logistic regression 
in SPSS.   
For analysis with the BJLM, the prior information was obtained by determining the 
counts of all possible haplotypes inferred with HapMap data
 137-140
.  These counts were then 
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incorporated into the inferring of haplotypes from the Hodgkin disease dataset.  Two hundred 
burn-in runs of the BJLM were conducted to remove haplotypes with no counts in the Hodgkin 
disease dataset.  Then, 900 runs of the BJLM were incorporated to extract the relevant haplotype 
information for each individual in the study.  Haplotype frequencies for each haplotype block, 
except for the most frequent haplotype, was saved and then presented to WINBUGS (version 
1.4.3) for further analysis.  Sample code for WINBUGS is shown below in Figure 5.1: 
 
Figure 5.1: Sample Code for WINBUGS for conducting Haplotype Analysis 
model 
{ 
for( i in 1 : N )  
{ 
casecntl[i] ~ dbin(p[i],1) 
logit(p[i]) <- alpha +beta1*Haplo2[i]  
}     
  # Priors for logit model 
  alpha ~ dnorm(0.0,1.0E-2) 
  beta1 ~ dnorm(0.0,1.0E-2) 
  # Determine p-value in Bayesian Context 
  beta1pabove <- step(beta1-0) 
  beta1pbelow <- 1-step(beta1-0) 
} 
 
Figure 5.1: With this code, the case/control status was modeled as a binomial variable with 
size one, and the logit function contained all haplotypes that were being compared to the most 
frequent haplotype.   For the prior information in dealing with the effects of each haplotypes, all 
alphas and betas were modeled as normal distribution with mean zero and variance 100, hence 
leading to non-informative priors.  Also, the frequencies of beta being above and below zero are 
calculated with the step functions, and this leads to an empirical p-value which is two times the 
minimum frequency among beta being above or below zero.   
 
This analysis is conducted for all three genetic models for each haplotype block, and 
haplotype results are collected after 50,000 iterations of the WINBUGS code (1
st
 5000 iterations 
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are burn-in, and are not counted in the analysis).  All haplotypes with empirical p-values less 
than 0.05 are presented for future analysis.   
When examining the genetic model for each haplotype whether using the Haplo.stats or 
the BJLM, the most significant haplotype out of the additive and dominant genetic models are 
selected for multivariate logistic regression analysis.  For haplotypes constructed in Haplo.stats, 
multivariate logistic regression analysis is conducted with SPSS, and for haplotypes constructed 
in the BJLM, WINBUGS is then used again with the same construction as in Figure 6.2.  Finally, 
the discriminatory power for both haplotype models are calculated in SPSS using the relative risk 
profiles calculated by the multivariate logistic risk models developed in either SPSS (frequentist) 
using haplotypes inferred from haplo.stats or the haplotypes inferred by the BJLM (Bayesian). 
To remove possible confounding by race, all non-Caucasians were removed from the 
analysis, and also to examine more rare haplotypes, all haplotypes were examined that had 
frequencies of at 1%.  This led to an analysis with 358 individuals, with 163 cases and 195 
controls, and models will be developed from SNPs from both significant SNPs and significant 
haplotypes, assuming additive and dominant genetic effects.  These haplotypes will also be 
modeled in the presence of the three matching risk variables in this study: Age, Sex, and 
Smoking Status.  Due to the small sample size, recessive genetic effects will not be modeled. 
5.3. Hodgkin Disease Results 
5.3.1. Haplotypes and Haplotype Frequencies for Hodgkin Cases and Controls  
Comparisons of haplotype frequencies are summarized in Table 5.2.   
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Table 5.2:  Estimated frequencies for haplotypes on chromosomes 1-3, 5-7, 10, 16, and 19.  
 
Gene (Chr) SNPs bp Haplo. Haplotype 
Frequency: 
Cases (%) 
Haplotype 
Frequency: 
Controls (%) 
p-value 
MTHFR (1) rs1801131 
rs1801133 
11788742 
11790644 
AC 
AT 
CC 
43.38 
30.80 
25.66 
37.05 
32.63 
29.65 
 
0.09 
IL10 (1) rs1800872 
rs1800871 
rs1800896 
203334802 
203335029 
203335292 
ACA 
ACG 
CTA 
31.38 
41.75 
26.37 
30.46 
44.09 
25.45 
 
0.38 
IL1B (2) rs1143627 
rs16944 
113310618 
113311098 
CT 
TC 
36.16 
62.79 
36.12 
62.88 
 
0.99 
XPC (3) rs2228001 
rs2228000 
14162450 
14174889 
CC 
CT 
AC 
34.11 
27.38 
38.49 
37.20 
20.76 
42.04 
 
0.08 
IL4 (5) rs2243250 
rs2070874 
132037053 
132037609 
CC 
TT 
82.50 
14.50 
79.08 
16.82 
 
0.45 
MGMT 
(10) 
rs2308321 
rs2308327 
131455054 
131455160 
AA 
GG 
89.50 
10.50 
90.45 
9.55 
 
0.61 
IL4R (16) rs1805012 
rs1805015 
27281465 
27281681 
TT 
TC 
CC 
85.85 
5.82 
8.33 
82.02 
8.89 
9.09 
 
0.21 
IL4R (16) rs1801275 
rs1805016 
27281901 
27282428 
AT 
AG 
GT 
14.53 
5.56 
79.90 
17.82 
8.18 
74.00 
 
0.09 
Chr = Chromosome 
bp = base pair location 
  Haplo = Haplotypes 
  Haplotypes with frequencies greater that 0.05 are shown.   
 
Only three inferred haplotypes resulted in significance at the 10% level, namely, the 
MTHFR haplotype (rs1801131 and rs1801133) on chromosome 1 (p = 0.09), the XPC haplotype 
(rs2228001 and rs2228000) on chromosome 3 (p=0.08), and a haplotype with the IL4R gene 
(rs1801275 and rs1805016) on chromosome 16 (p=0.09).  On chromosome 1, the largest 
differences in haplotype frequency between cases and controls were observed with haplotype 
AC; on chromosome 3, the largest differences in frequency were observed with haplotype CT; 
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and haplotype GT on chromosome 16.  Figure 5.2 shows the haplotypes on chromosomes 1 and 
16, as determined by the gold plot. 
 
Figure 5.2: Chromosome 1 and Chromosome 16 Gold Plots from Hodgkin Study 
A) Gold Plot for SNPs on Chromosome 1   B) Gold Plot for SNPs on Chromosome 16 
       
 
Figure 5.2: Gold Plots constructed from Single Nucleotide Polymorphisms on Chromosome 1 
(1a) and Chromosome 16 (1b).  The rs numbers for each SNP are listed at the top of each figure, 
and those SNPs bolded are the SNPs which forms a haplotype.  Haplotypes are constructed with 
the Gabriel method, and are shown as blocks on the gold plot with the length of these haplotypes 
in kilobases.  Diamond values represent the D’ for the 2 SNPs being examined.  For example, the 
D’ value for SNPs rs1801131 and rs1801133 is 0.95. 
 
For example, using the SNPs on chromosome 1 that were genotyped in association with 
this HL study, the first two SNPs, and the 4
th
 through 6
th
 SNPs are linked together in separate 
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blocks.  For the XPD gene, SNPs were not linked strongly enough according to the Gabriel 
confidence interval method
53
 to conduct haplotype analysis. 
 5.3.2.  Determining Associations between Haplotypes and Hodgkin Disease 
Associations between inferred haplotypes for each set of linked SNPs and HL are 
summarized in Table 5.3 assuming both additive and dominant genetic effects.  
 
Table 5.3: Determining associations between haplotypes and HL using the joint effect 
logistic model controlling for age, sex, race, and smoking status 
 
 Genetic Effects 
Additive Dominant 
Gene 
(Chromosome) 
Haplotype OR (95% CI) p-value OR (95% CI) p-value 
MTHFR (1) AC 
AT 
CC 
1.00 
0.87(0.64-1.20) 
0.73(0.52-1.04) 
NA 
0.414 
0.079 
1.00 
0.78(0.51-1.20) 
0.80(0.53-1.22) 
NA 
0.226 
0.300 
IL10 (1) ACA 
ACG 
CTA 
1.09(0.77-1.54) 
1.00 
1.08(0.76-1.52) 
0.617 
NA 
0.675 
1.20(0.79-1.82) 
1.00 
1.10(0.73-1.66) 
0.385 
NA 
0.643 
IL1B (2) CT 
TC 
1.00 (0.76-1.32) 
1.00 
0.992 
NA 
0.97(0.65-1.45) 
1.00 
0.879 
NA 
XPC (3) CC 
CT 
AC 
0.98(0.72-1.32) 
1.49(1.03-2.16)
 
1.00 
0.873 
0.037 
NA 
0.91(0.60-1.38) 
1.75(1.15-2.65)
 
1.00 
0.671 
0.009 
NA 
IL4 (5) CC 
TT 
1.00 
0.80(0.55-1.16) 
NA 
0.244 
1.00 
0.83(0.54-1.30) 
NA 
0.422 
MGMT (10) AA 
GG 
1.00 
1.19(0.75-1.89) 
NA 
0.448 
1.00 
1.14(0.69-1.87)  
NA 
0.607 
IL4R (16) TT 
TC 
CC 
1.00 
0.63(0.34-1.00)
 
0.93(0.57-1.51) 
NA 
0.052 
0.757 
1.00 
0.48(0.26-0.88)
 
0.88(0.52-1.50) 
NA 
0.017 
0.647 
IL4R (16) AT 
AG 
GT 
0.72(0.50-1.05) 
0.57(0.33-0.99)
 
1.00 
0.085 
0.045 
NA 
0.70(0.46-1.09) 
0.58(0.32-1.06) 
1.00 
0.117 
0.076 
NA 
NA = Not Applicable 
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Significant associations (p<0.05) were observed on chromosomes 3 and 16, and 
borderline significant associations (p<0.10) were observed on chromosomes 1 and 16.  A 
significantly increased risk of HL was observed with haplotype CT, inferred from SNPs 
rs2228001 and rs2228000 on the XPC gene, assuming either dominant genetic effects (OR = 
1.75, 95% CI = 1.15-2.65, p-value = 0.009) or additive genetic effects (OR = 1.49, 95% CI = 
1.03-2.16, p-value = 0.037).  A significant protective association between inferred haplotypes 
and HL was calculated for chromosome 16 with haplotype TC, inferred from SNPs rs1805012 
and rs1805015 on the IL4R gene, assuming dominant genetic effects (OR = 0.48, 95% CI = 
0.26-0.88, p-value = 0.017). However with this same haplotype, the protective association was 
borderline significant when assuming additive genetic effects (OR = 0.63, 95% CI = 0.34-1.00, 
p-value = 0.052).  Another protective association was calculated with haplotype AG from the 
IL4R gene, inferred from SNPs rs1801275 and rs1805016, assuming additive genetic effects (OR 
= 0.57, 95% CI = 0.33-0.99, p-value = 0.045) but the protective association was only borderline 
significant when assuming dominant genetic effects (OR = 0.58, 95% CI = 0.32-1.06, p-value = 
0.076).  Another borderline protective haplotype was calculated with haplotype CC from the 
MTHFR gene, inferred from SNPs rs1801131 and rs1801133, assuming additive genetic effects 
(OR = 0.73, 95% CI = 0.52-1.04) and no association was found assuming dominant genetic 
effects. 
5.3.3. Incorporation of the BJLM for Hodgkin Disease Study 
Both haplo.stats and the BJLM resulted in four haplotypes that showed some significance 
(p < 0.20) with Hodgkin disease in a multivariable logistic model assuming additive genetic 
effects, and these results are listed in Table 5.4. 
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Table 5.4:  Haplotype model results using haplotypes inferred with both haplo.stats and 
BJLM assuming an additive genetic model 
 
For the analysis with the BJLM, an empirical p-value is estimated using the WINBUGS code 
from Figure 5.1 
 
 Genetic Model Program 
Haplo.stats BJLM 
Gene 
(Chromosome) 
Haplotype OR (95% 
Confidence 
Interval) 
p-value OR (95% 
Credible Interval) 
p-value 
XPC (3) CT 1.33 (0.92-1.94)
 
0.134 1.41 (0.93-2.15)
 
0.107 
IL4 (5) TC 10.8 (1.98-58.3) 0.006  17.4 (3.18-145.2) 0.001 
IL4R (16) TT 1.93 (0.86-4.34) 0.111 2.19 (0.93-5.36) 0.073 
IL4R (16) AT 0.50 (0.27-0.95) 0.035 0.43 (0.20-0.88) 0.019 
 
Using these four haplotypes inferred from the BJLM, results for CT haplotype from the 
XPC gene, the TC haplotype from the IL4 gene, the CC haplotype on the 1
st
 haplotype block 
from the IL4R gene, and the AT haplotype from the 2
nd
 haplotype block from the IL4R gene all 
had odds ratios that were further away from one, and also had more significant p-values. 
However, when comparing these models against each other, the genetic model with haplotypes 
inferred from haplo.stats (AUC = 0.632, 95% CI = 0.567-0.690) and the genetic model with 
haplotypes inferred from the BJLM (AUC = 0.634, 95% CI = 0.569-0.691) are not significantly 
different in discriminatory power (p-value = 0.1562). 
  Both haplo.stats and the BJLM resulted in four haplotypes that showed some 
significance (p < 0.20) with Hodgkin disease in a multivariable logistic model assuming 
dominant genetic effects, and these results are listed in Table 5.5. 
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Table 5.5:  Estimation of Odds Ratios for haplotypes using both haplo.stats and the BJLM 
For the analysis with the BJLM, an empirical p-value is estimated using the WINBUGS code 
from Figure 5.1 
 
Gene  
(Chr) 
SNPs Haplo. Haplo.stats  
OR (95%  
Confidence Interval)  
BJLM 
OR (95% Credible 
Interval)  
XPC (3) rs2228001 
rs2228000  
CT  1.51 (0.97-2.36) 
p-value = 0.069 
1.50 (0.95-2.33) 
p-value = 0.061  
IL4 (5) rs2243250 
rs2070874  
TC  9.24 (1.81-47.2) 
p-value = 0.008  
12.16 (2.47-90.1) 
p-value =  0.00044  
IL4R (16) rs1805012 
rs1805015  
CC  1.94 (0.79-4.76) 
p-value = 0.149 
2.05 (0.84-5.18) 
p-value = 0.118  
IL4R (16) rs1801275 
rs8105016  
AT  0.46 (0.21-0.98) 
p-value = 0.044  
0.43 (0.19-0.90) 
p-value = 0.028  
 
 Just like with the additive genetic effects, the BJLM showed a much stronger association 
for the TC haplotype on the IL4 gene, although with the dominant effects, the association was 
almost identical for the CT haplotype on the XPC gene when either haplo.stats or the BJLM are 
used to infer haplotypes.  When examining the discriminatory power of genetic models inferred 
using dominant genetic effects, the genetic model with haplotypes inferred from haplo.stats 
(AUC = 0.643, 95% CI = 0.580-0.699) and the genetic model with haplotypes inferred from the 
BJLM (AUC = 0.644, 95% CI = 0.581-0.699) did not have significantly different results          
(p-value = 0.3477).     
5.4. Hodgkin Disease Study Discussion 
The purpose of this study was to use haplotype analysis to elucidate associations in HL 
that could not be obtained solely with single SNP based strategies.  Although differences in 
frequency between case and control haplotypes were only borderline significant in the overall 
HL set (i.e., MTHFR gene on chromosome 1, XPC gene on chromosome 3, and IL4R gene on 
chromosome 16), there were some haplotypes which showed either susceptibility to HL 
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development or protection from HL development.  Two sets of linked SNPs on IL4R: rs1805012 
and rs1805015, as well as rs1801275 and rs1805016, showed significant protective associations. 
A set of linked SNPs on XPC from chromosome 3 (rs2228001 and rs2228000) showed strong 
associations with HL.  When attempting to develop risk models for the study of Hodgkin disease, 
the BJLM with the Hodgkin data did estimate stronger associations with more significant p-
values compared to the haplo.stats inferred haplotypes for individual haplotypes.  But, when the 
haplotypes were combined to form full genetic models, models with haplotypes inferred with the 
BJLM did not perform significantly better than models with haplotypes inferred with haplo.stats 
even though the discriminatory power was slightly higher with BJLM inferred haplotype models.  
In previous studies, variant alleles on the MTHFR gene have been shown to be protective 
for non HL risk
49
 and relapse cancer events when both variant alleles are present for MTHFR 
677 C>T SNP (rs1801133) and the MTHFR 1298 A>C SNP (rs1801131)
191
.  These variant 
alleles result in decreased MTHFR gene activity, which leads to rises in methyl donors that limit 
possible breaks in cell mitosis, and possible cancer proliferation
191
.  A variation of genes that 
catalyze the conversion of 5-10-methyl-tetrahydrofolate (THF) into 5-methyl-THF, the more 
commonly circulated form of folate throughout the body, was shown to affect the risk of non-HL 
development
144
.  Further the alteration of the Methylenetetrahydrofolate reductase (MTHFR) 
gene has been shown to decrease in the enzyme needed to catalyze the conversion into the more 
common form of folate by 30 to 60 percent
192,193
.  In this study, the decrease in risk of HL was 
only borderline significant in the presence of haplotypes inferred from these two SNPs for both 
differences in haplotype frequency while assuming an additive genetic mode, but when assuming 
a dominant genetic model, the effect of MTHFR is minimal.  For non-Hodgkin lymphoma, the 
effect of folate has been studied extensively, and the results have been mixed
194,195
.  More studies 
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will be needed to elucidate the relationship between genes that regulate folate, and Hodgkin 
lymphoma. 
SNPs in DNA repair genes, such as XPC and XPD genes, have been linked to many 
cancers
133,196,197
.  DNA damage and subsequent repair are critical for maintaining genomic 
integrity and stability.  Modifications with SNPs in DNA repair genes may modulate the DNA 
repair phenotype, particularly when these SNPs are located within coding or regulating regions, 
leading to alterations in protein expression and in functional properties of repair enzymes
176,177
.  
In our study, study subjects with both variant alleles for the XPC haplotype had an increased risk 
for HL with the joint effect haplotype model.  Interestingly enough, haplotypes with only the 1
st
 
XPC SNP as a variant allele showed little association with HL, but the combination of the 2
nd
 
variant allele with the 2
nd
 XPC SNP caused an increase in the cancer risk.  This finding also 
highlights the importance of haplotype analysis.  If only the SNP rs2228001 would have been 
tested, the association between DNA damage modification on the XPC gene and HL would have 
been missed.    
In a hospital-based case control study of 322 lung cancer patients and 326 healthy 
controls conducted in a Chinese population, haplotypes of XPC genes consisting of variant 
alleles of SNPs rs2228001 (XPC 499 A>C) and rs2228000 (XPC 939 C>T) showed an increased 
risk associated with lung cancer, especially haplotype CT (OR = 2.37, 95% CI = 1.33-4.21)
198
.  
Increased susceptibility of cancer in the presence of variant alleles associated with the XPC gene 
are due to decreased DNA repair capacity, possibly resulting from a transfer in amino acid 
production from lysine to glutamine
197-199
.   
In chronic inflammation, the cell death process is stopped, and cell growth is 
uncontrolled
178
.  With HL, the inflammatory response is initiated by the presence of the 
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malignant Hodgkin and Reed Sternberg cells
179
 and is characterized by the massive presence of 
reactive inflammatory cells in response to the malignant Hodgkin and Reed Sternberg cells, thus 
99% of the tumor mass consists of the inflammatory cells
182,183
.  Inflammation genes have been 
strongly associated with cancer, including stomach, breast, and HL
178-181,188
. In this study, 
haplotypes consisting of variant alleles from SNP rs1801275 and SNP rs1805016 from gene 
IL4R gene show decreased risk of HL.  A plausible explanation for these results is that 
interleukin 4 receptors, IL4Rα and IL-13Rα1, are expressed in Hodgkin tumor cells200,201.  
Therefore the common polymorphisms in promoter regions of genes related to the pro- and anti-
inflammatory response may contribute to susceptibility to HL and serve as plausible candidates 
for further study.   
One of the study limitations is the relatively small sample size, with 420 individuals 
available for analysis.  Despite the small sample size, this study demonstrated the use of 
haplotype analysis to analyze the effects of linked SNPs associated with HL.  Larger studies are 
warranted to further elucidate our results.  In conclusion, the interactions between specific SNPs 
in both the inflammation and the DNA repair pathway have been shown to play an important role 
in possible HL development.  Haplotype analysis may be useful to detect interactions that could 
not be detected through single SNP analyses, and this will be further studied using the BJLM in 
the next two chapters. 
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Chapter 6:  Application Two of the BJLM:  Elucidating Significant Haplotype Associations 
between Genes and Lung Cancer 
6.1. Introduction to Expanding Spitz Lung Cancer Risk Model with Haplotypes 
 In Chapter 3, the first attempt at extending the Spitz model with haplotypes was 
conducted using areas from chromosome 15 (rs8034191 and rs1051730) and chromosome 5 
(rs2736100 and rs401681).  This model did improve discriminatory power with the risk model 
substantially (p < 0.001) in a subset of 2253 individuals (1118 cases/1135 controls) from 0.659 
(95% CI = 0.636-0.681) in the original Spitz model to 0.675 (95% CI = 0.653-0.697), and this 
increase is significant (p = 0.003).  Also, the new model has much better ability to classify 
case/control status in all individuals compared to the original Spitz model according to the NRI 
value, (0.254, p-value = < 0.001).  This NRI increase is more prevalent with true cases (NRI = 
0.349, p-value = < 0.001), compared to controls (NRI = -0.094, p-value = 0.001).  However, 
when this risk model was compared to a risk model with 3 SNPs (rs2736100, rs401681, and 
rs1051730) this model and the haplotype model were similar in discriminatory power (0.675 for 
three SNP vs. 0.676 for haplotype) and the improvement in the NRI compared to the Original 
Spitz model was superior for the 3 SNP model (NRI = 0.268, p-value = < 0.001) compared to the 
improvement with the haplotype model.  These results strongly suggest that haplotypes need to 
be selected more carefully to fully extract their potential to improve discriminatory power. 
 In 2009, the NCI conducted an extensive lung GWAS with 5,739 lung cancer cases and 
5848 controls to examine specific SNPs that could be associated with specific histology’s of lung 
cancer
165,202-205
.  They also conducted a meta-analysis from ten additional lung GWAS, which 
included the Texas lung GWAS
45
, and this added 7561 cases and 13818 controls to the analysis.  
With a fixed effect model
206
, the estimates for per-allele odds ratios and their standard error was 
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determined with the meta-analysis, and the top 200 SNPs with the lowest p-values were 
summarized in a supplementary table.  The SNPs available in the Texas lung GWAS that match 
the top 200 SNPs from the meta-analysis will be tested to see if these SNPs can form haplotypes 
from each other, and whether a better Spitz risk model with haplotypes can be constructed. 
6.2.   Methods to Conduct Expansion of Spitz Model with Top SNPs from Lung meta-
analysis 
6.2.1. Study Population and Selection of SNPs for Expansion of Spitz Model with 
Haplotypes 
A total of 2291 lung cancer patients and controls from the original Spitz lung cancer 
study and also the Texas Lung Cancer GWAS were accrued for this study
27,45
.  Lung cancer 
patients (N=1154) were enrolled from the Thoracic Center at the University of Texas MD 
Anderson Cancer Center starting in July of 1995 and ending in May 2006
27
.  All lung cancers 
were histologically confirmed, were newly diagnosed, and had no treatment (chemo or radiation) 
for lung cancer
27
.  Controls (N=1137) were recruited from the Kelsey-Seybold clinics, and these 
individuals were lung cancer-free individuals with no prior history of cancer (except for 
nonmelanoma skin cancer).  These controls were frequency matched by age (±5 years), sex, 
ethnicity, and smoking status
27
.  The risk factors in the original Spitz study are listed in Table 
2.1 in Chapter 2 on page 27.  Only ever smokers (individuals that have only smoked > 100 
cigarettes in their lifetimes) are included in this analysis.  All cases (N = 1154) and controls (N = 
1137) were genotyped with the Illumina HumanHap300 v.1.1 BeadChips, and 317,498 tagSNPs 
were obtained for potential analysis
45
. These SNPs were then matched with a list of 200 top 
SNPs from the lung GWAS meta-analysis paper
165
, and 157 top SNPs from the meta-analysis 
paper exist in the Texas lung GWAS study from MD Anderson. 
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6.2.2.  Selecting the Haplotype Blocks for Future Analysis 
To extract the potential haplotype blocks, chromosome and base pair information for all 
157 SNPs was extracted from Supplemental Table 2 in the Lung Cancer Meta-Analysis
45
.  For 
these 157 SNPs, all SNPs were loaded into Haploview
56
 using data from the Texas Lung GWAS 
to determine the potential haplotypes that could be examined for addition into the Spitz model.   
An example of the potential haplotype blocks from Chromosome 15 to be examined in the 
extension of the Spitz lung cancer risk model was shown in Figure 6.1. 
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Figure 6.1:  Haploview Gold Plot showing two haplotype blocks from Texas Lung GWAS 
data that contains SNPs within the top 200 SNP list from the lung cancer GWAS meta-
analysis 
 
 
Figure 6.1:  This section of SNPs from chromosome 15 encompasses two haplotype blocks that 
is inferred from 4 SNPs (rs4887053, rs1339471, rs12903150, and rs10519198) and 5 SNPs 
(rs3885951, rs2036534, rs6495306, rs680244, and rs1051730) respectively, and these haplotype 
block was formed with the Gabriel’s et.al.53 confidence interval method.  These haplotype blocks 
contain haplotypes that could be used to extend the Spitz lung cancer risk model in former 
smokers and ever smokers respectively.   
 
From these 157 SNPs, 20 haplotype blocks were formed that contained a combined 55 SNPs, 
and the information for these blocks and SNPs are listed in Table 6.1.   
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Table 6.1:  Chromosome and Base-Pair Information for all SNPs included in the expansion 
of the Spitz Model.   
These SNPs will form 9 haplotype blocks that will be used to extract potential haplotypes for use 
in the genetic section of the updated Spitz model  
 
Haplotype  
Block 
Rs Number Chromosome Base-pair Used for Model 
1 rs4635969 5 1361552 Former, Current 
rs4975616 5 1368660 
2 rs2256543 6 30045812 Former, Current 
rs2523946 6 30049922 
3 rs2844773 6 30315474 Former, Current 
rs3094073 6 30339203 
rs3130380 6 30387109 
rs3130350 6 30435818 
4 rs3132610 6 30652380 Current 
rs9262143 6 30760760 
rs3094127 6 30805426 
rs2535319 6 30822458 
5 rs4887053 15 76499754 Former, Current 
rs1394371 15 76511524 
rs12903150 15 76511700 
rs10519198 15 76529809 
6 rs3885951 15 76612972 Former, Current 
rs2036534 15 76614003 
rs6495306 15 76652948 
rs680244 15 76658343 
rs1051730 15 76681394 
7 rs6495309 15 76702300 Former, Current 
rs1948 15 76704454 
8 rs12594247 15 76733688 Current 
rs6495314 15 76747584 
rs8038920 15 76761600 
rs11638372 15 76770614 
9 rs2277547 15 76869486 Current 
rs3743057 15 76876062 
 
These 9 haplotype blocks were then further analyzed with both Haplo.stats
62
 and the BJLM 
(from Chapter 4).  Haplo.stats allows for the estimation of odds ratios to represent the association 
between either a haplotype or a covariate and disease with the use of a joint-effect linear model 
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developed by the Lake group in which each haplotype is compared to the most frequent 
haplotype
62,63.  With the assumption that the most frequent haplotype represents the “normal” 
haplotype status, one can examine whether variant haplotypes are associated with disease.  This 
analysis is conducted for all three genetic models for each haplotype block.  All haplotypes with 
empirical p-values less than 0.05 and are the most significant assuming additive, dominant, or 
genetic effects in each haplotype block are presented for future analysis.   
 For analysis with the BJLM, the same procedure as listed in Chapter 5 is conducted, but 
briefly, the prior information was obtained by determining the counts of all possible haplotypes 
inferred with HapMap data
 137-140
.  These counts were then incorporated into the inferring of 
haplotypes from the Texas Lung GWAS dataset.  Two hundred burn-in runs of the BJLM were 
conducted to remove haplotypes with no counts in the Texas Lung GWAS dataset.  Then, 900 
runs of the BJLM were incorporated to extract the relevant haplotype information for each 
individual in the study.  Haplotype frequencies for each haplotype block, except for the most 
frequent haplotype, was saved and then presented to WINBUGS (version 1.4.3) for further 
analysis.  Sample code for WINBUGS is shown in Figure 5.1.  This analysis is conducted for all 
three genetic models for each haplotype block, and haplotype results are collected after 50,000 
iterations of the WINBUGS code (1
st
 5000 iterations are burn-in, and are not counted in the 
analysis).  All haplotypes with empirical p-values less than 0.05 and are the most significant 
among the three risk models in each haplotype block are presented for future analysis.   
When developing updated Spitz lung cancer risk models that incorporate haplotypes, the 
most significant haplotype that was modeled assuming additive, dominant, or recessive genetic 
traits were selected for multivariate logistic regression analysis.  These haplotypes are added to 
the original Spitz lung cancer risk variables for both former and current smokers, and those 
104 
 
haplotypes with p-values less than 0.05 are added to the Spitz models. For haplotypes 
constructed in Haplo.stats, multivariate logistic regression analysis with the original Spitz 
variables is conducted with SPSS, and for haplotypes constructed in the BJLM, WINBUGS is 
then used again with the construction listed below (Figure 6.2): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
Figure 6.2:  Example WinBugs Code for the Development of a Bayesian Logistic Risk 
Model Incorporating Haplotypes inferred from the BJLM 
 model 
{ 
for( i in 1 : N ) { 
  casecntl[i] ~ dbin(p[i],1) 
  logit(p[i]) <- alpha + (beta[1]*dusts[i]) + (beta[2]*emphys[i]) 
  + (beta[3]*hayfev[i]) + (beta[4]*newfamcan[i]) + (beta[5]*agequit1[i])  
  + (beta[6]*agequit2[i]) + (beta[7]*Hap12Chm5_Dom[i])  
} 
   # Priors for logit model 
   alpha ~ dnorm(0.0,1.0E-2) 
   beta[1] ~ dnorm(0.0,1.0E-2) 
   beta[2] ~ dnorm(0.0,1.0E-2) 
   beta[3] ~ dnorm(0.0,1.0E-2) 
   beta[4] ~ dnorm(0.0,1.0E-2) 
   beta[5] ~ dnorm(0.0,1.0E-2) 
   beta[6] ~ dnorm(0.0,1.0E-2) 
   beta[7] ~ dnorm(0.0,1.0E-2) 
 
   # Determine p-value in Bayesian Context 
   for (o in 1:P)  
   { 
    betapabove[o] <- step(beta[o]-0) 
    betapbelow[o] <- 1-step(beta[o]-0) 
   } 
}  
 # Insert Data 
 
 Inits1  list(alpha = 0, beta = c(0,0,0,0,0,0,0))  
Figure 6.2:  With this code, the original Spitz lung cancer risk variables for former smokers are 
listed first
27
, and the significant haplotype for former smokers is listed next.  The case/control 
status was modeled as a binomial variable with size one, and the logit function contained all 
haplotypes that were being compared to the most frequent haplotype.   For the prior information 
in dealing with the effects of each haplotypes, all alphas and betas were modeled as normal 
distribution with mean zero and variance 100, hence leading to non-informative priors.  Also, the 
frequencies of beta being above and below zero are calculated, and this leads to an empirical p-
value which is two times the minimum frequency among beta being above or below zero.   
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Finally, the discriminatory power for both haplotype models are calculated in 
NCSS/PASS using the relative risk profiles calculated by the multivariate logistic risk models 
developed in either SPSS (frequentist) using haplotypes inferred from haplo.stats or the 
haplotypes inferred by the BJLM (Bayesian). 
6.3. Results for Expanding Spitz Models Using SNPs derived from the Top 200 SNP list 
in the Lung Cancer Meta-Analysis 
6.3.1 Univariate Haplotype Block Analysis to Extend Spitz Model 
   Joint-effect logistic model analysis is then conducted with the haplotypes blocks listed in 
Table 6.1, and results assuming an additive, dominant, and recessive genetic trait are generated.  
Genetic models that lead to the most significant results for each haplotype with both Haplo.stats 
and the BJLM are displayed in Table 6.2 for former smokers and Table 6.3 for current smokers 
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Table 6.2:  Individual haplotype block analysis using Haplo.stats and the BJLM for former 
smokers   
Haplotype information is listed on the 1
st
 4 columns on the left, and the results from Haplo.stats 
and BJLM are listed in the last 4 columns on the right.  Significant associations from each 
haplotype block are highlighted in this table. 
 
Former Smokers 
 Haplo.stats BJLM 
Chm 
 
Haplo. Gene Genetic 
Model 
OR  
(Confidence 
 Interval) 
(2.5% to  
97.5%) 
P-
Value
 
OR  
(Credible 
 Interval) 
(2.5% to 
97.5%) 
Empirical 
P- 
Value
 
5  AG TERT Dominant 0.737  
(0.579-0.938) 
0.0133 0.734 
(0.576-0.934) 
0.0140 
6  AG HCG4P4 Additive 1.246 
(1.054-1.473) 
0.0098 1.247 
(1.056-1.473) 
0.0090 
6  AAGC HLA-L Additive 1.585 
(1.048-2.396) 
0.0293 1.559 
(1.037-2.361) 
0.0322 
15  AGAC IREB2 Additive 0.777  
(0.615-0.981) 
0.0342 0.774 
(0.612-0.981) 
0.0337 
15  CGGA IREB2 Additive 0.765 
(0.624-0.938) 
0.0101 0.763 
(0.621-0.935) 
0.0092 
15  CGAC IREB2 Recessive 6.56 
(0.787-54.66) 
0.0857 9.85 
(1.25-218.1) 
0.0250 
15  AAAGA PSMA4 Additive 1.305 
(1.064-1.599) 
0.0104 1.307 
(1.070-1.602) 
0.0094 
15  GA CHRNA
3 
Dominant 0.723 
(0.573-0.911) 
0.0060 0.722 
(0.573-0.906) 
0.0045 
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Table 6.3:  Individual haplotype block analysis using Haplo.stats and the BJLM for current 
smokers   
Haplotype information is listed on the 1
st
 4 columns on the left, and the results from Haplo.stats 
and BJLM are listed in the last 4 columns on the right.  Significant associations from each 
haplotype block are highlighted in this table. 
 
Current Smokers 
 Haplo.stats BJLM 
Chm 
 
Haplo. Gene Genetic 
Model 
OR  
(Confidence 
 Interval) 
(2.5% to  
97.5%) 
P-
Value
 
OR  
(Credible 
 Interval) 
(2.5% to 
97.5%) 
Empirical 
P- 
Value
 
5  AG TERT Dominant 0.754 
(0.580-0.980) 
0.0357 0.753 
(0.580-0.979) 
0.0344 
6  AAGC HLA-L Additive 0.518 
(0.329-0.815) 
0.0046 0.527 
(0.333-0.822) 
0.0040 
6 AGAG GNL1 Additive 1.269  
(1.005-1.603) 
0.0458 1.269 
(1.005-1.605) 
0.0454 
6 AGGG GNL1 Recessive 0.175 
(0.020-1.503) 
0.1126 0.115 
(0.005-0.959) 
0.0450 
15  AGAC IREB2 Additive 0.746 
(0.574-0.971) 
0.0295 0.744 
(0.571-0.969) 
0.0284 
15  CGGA IREB2 Additive 0.793 
(0.632-0.995) 
0.0463 0.790 
(0.626-0.991) 
0.0416 
15 AAAGG PSMA4 Additive 0.444 
(0.249-0.792) 
0.0061 0.428 
(0.236-0.758) 
0.0031 
15 AGAGG PSMA4 Dominant 0.726 
(0.550-0.959) 
0.0224 0.731 
(0.553-0.966) 
0.0269 
 
With these results, assuming dominant genetic traits leads to the most significant joint-effect 
logistic model results for five haplotypes, while for additive and recessive genetic traits, leads to 
the most significant univariate logistic regression results for thirteen and three haplotypes 
respectively.  The most susceptible haplotype for lung cancer development is haplotype CGAC 
on the IREB gene using either Haplo.stats (OR = 6.56, 95 % CI = 0.787-54.66) or the BJLM (OR 
= 9.85, 95% CI = 1.25-218.2) in former smokers, and the most significant protective haplotype 
against lung cancer development is haplotype AAAGG on the PSMA4 gene using either 
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Haplo.stats (OR = 0.444, 95% CI =0.249-0.792, p-value = 0.0061) or the BJLM (OR = 0.428, 
95% CI = 0.236-0.758, p-value = 0.0031).   
6.3.2 Developing New Spitz Lung Cancer Risk Models 
The results from section 6.3.1 were then incorporated into full Spitz lung cancer risk 
models for former and current smokers. Each haplotype listed in section 6.3.1 was added to the 
original Spitz lung cancer risk factors.  Haplo.stats results were collected within the Haplo.stats 
program and modeled within a multivariate logistic regression regime with SPSS, and BJLM 
results were modeled with non-informative priors in WINBUGS.  Results are shown in Table 
6.4. 
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Table 6.4:  Full Updated Spitz Lung Cancer Risk Model Development Using Haplotypes 
inferred with Haplo.stats and the BJLM.   
Results are generated for former and current smokers separately since in the original Spitz lung 
cancer risk models, smoking status was a matching variable. 
 
Former Smokers 
 Haplo.stats results BJLM results 
Chm. 
(Gene) 
Haplo. Genetic  
Trait 
OR (95% 
Confidence  
Interval) 
P-value OR (95% 
Credible  
Interval) 
Empirical 
P-value
 
5 (TERT) AG Dominant 0.72 (0.56-0.91) 0.007 0.71 (0.55-0.91) 0.006 
6 
(HCG4P4) 
AG Additive 1.21 (1.02-1.43) 0.026 1.21 (1.02-1.43) 0.024 
6 (HLA-L) AAGC Additive 1.82 (1.18-2.81) 0.007 1.81 (1.17-2.80) 0.008 
15 (IREB2) CGAC Recessive N/A N/A 11.5 (1.31-249) 0.025 
Non-Genetic Risk Factors  
Dusts (Yes vs. No) 1.58 (1.24-2.02) < 0.001 1.60 (1.25-2.04) < 0.001 
Emphysema (Yes vs. No) 2.60 (1.82-3.71) < 0.001 2.63 (1.85-3.77) < 0.001 
Hay Fever (Yes vs. No) 0.67 (0.49-0.90) 0.008 0.65 (0.48-0.88) 0.006 
Family History (≥ 2 vs. < 2) 1.63 (1.27-2.10) < 0.001 1.64 (1.27-2.12) < 0.001 
Quitting Age (42-53 yrs) 1.07 (0.80-1.45) 0.639 1.10 (0.81-1.48) 0.554 
Quitting Age (> 54 yrs) 1.51 (1.13-2.03) 0.006 1.53 (1.13-2.06) 0.006 
Constant 0.470 < 0.001 0.462 N/A 
Current Smokers 
Chm. 
(Gene) 
Haplotype Genetic  
Trait 
OR (95% 
Confidence  
Interval) 
P-value OR (95% 
Credible  
Interval) 
P-value
 
5 (TERT) AG Dominant 0.69 (0.52-0.91) 0.009 0.68 (0.51-0.90) 0.008 
6 (HLA-L) AAGC Additive 0.52 (0.32-0.85) 0.009 0.53 (0.32-0.86) 0.009 
15 
(PSMA4) 
AAAGG Additive 0.41 (0.22-0.77) 0.006 0.38 (0.20-0.71) 0.002 
15 
(PSMA4) 
AAAGA Recessive 3.03 (1.58-5.82) 0.001 3.12 (1.63-6.20) < 0.001 
Non-Genetic Risk Factors     
Asbestos (Yes vs. No) 1.70 (1.14-2.53) 0.010 1.71 (1.14-2.56) 0.008 
Dusts (Yes vs. No) 1.24 (0.94-1.64) 0.129 1.25 (0.94-1.65) 0.122 
Emphysema (Yes vs. No) 2.66 (1.83-3.89) < 0.001 2.71 (1.86-3.98) < 0.001 
Hay Fever (Yes vs. No) 0.67 (0.47-0.95) 0.025 0.66 (0.47-0.95) 0.022 
Smoking Family History of Cancer 1.75 (1.29-2.37) < 0.001 1.76 (1.30-2.39) < 0.001 
Pack-Years (28-42 vs. < 28) 1.22 (0.81-1.84) 0.350 1.22 (0.81-1.84) 0.342 
Pack-Years (42-57.5 vs. < 28) 1.41 (0.94-2.10) 0.094 1.41 (0.95-2.10) 0.093 
Pack-Years (> 57.5 vs. < 28) 1.92 (1.30-2.82) 0.001 1.93 (1.32-2.85) 0.001 
Constant 0.617 0.006 0.615 N/A 
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The most susceptible haplotype in the updated Spitz lung cancer risk model for lung 
cancer development is haplotype CGAC on the IREB gene using the BJLM (OR = 11.5, 95% CI 
= 1.31-249) for former smokers, and this haplotype is notable because it is significant with the 
BJLM only.  The haplotype AG on the TERT gene located on the chromosome five, and 
haplotype AAGC on the HLA-L gene on chromosome six are the only haplotype present in the 
former smoker and current smoker models.  Emphysema is the most significant non-genetic risk 
variable in the updated models. 
6.3.3. Comparing the Updated Spitz Lung Cancer Risk Models 
To test the effectiveness of the full genetic models (with BJLM inferred haplotypes, and 
haplo.stats inferred haplotypes respectively) compared to models with only the original Spitz 
lung cancer risk model, the discriminatory power (Table 6.5) and NRI (Table 6.6) will be 
calculated and examined for all three types of models.   
 
 
 
 
 
 
 
 
 
 
 
112 
 
Table 6.5:  Discriminatory Power Results for the Original Spitz Lung Model, the Spitz 
model with Haplo.stats inferred haplotypes, and the Spitz Model with BJLM inferred 
haplotypes. 
(1) = Comparison of the Original Spitz models to the Haplotype extended Spitz models 
(2) = Comparison of the haplotype extended Spitz models 
 
Discriminatory Power in All Individuals (1154 cases and 1137 controls) 
Model AUC (95% CI) p-value 
 (1) (2) 
Original Spitz 0.659 (0.636-0.681) --- --- 
Original Spitz + BJLM 0.687 (0.665-0.708)  < 0.0001 --- 
Original Spitz + Haplo.stats 0.684 (0.662-0.705) < 0.0001 0.0328 
Discriminatory Power for Former Smokers (604 cases and 656 controls) 
Original Spitz 0.641 (0.610-0.671) --- --- 
Original Spitz + BJLM 0.665 (0.634-0.694) 0.0047 --- 
Original Spitz + Haplo.stats 0.659 (0.628-0.689) 0.0213 0.0440 
Discriminatory Power for Current Smokers (550 cases and 481 controls) 
Original Spitz 0.672 (0.638-0.704) --- --- 
Original Spitz + BJLM 0.708 (0.675-0.738) 0.0003 --- 
Original Spitz + Haplo.stats 0.707 (0.674-0.737) 0.0004 0.3593 
 
With the full SNP and haplotype model with haplotypes modeled by haplo.stats and the 
BJLM, discriminatory power is significantly improved (p-value < 0.0001 for both models) 
compared to the original Spitz model for all individuals.  However, for all individuals, these 
models constructed with haplotypes inferred from the BJLM are significantly superior to models 
constructed with haplo.stats inferred haplotypes (p = 0.0328) from each other, and there are 
significant differences between these models when separated by smoking status for former 
smokers (p-value = 0.0440), but not for current smokers (p-value = 0.3593).  
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Table 6.6:  Net Reclassification Index results for comparing the Original Spitz Lung Model, 
the Spitz model with Haplo.stats inferred haplotypes, and the Spitz Model with BJLM 
inferred haplotypes 
(1)  Comparison of the Original Spitz models to the Haplotype extended Spitz models 
(2)  Comparison of the haplotype extended Spitz models 
 
NRI for All Individuals 
Model (1) (2) 
 NRI p-value NRI p-value 
Original Spitz --- --- --- --- 
Original Spitz + Haplo.stats 0.2661 < 0.0001 --- --- 
Original Spitz + BJLM 0.3011 < 0.0001 0.3820 < 0.0001 
NRI for Cases 
Original Spitz --- --- --- --- 
Original Spitz + Haplo.stats 0.4132 < 0.0001 --- --- 
Original Spitz + BJLM 0.3953 < 0.0001 0.0930 0.0018 
NRI for Controls 
Original Spitz --- --- --- --- 
Original Spitz + Haplo.stats -0.1471 < 0.0001  --- --- 
Original Spitz + BJLM -0.0943 0.0014 0.2890 0.0001 
 
The increase in overall NRI is higher and more significant when examining the full 
genetic model (for both haplo.stats and the BJLM) compared to the original Spitz lung cancer 
models; however, for controls only, the original Spitz lung cancer risk models outperform the 
models with haplotypes added to the original models.  These results confirm the discriminatory 
power results because the model with BJLM inferred haplotypes is seen as the superior model 
(NRI = 0.3820, p-value < 0.0001).   
6.4. Discussion for Expanding Spitz Models Using SNPs derived from the Top 200 SNP 
list in the Lung Cancer Meta-Analysis 
The purpose of this analysis was to extend the Spitz lung cancer risk models by 
incorporating haplotypes to elucidate associations in lung cancer that could not be obtained 
solely with single SNP based strategies.  This study showed that haplotypes can increase the 
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discriminatory power and the correct estimation of risk in cases compared to the original Spitz 
lung cancer risk models.  For instance, the TERT, HCG4P4, HLA-L, IREB2, and PSMA4 genes 
all contained haplotypes in the extended Spitz models.  The strongest genetic effect that showed 
susceptibility with Lung Cancer development occurred with the inferred haplotype CGAC from 
the IREB2 gene on chromosome 15.  Also, the recessive genetic effect for this haplotype existed 
only in the Bayesian model, which suggests that incorporating prior data to rare haplotypes 
might lead to increased odds ratios for susceptible rare haplotypes.  
Three aspects of the results from section 6.3 deserve future inquiry. First, when 
comparing the models developed with haplotypes inferred from haplo.stats and the BJLM, the 
model with BJLM inferred haplotypes was superior.  Discriminatory power analysis suggests 
that the model BJLM inferred haplotypes perform better compare to the model with haplo.stats 
inferred haplotypes, although these results are not significant for current smokers.  However, 
when examining the NRI, the model with BJLM inferred haplotypes have better results 
compared to the model with haplo.stats inferred haplotypes (NRI = 0.3820, p-values < 0.0001).   
The NRI showed that the lung cancer risk was increased in cases when measured with the BJLM 
model, and also showed that the lung cancer risk was decreased in controls with the BJLM, and 
this eludicates the notion that when measured by the NRI, BJLM modeling was superior to 
haplo.stats in the Texas Lung GWAS dataset. 
The second aspect of the results that requires further inquiry was that both haplotype 
extended Spitz models, according to the NRI, were significantly worse in determining the risk 
profile of controls.  This suggests that there could be better haplotype blocks that were not 
modeled in this analysis that could improve the risk profile of controls.  A future analysis that 
could attempt to solve this problem would be to search for haplotypes throughout the Texas 
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Lung GWAS, or to infer SNPs in the top 200 lung cancer meta-analysis SNP list that are not in 
the Texas Lung GWAS but are in LD with SNPs that form haplotypes in the Texas Lung GWAS 
study.  
The final aspect of these results that require further inquiry was the decreased risk of 
pack-years for those with pack-year values between 42 and 57.5.  The odds ratio for those that 
have pack-years from 42 to 57.5 decreased from 1.45 (95% CI = 1.05-2.01, p-value = 0.024) in 
the original Spitz lung cancer risk model, to 1.41 (95% CI = 0.94-2.10, p-value = 0.094) in the 
Spitz model with haplo.stats inferred haplotypes, and the odds ratio decreased as well in the 
Spitz model with BJLM inferred haplotypes to 1.41 (95% CI = 0.95-2.10, p-value = 0.093).  
There is evidence that suggests that the genes located on the 15q25 section of the genome 
(LOC123688 and CHRNA5) have predisposition to nicotine dependence
207
.  In a study of 15,000 
European individuals, those who smoke more than 15 cigarettes per day, and especially those 
who smoke 25 cigarettes per day are strongly linked with SNPs and Haplotypes located in the 
15q25 section of the genome
207
.  One SNP in particular, rs1317286, is located on the same 
haplotype block in HapMap data as the AAAGG haplotype for gene PSMA4 that was protective 
for lung cancer, and in the study of 15,000 European individuals, SNP rs1317286 was strongly 
associated with those that smoke at least 25 cigarettes per day (p = 0.0000026)
207
.  Eighty eight 
of the 256 individuals in the Texas Lung GWAS that have pack-years between 42 and 57.5 
smoke at least 25 cigarettes per day.  The presence of haplotype GAGA in this study which is 
protective could be decreasing the effect of smoking intensity for those in the pack-year group 
(42-57.5), a group that showed significance (p < 0.05), but not strong significance (p < 0.01) in 
the original Spitz lung cancer risk study. 
116 
 
In this analysis, the Spitz lung cancer risk models have been expanded with haplotypes 
from the Texas Lung GWAS that were inferred from SNPs that match both the Top 200 SNP in 
the lung cancer meta-analysis manuscript and the Texas Lung GWAS.  Improved discriminatory 
power was noted in current smokers and ever smokers.  However, to further improve the 
effectiveness of risk models with haplotypes, SNPs that are highly significant but not linked to 
any haplotypes can be added to these models in an attempt to increase discriminatory power.  In 
the final application of the BJLM, the inflammation pathway of a Glioma GWAS will be studied 
and genetic risk models will be created for the first time with top SNPs and top Haplotypes. 
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Chapter 7:  Application Three of the BJLM: Using Haplotype Analysis and the BJLM to 
Determine Significant Genetic Risk Factors for Glioma  
To further understand and elucidate the genetic risk factors for Glioma will substantially 
improve both cancer prevention and treatment options for this insidious disease.  Genetic 
analysis, both single SNP and haplotype, has been very beneficial in finding genetic associations 
for many cancers, like breast and lung.  In this analysis, a complete risk model with both single 
SNPs and haplotypes will be developed to better determine the genetic risk profile of Glioma.     
Cases consists of 1224 histological-confirmed Caucasian Glioma cases from MD 
Anderson Cancer Center in Houston, Texas, and controls consists of 2224 individuals from the 
Cancer Genetic Markers of Susceptibility (CGEMS) group.  Genetic information from both 
populations was available for 4647 SNPs from 204 genes.  Plink and Haploview were used to 
determine the top 20 SNPs and top 20 haplotype blocks respectively.  Then, univariate logistic 
regression was used to determine the best genetic model for the top SNPs.  Joint logistic risk 
model regression was used to determine haplotype risk for each individual haplotype block.  
Finally, multivariate logistic regression was used to develop complete risk model using SNPs 
only, Haplotypes only, and SNPs plus haplotypes. 
 When incorporating haplotypes into risk models, the discriminatory power increased.  
The SNP only risk model contained 17 SNPs, and had discriminatory power of 63.7% (95% CI = 
0.617-0.657), while a risk model from the top 20 Haplotypes blocks had a discriminatory power 
of 64.1% (95% CI = 0.622-0.661).  Finally, incorporating 15 top SNPs and 10 top Haplotypes 
which does not have any of the top 15 SNPs have a discriminatory power of 65.4% (95% CI = 
0.634-0.673).  Also, adding top haplotypes lead to a significant increase in risk modeling power 
as calculated by the net reclassification index (NRI = 0.1541, p-value = <0.0001). 
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7.1. Introducing Glioma for Genetic Analysis 
According to the latest 2011 Cancer Facts and Figures report, an estimated 22,340 
American individuals will be diagnosed with brain cancer this year, and 13,110 American 
individuals will die from this disease
208
.  Roughly 77% of all brain cancers are gliomas, even 
though only 42% of brain tumors are Glioma, and certain types of Gliomas like Astrocytomas 
and Oligodendrogliomas are the most dangerous because they typically cannot be removed by 
surgery
209,210
.  Non-genetic risk factors for Glioma have been studied extensively, but many of 
the hypothesized risk factors (smoking, hazards from certain occupations, heavy cell phone use, 
and radiation exposure) show results that are weak and sometimes contradictory
211-218
.  
To find some genetic risk factors for Glioma, there seems to be some promise for those 
that focus on inflammation genes.  Some studies have found single nucleotide polymorphisms 
that can both protective and susceptible to Glioma, and also have found biomarkers, like 
Immunogloubin E levels, that can show protection against Glioma formation
209, 219-224
.  Recently, 
a study examining interactions among pairs of SNPs has shown promise with finding new risk 
factors for Glioma, as the MAP3K7 and the CRADD genes have about 14% of the significant 
interactions among SNPs in individuals with Glioma
224
.  This information suggests that risk 
models from genetic risk factors in the inflammation pathway can be a viable option in both 
cancer prevention and cancer recognition for Glioma.   
Risk models can be developed using both frequentist and Bayesian methods.  With 
frequentist methods, models are created with the information readily available for that specific 
study and with no mathematical assumptions using prior information.  For instance, in the 
original development of the Spitz model, risk models for never, former, and current smokers 
were developed based on the available information of 1851 cases and 2001 controls with 
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smoking intensity, family history of lung cancer, self-reported emphysema, and other risk 
factors
27
.  With Bayesian methods, one can add prior information to the dataset being examined 
with the hopes of strengthen associations or non-associations with disease.  For instance, 
HapMap
44
 and 1000 genome information
43
 can be used to better infer haplotypes in individuals 
in which the SNP information is known or unknown, and this is the basis for the BJLM 
introduced in Chapter 4 of this thesis.  In this analysis, genetic risk factors will be analyzed using 
SNP information available from American Glioma cases at MD Anderson Cancer Center and 
controls from the CGEMS studies
225-227
.  Both top haplotypes and top SNPs will be extracted in 
separate analysis to determine their risk profiles.  Afterward, logistic regression analysis will be 
conducted with use of both SPSS (for a frequentist prospective) and the BJLM to determine the 
best possible model for haplotypes.  Finally, both Bayesian and frequentist methods will be 
incorporated to determine the best risk model combining both top SNPs and top Haplotypes. 
7.2.  Methods for Glioma Analysis 
 7.2.1.   Study population and Selection of SNPs for Glioma Analysis 
 A study population of 3448 individuals (1224 cases and 2224 controls) was accrued for 
this analysis.  Study population information for the cases and controls have been discussed 
previously, but briefly, Glioma cases (N = 1224) were ascertained from MD Anderson cancer 
center from 1990 to 2008, and all individuals were Caucasian adults
 224
.   A small aliquot of 
blood (20-ml) was collected from each case
 
for genetic analysis
224
, and genotyping was 
conducting using Illumina HumanHap 610 SNP Chip, which contained 575,837 SNPs for 
possible analysis
225
.  The controls for this experiment (N = 2224) were ascertained from 
CGEMS, which was launched in 2005 to identify breast and prostate cancer variants
228
, and all 
of these samples were of Caucasian descent.   CGEMS initially contained 1,142 breast cancer 
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controls and 1,101 prostate cancer controls which were genotyped with the Illumina 550K Bead-
Chip
225-227
.  After removal of individuals who had low call rates or of non-European descent, 
2224 controls were available for analysis.  The study received institutional review board 
approval from MD Anderson Cancer Center. 
The selection of SNPs in the cases has been discussed previously
224
, but briefly, an all 
encompassing list of key signaling pathways for inflammation was extracted using both the 
Biocarta pathway maps website (http://www.biocarta.com/genes/allpathways.asp) and the 
Anatomy project for Cancer Genomes project (http://cgap.nci.nih.gov/Pathways) website.  
Twenty eight inflammation pathways containing 204 genes were found for possible analysis, and 
in these 204 genes, there were 5304 SNPs in the case dataset.  Out of these 5304 SNPs, 4647 
SNPs were also available in the CGEMS control data set, and all of these SNPs had call rates > 
95%, a minor allele frequency greater than >1% in the controls, and HWE equilibrium p-values 
of > 1*10
-5
 in the controls.  
7.2.2.   Determining top SNPs for Model Analysis 
 Genetic information from section 7.2.1 was transformed into a .ped file, which is a 
standard file format for genetic analysis, and ran in PLINK
229
 using the basic case/control 
association analysis option (plink –file mydata –assoc).  With this option, PLINK runs a simple 
chi-square test for each SNP in the study.  After completion of this analysis, the 20 SNPs with 
the lowest p-values are extracted.  With these top 20 SNPs, univariate logistic regression in SPSS 
(version PASW Statistics 17.0) is conducted on each SNP using these three genetic traits: 
Additive, Dominant, and Recessive, to determine which genetic trait has the lowest p-value in 
the analysis.  Finally, the top 20 SNPs with the best genetic model for each SNPs are examined 
together with multivariate logistic regression in SPSS to determine which SNPs have the best 
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association with Glioma, and also to develop a risk model with SNPs as the only risk factors.  
Finally, the discriminatory power for this specific model was calculated in SPSS. 
7.2.3.   Determining top Haplotypes for Glioma Model Analysis 
 To extract the best haplotypes within the top 20 haplotype blocks, chromosome and base 
pair information for all 4647 SNPs was determined from a genetic map SNP site associated with 
the Conway Institute Bioinformatics Service (http://integrin.ucd.ie/cgi-bin/rs2cm.cgi).  For each 
chromosome, all SNPs were loaded into Haploview
56
, and all results from the Association tab 
and Haplotypes sub-tab were extracted.  All haplotypes are formed with the Gabriel’s et.al.53 
confidence interval method.  Then, all haplotype blocks that contained haplotypes with p-values 
of less than 0.01 were collected from all chromosomes.  After collection of these haplotype 
blocks, the top 20 haplotypes blocks were then selected for further analysis.   
 All haplotypes within the 20 top haplotype blocks were then further analyzed with both 
Haplo.stats
60
 and the BJLM (from Chapter 4).  The procedure to conduct this analysis was 
discussed in section 5.2.4, but briefly, each haplotype block will be analyzed with Haplo.stats 
first to determine the odds ratio and p-value of the significant haplotypes that will be used to 
begin construction of a haplotype only Glioma model.  All haplotypes with empirical p-values 
less than 0.05 and are the most significant among the three risk models in each haplotype block 
are presented for future analysis.  This analysis is conducted for assuming additive, dominant, 
and recessive genetic traits for each haplotype block.   
 The procedure for adding haplotypes to risk models when using the BJLM was also 
discussed in section 5.2.4., but briefly, the prior information was obtained by determining the 
counts of all possible haplotypes inferred with HapMap data
 137-140
.  These counts were then 
incorporated into the inferring of haplotypes from the Glioma dataset.  After running the BJLM, 
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the haplotype frequencies for each haplotype block, except for the most frequent haplotype, was 
saved and then presented to WINBUGS (version 1.4.3) for analysis with each haplotype block.   
This analysis is conducted for all three genetic models for each haplotype block, and haplotype 
results are collected after 50,000 iterations of the WINBUGS code (1
st
 5000 iterations are burn-
in, and are not counted in the analysis).  All haplotypes with empirical p-values less than 0.05 
and are the most significant among the three risk models in each haplotype block are presented 
for future analysis.   
For determining the haplotypes used in development of a Glioma risk model, the same 
procedure to incorporate the results from each haplotype block was also used to expand the Spitz 
lung cancer risk model.  The most significant haplotype out of the three genetic models are 
selected for multivariate logistic regression analysis in both haplo.stats and the BJLM.  The 
discriminatory power for both haplotype models are calculated in SPSS using the relative risk 
profiles calculated by the multivariate logistic risk models developed in either SPSS (frequentist) 
using haplotypes inferred from haplo.stats or the haplotypes inferred by the BJLM (Bayesian). 
7.2.4.   Combining both SNP and Haplotype Data 
To develop a model based on the best SNPs and best Haplotypes (using the BJLM) from 
the previous two parts, it is imperative to make sure that there is no inclusion of a top 20 SNP 
that is also included in the same model as a haplotype containing the most significant SNPs.   In 
this case, all haplotypes that are not inferred with a top 20 significant SNP will be added to the 
model consisting of single SNPs.  The list of haplotypes that are missing the most significant 
SNPs are listed in the 1
st
 Table of Appendix 3 (Appendix 3: Table 1). 
The top 20 SNPs are then added to the haplotypes from Appendix 3: Table 1 to construct 
a more complete model for Glioma using multivariate logistic regression.  Three models will be 
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constructed and analyzed.  The SNPs included in the single SNP model will be modeled with the 
haplotypes determined by Haplo.stats in one model, and with haplotypes determined by the 
BJLM for the other two models.  From the two models with BJLM inferred haplotypes, one 
model will contain non-informative priors that are normal distributions with mean zero and 
precision of 0.01 for the SNPs and haplotypes.  The other model will incorporate informative 
priors with normal prior distributions based on the means and precisions of the results from the 
univariate logistical regression and joint-effect logistic analysis for SNPs and haplotypes 
respectively.  WINBUGS code for this model will be listed in Appendix 3: Figure 1.  Models 
including haplotype information from haplo.stats will be examined with SPSS, while those 
models with BJLM inferred haplotypes will be examined with WINBUGS.  Discriminatory 
power will be calculated with all three models with NCSS/PASS, and also the Net 
Reclassification Index (NRI)
230
 will be calculated with these three models separately compared 
to the models with SNPs only and haplotypes only. 
7.3. Results for Glioma Analysis 
 7.3.1. Single SNP model development  
 After running PLINK for all 4647 inflammation SNPs, the top 20 most significant SNPs 
are listed in Appendix 3: Table 2 and highlighted in the Manhattan plot below (Figure 7.1). 
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Figure 7.1: Manhattan Plot showing the 4647 SNPs examined for Glioma Analysis 
 
Figure 7.1:  Chromosome six contains the most significant inflammation SNPs with five, while 
chromosomes 2, 4, 12, and 17 contain at least two significant inflammation SNPs.  All SNPs 
have p-values less than 0.003, which suggests that these SNPs could be viable markers for 
Glioma detection.  Five SNPs in particular, rs4761533, rs8079544, rs10009998, rs7963343, and 
rs865926, have p-values less than 0.001.  Twenty SNPs have p-values smaller than 0.002712, 
which is transformed by negative log 10. 
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Univariate logistic regression analysis is then conducted with the SNPs listed in 
Appendix 3: Table 2, and results assuming an additive, dominant, and recessive genetic trait are 
generated.  Genetic models that lead to the most significant results for each SNP are displayed in 
the Appendix 3: Table 3.  With these results, assuming dominant genetic traits leads to the most 
significant univariate logistic regression results for 11 SNPs, while for additive and recessive 
genetic traits, leads to the most significant univariate logistic regression results for eight and one 
SNP model.  The most susceptible SNP for Glioma development are SNP rs11265208 assuming 
an additive genetic trait (OR = 1.303, 95% CI = 1.111-1.529), and SNP rs8079544 assuming a 
dominant genetic trait (OR = 1.499, 95% CI = 1.212-1.854).  No significant susceptible SNPs are 
available assuming a recessive genetic trait; however, the most protective SNP, rs10009998, 
against Glioma is assumed from a recessive genetic trait (OR = 0.109, 95% CI = 0.034-0.350).   
Multivariate logistic regression was conducted for the 20 SNPs with the best genetic 
model for each SNP as determined with Appendix 3: Table 3, and the results are displayed in 
Table 7.1. 
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Table 7.1:  Full Single SNP model using Inflammation SNPs for Glioma 
The rs number for each SNP is listed on the 1
st
 column from the left, and the genetic trait 
modeled for each SNP is listed on the 2
nd
 column from the left.  The magnitude of susceptibility 
to Glioma for each SNP is defined in terms of betas and odds ratio in columns 3 and 4 
respectively with its associated p-value in the final column. 
 
SNP Genetic Trait Beta OR (95% CI) P-Value 
rs4761533 Dominant 0.346 1.413 (1.186-1.685) < 0.001 
rs8079544 Dominant 0.442 1.556 (1.242-1.949) < 0.001 
rs10009998 Recessive -2.256 0.105 (0.032-0.340) < 0.001 
rs865926 Dominant 0.352 1.421 (1.104-1.830) 0.006 
rs314253 Additive 0.190 1.210 (1.085-1.349) 0.001 
rs16833157 Additive -0.419 0.658 (0.504-0.859) 0.002 
rs10484796 Additive -0.121 0.886 (0.797-0.985) 0.025 
rs11265608 Additive 0.318 1.375 (1.162-1.627) < 0.001 
rs1319868 Dominant 0.286 1.332 (1.120-1.582) 0.001 
rs791589 Additive 0.227 1.255 (1.078-1.462) 0.003 
rs10857092 Dominant 0.235 1.264 (1.023-1.563) 0.030 
rs6879021 Additive 0.146 1.157 (1.043-1.283) 0.006 
rs693293 Dominant -0.333 0.717 (0.591-0.869) 0.001 
rs2395175 Additive 0.176 1.193 (1.035-1.375) 0.015 
rs959382 Dominant 0.196 1.217 (1.040-1.423) 0.014 
rs2061450 Additive -0.176 0.839 (0.741-0.948) 0.005 
rs276467 Dominant 0.199 1.221 (1.049-1.421) 0.010 
Constant -1.169 0.311 <0.001 
 
With these results, the SNP with the most susceptibility toward Glioma development and the 
most protective SNP against Glioma are the same as shown in the univariate logistic regression 
analysis.  Three SNPs, rs7963343, rs2840191, and rs7341365 lose their significance when 
examined with the rest of the SNPs that compose the single SNP model.  Finally, almost half of 
the SNPs in this full SNP model have p-values of less than or equal to 0.001, which shows 
potential strong factors for Glioma susceptibility or protection. 
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7.3.2. Haplotype model development for Glioma Data Set 
In terms of most significant p-value, the top 20 haplotypes as calculated by Haploview 
are shown in Table 7.2. 
 
Table 7.2: Best Haplotypes within Glioma Inflammation Dataset as Calculated by 
Haploview 
Haplotype information is listed on the 1
st
 2 columns on the left, and the frequency of each 
significant haplotype with its associated Chi-Square and P-Values are listed in the last three 
columns.  All results are generated by testing the frequency differences between cases and 
controls in Haploview. 
 
Chromosome (Gene) Haplotype Frequency Chi-Square P-Value 
12 (CRADD) GCAGA 0.116 14.414 0.0001 
1 (IL6R) GGAA 0.103 11.186 0.0008 
1 (CD247) AGG 0.012 11.209 0.0008 
17 (DLG4) AG 0.345 10.455 0.0012 
6 (HLA-DRA) ATT 0.166 10.181 0.0014 
12 (IGF1) AAT 0.054 10.025 0.0015 
15 (IGF1R) AT 0.119 10.117 0.0015 
6 (IL22RA2) CCTGA 0.524 9.869 0.0017 
3 (PIK3CB) TGCGACC 0.100 9.777 0.0018 
6 (MAP3K7) GT 0.272 9.624 0.0019 
12 (CRADD) AGCGG 0.083 9.69 0.0019 
15 (SMAD3) GTTTA 0.231 9.334 0.0022 
16 (ITGAX) CGA 0.433 9.307 0.0023 
6 (HLA-DRA) GCGACCAGTAC 0.156 9.047 0.0026 
1 (CD247) TA 0.496 8.993 0.0027 
2 (STAT) AGA 0.249 8.789 0.003 
6 (MAP3K7) AC 0.724 8.623 0.0033 
10 (PRF1) CGT 0.669 8.446 0.0037 
7 (GNAI1) TTTCA 0.226 8.325 0.0039 
6 (HLA-DRA) ACGACCGGGGC 0.133 8.194 0.0042 
 
From these top 20 haplotypes, 18 of these haplotypes were on unique haplotype blocks, with two 
top haplotypes inferred on the same haplotype block in genes HLA-DRA and MAP3K7.  All of 
the top haplotypes were highly significant with P-values less than 0.005. One haplotype from the 
CRADD, IL6R, and CD247 genes had p-values less than 0.001.  Finally, haplotype length played 
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no role in association results, as haplotypes of length 2 to 5 SNPs, 7 SNPs, and 11 SNPs all 
showed significant associations with Glioma. 
Joint-effect logistic model analysis is then conducted with the haplotypes listed in Table 
26, and results assuming an additive, dominant, and recessive genetic trait are generated.  
Genetic models that lead to the most significant results for each haplotype with both Haplo.stats 
and the BJLM are displayed in the Appendix 3: Table 4.  With these results, assuming dominant 
genetic traits leads to the most significant joint-effect logistic model results for 10 haplotypes, 
while for additive and recessive genetic traits, leads to the most significant univariate logistic 
regression results for eight and two haplotypes respectively.  The most susceptible haplotype for 
Glioma development is haplotype AGG on the CD247 gene using either Haplo.stats (OR = 2.10, 
95 %CI = 1.35-3.25) or the BJLM (OR = 2.1, 95% CI = 1.36-3.27), and the most protective 
haplotype against Glioma development is haplotype GCTCA on the SMAD3 gene using either 
Haplo.stats (OR = 0.26, 95% CI =0.08-0.86) or the BJLM (OR = 0.22, 95% CI = 0.05-0.70).  
With the haplotype GCTCA from the SMAD3 gene, the p-value was much more significant 
when using the BJLM (p-value = 0.00677) compared to using Haplo.stats (p-value = 0.0277) to 
infer the haplotypes.  
These results were then incorporated into a full haplotype model analysis in which each 
haplotype listed above were tested together.  Haplo.stats results were collected within the 
Haplo.stats program and modeled within a multivariate logistic regression regime with SPSS, 
and BJLM results were modeled with non-informative priors in WINBUGS.  Results are shown 
in Table 7.3. 
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Table 7.3:  Multivariate logistic regression for inferred haplotypes from both BJLM and 
Haplo.stats 
Haplotype information is listed on the 1
st
 3 columns on the left, and the results from Haplo.stats 
and BJLM are listed in the last 4 columns on the right.  Significant associations from each 
haplotype block are highlighted in this table. 
 
(1) = Empirical Bayes P-Value as calculated in Chapter 4 of this thesis 
 
 Haplo.stats results BJLM results 
Chm. (Gene) Haplotype Genetic 
Trait 
OR (95% CI) P-value OR (95% CI) P-value
(1) 
12 (CRADD) GCAGA Dominant 1.39 (1.17-1.65) < 0.001 1.39 (1.17-1.65) <0.001 
1 (IL6R) GGAA Additive 1.29 (1.09-1.52) 0.003 1.29 (1.09-1.51) 0.002 
1 (CD247) AGG Dominant 1.96 (1.24-3.09) 0.004 1.99 (1.26-3.15) 0.003 
17 (DLG4) AG Additive 1.22 (1.09-1.35) < 0.001 1.21 (1.09-1.35) < 0.001 
6 
(HLA-DRA) 
ATT Additive 0.81 (0.70-0.93) 0.004 0.81 (0.70-0.93) 0.004 
12 (IGF1) AAT Dominant 1.44 (1.15-1.81) 0.002 1.44 (1.15-1.81) 0.003 
15 (IGF1R) AG Dominant 1.26 (1.08-1.48) 0.004 1.26 (1.08-1.48) 0.003 
15 (IGF1R) AT Dominant 1.41 (1.19-1.68) < 0.001 1.42 (1.19-1.69) < 0.001 
6 (IL22RA2) TCGGG Additive 0.86 (0.76-0.97) 0.017 0.86 (0.76-0.97) 0.016 
6 (IL22RA2) TTGAA Dominant 0.76 (0.63-0.93) 0.008 0.76 (0.62-0.93) 0.007 
3 (PIK3CB) TGCGAC
C 
Dominant 0.72 (0.60-0.88) 0.001 0.73 (0.60-0.88) 0.001 
6 (MAP3K7) GT Dominant 1.33 (1.15-1.54) <0.001 1.33 (1.15-1.54) <0.001 
12 (CRADD) AGCGG Recessive 2.48 (1.00-6.13) 0.049 2.53 (1.03-6.62) 0.042 
15 (SMAD3) GCTCA Recessive 0.22 (0.06-0.75) 0.016 0.20 (0.04-0.62) 0.003 
15 (SMAD3) GTTTA Additive 0.83 (0.73-0.93) 0.002 0.82 (0.73-0.93) 0.002 
16 (ITGAX) AGG Dominant 1.25 (1.08-1.44) 0.003 1.25 (1.08-1.45) 0.002 
6 
(HLA-DRA) 
GCGACC
AGTAC 
Additive 1.17 (1.02-1.35) 0.026 1.18 (1.02-1.35) 0.026 
1 (CD247) TG Additive 1.15 (1.03-1.30) 0.016 1.14 (1.02-1.28) 0.027 
1 (CD247) GA Additive 1.19 (1.03-1.37) 0.016 1.17 (1.02-1.34) 0.031 
2 (STAT)
 
AGA Additive 0.85 (0.76-0.96) 0.008 0.85 (0.75-0.96) 0.007 
10 (PRF1) TGC Additive 1.14 (1.02-1.28) 0.020 1.15 (1.02-1.28) 0.020 
7 (GNAI1) TTTCA Dominant 1.26 (1.09-1.46) 0.002 1.27 (1.09-1.47) 0.001 
Constant 0.251 (N/A) < 0.001 0.253 (N/A) < 0.001 
 
With these results, the GCTCA haplotype on gene SMAD3 was still the most protective 
haplotype against Glioma using either Haplo.stats to infer the haplotypes (OR = 0.22, 95% CI = 
0.06-0.75) or the BJLM (OR = 0.20, 95% CI = 0.04-0.62).  However, the AGCGG haplotype on 
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the CRADD gene was now the most susceptible haplotype toward Glioma development using 
either haplotypes inferred from Haplo.stats (OR = 2.48, 95% CI = 1.00-6.13) or the BJLM (OR = 
2.53, 95% CI = 1.03-6.62).    In this model, the AGCGG haplotype on the CRADD gene was 
modeled assuming a recessive genetic trait because this haplotype failed significance assuming 
both additive and dominant genetic traits in the multivariate logistic regression. 
7.3.3. Model development with both SNPs and Haplotypes for Glioma 
 7.3.3.1.      Best SNPs + Best Haplo.stats Inferred Haplotypes for Glioma 
A full genetic model which incorporates both the single SNP model results from section 
7.3.1, and the haplotype results from section 7.3.2 are developed with both SPSS and the BJLM.  
Full SNP and haplotype data is available for 1194 cases and 2056 controls.  Results using 
haplotypes from Haplo.stats and SNP data are listed in Table 7.4. 
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Table 7.4: Best SNPs plus Haplo.stats inferred haplotypes for full genetic Glioma model 
Best SNPs  
SNP Genetic Trait Beta OR (95% CI) P-Value 
rs4761533 Dominant 0.311 1.365 (1.141-1.633) 0.001 
rs8079544 Dominant 0.456 1.577 (1.256-1.981) < 0.001 
rs10009998 Recessive -2.268 0.104 (0.032-0.338) < 0.001 
rs314253 Additive 0.208 1.231 (1.102-1.375) < 0.001 
rs16833157 Additive -0.425 0.654 (0.500-0.855) 0.002 
rs10484796 Additive -0.140 0.870 (0.781-0.968) 0.011 
rs11265608 Additive 0.316 1.372 (1.158-1.627) < 0.001 
rs1319868 Dominant 0.265 1.303 (1.095-1.551) 0.003 
rs791589 Additive 0.221 1.248 (1.071-1.454) 0.005 
rs10857092 Dominant 0.248 1.281 (1.035-1.585) 0.023 
rs6879021 Additive 0.144 1.155 (1.041-1.282) 0.007 
rs693293 Dominant -0.328 0.720 (0.593-0.875) 0.001 
rs959382 Dominant 0.238 1.268 (1.083-1.486) 0.003 
rs2061450 Additive -0.184 0.832 (0.734-0.942) 0.004 
rs276467 Dominant 0.198 1.219 (1.046-1.421) 0.011 
 
Best Haplotypes without Best SNPs  
Chm. (Gene) Haplotype Genetic Trait OR (95% CI) P-Value 
1 (CD247) AGG Dominant 2.146 (1.336-3.448) 0.002 
6 (HLA-DRA) ATT Additive 0.787 (0.679-0.911) 0.001 
12 (CRADD) AGCGG Recessive 3.291 (1.242-8.725) 0.017 
15 (SMAD3) GCTCA Additive 0.826 (0.728-0.938) 0.003 
15 (SMAD3) GTTTA Recessive 0.236 (0.068-0.818) 0.023 
16 (ITGAX) AGG Dominant 1.251 (1.076-1.454) 0.004 
1 (CD247) TG Additive 1.149 (1.020-1.295) 0.023 
1 (CD247) GA Additive 1.166 (1.008-1.348) 0.039 
10 (PRF1) TGC Additive 1.136 (1.012-1.277) 0.031 
7 (GNAI1) TTTCA Dominant 1.259 (1.083-1.464) 0.003 
 
 Beta Odds Ratio P-Value 
Constant -1.384 0.251 <0.001 
 
In this model, the strongest variable toward Glioma development is the inferred haplotype 
AGCGG on the CRADD gene (OR = 3.291, 95% CI = 1.242-8.725), while the most protective 
variable against Glioma exists with SNP rs10009998 (OR = 0.104, 95% CI = 0.032-0.338).  
Also, both of these genetic risk factors were modeled assuming recessive genetic traits.  None of 
the haplotypes had p-values less than 0.001, while 4 SNPs had p-values less than 0.001.  The 
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most susceptible genetic risk variable assuming either an additive or dominant genetic trait was 
the haplotype AGG on gene CD247 assuming a dominant genetic trait (OR = 2.146, 95% CI = 
1.336-3.448), and the most protective genetic risk variable that was not calculated assuming 
recessive genetics was SNP rs16833157 when assuming an additive genetic trait (OR = 0.654, 
95% CI = 0.500-0.855). 
 To test the effectiveness of the full genetic model (with Haplo.stats inferred haplotypes) 
compared to models with just haplotypes and SNPs only, the discriminatory power and NRI will 
be calculated and examined for all three types of models.  With the full SNP and haplotype 
model with haplotypes modeled by Haplo.stats, discriminatory power is significantly improved 
(p-value = 0.0112) with the full genetic model (AUC = 0.654, 95% CI = 0.634-0.673) compared 
to the SNP only model (AUC = 0.637, 95% CI = 0.617-0.656).  The full genetic model did have 
improved discriminatory power compared to the haplotype only model (AUC = 0.642, 95% CI = 
0.622-0.661), but these results are not significant (p-value = 0.1295).  The increase in overall 
NRI is higher and more significant when examining the full genetic model compared to the SNP 
only model (NRI = 0.1541, p-value = <0.0001), then examining the full genetic model compared 
to the haplotype only model (NRI = 0.0766, p-value = 0.0335).  More improvement is shown for 
cases when SNPs are added to a haplotype only model (NRI = 0.1752, p-value = <0.0001) 
compared to when haplotypes are added to a SNP only model (NRI = 0.0545, p-value = 0.0595).  
Finally, adding haplotypes to a SNP only model substantially improves the results for the 
controls (NRI = 0.0996, p-value = < 0.0001) compared to adding SNPs to a Haplotype only 
model (NRI = -0.0986, p-value = < 0.0001). 
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7.3.3.2.      Best SNPs + Best BJLM Inferred Haplotypes for Glioma 
The next step is to conduct this same analysis using WINBUGS in which all SNPs and 
Haplotypes from the previous section are modeled with non-informative priors and with 5000 
burn-in and 45000 non-burnin iterations.  Models will be constructed using both non-informative 
priors and informative priors for each SNP and haplotype.   Results using haplotypes from 
Haplo.stats and SNP data are listed in Table 7.5. 
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Table 7.5: Complete Genetic Risk Model with SNPs and Haplotypes modeled together 
using WINBUGS 
Non-Inform priors refers to Priors as defined in Figure 6.2 on page 105, where the distribution 
is normal with mean zero and variance of 100.  Informative priors refer to the Priors from 
Appendix 3: Figure One on page 196 and page 197 
 
 Non-Inform Priors Informative Priors 
SNP OR (95% CI) P-Value OR (95% CI) P-Value 
rs4761533 1.37 (1.14-1.64) 0.000711 1.39 (1.23-1.57) < 2.1*10
-5
 
rs8079544 1.58 (1.26-1.98) 0.000089 1.54 (1.31-1.79) < 2.1*10
-5 
rs10009998 0.09 (0.02-0.27) < 2.1*10
-5 
0.10 (0.04-0.23) < 2.1*10
-5 
rs314253 1.23 (1.10-1.38) 0.000178 1.21 (1.12-1.30) < 2.1*10
-5 
rs16833157 0.65 (0.49-0.85) 0.001422 0.66 (0.55-0.79) < 2.1*10
-5
 
rs10484796 0.87 (0.78-0.97) 0.011200 0.86 (0.80-0.93) 0.000089 
rs11265608 1.38 (1.16-1.63) 0.000222 1.34 (1.19-1.50) < 2.1*10
-5
 
rs1319868 1.31 (1.10-1.55) 0.005066 1.33 (1.18-1.49) < 2.1*10
-5
 
rs791589 1.25 (1.07-1.46) 0.005066 1.25 (1.13-1.39) < 2.1*10
-5
 
rs10857092 1.28 (1.03-1.59) 0.023340 1.33 (1.15-1.54) 0.000133 
rs6879021 1.16 (1.04-1.28) 0.007556 1.16 (1.08-1.25) < 2.1*10
-5
 
rs693293 0.72 (0.59-0.87) 0.000711 0.73 (0.63-0.83) < 2.1*10
-5
 
rs959382 1.27 (1.08-1.49) 0.003734 1.29 (1.16-1.44) < 2.1*10
-5
 
rs2061450 0.83 (0.73-0.94) 0.002666 0.83 (0.77-0.91) < 2.1*10
-5
 
rs276467 1.22 (1.05-1.42) 0.010978 1.24 (1.12-1.38) 0.000044 
     
Haplotype 
(Gene) 
OR (95% CI) P-Value OR (95% CI) P-Value 
AGG (CD247) 2.16 (1.34-3.51) 0.001244 2.12 (1.54-2.91) < 2.1*10
-5
 
ATT (HLA-
DRA) 
0.79 (0.68-0.91) 0.001467 0.79 (0.71-0.87) < 2.1*10
-5
 
AGCGG 
(CRADD) 
3.43 (1.30-9.78) 0.011734 3.30 (1.73-6.34) 0.000178 
GCTCA 
(SMAD3) 
0.82 (0.73-0.94) 0.003288 0.83 (0.75-0.91) 0.00044 
GTTTA 
(SMAD3) 
0.20 (0.05-0.67) 0.006222 0.24 (0.10-0.55) 0.000311 
AGG (ITGAX) 1.25 (1.08-1.46) 0.003422 1.26 (1.14-1.40) 0.00044 
TG (CD247) 1.15 (1.02-1.30) 0.020940 1.15 (1.07-1.25) 0.000711 
GA (CD247) 1.17 (1.01-1.35) 0.036660 1.17 (1.07-1.30) 0.001289 
TGC (PRF1) 1.14 (1.01-1.28) 0.029560 1.15 (1.06-1.25) 0.000400 
TTTCA 
(GNAI1) 
1.26 (1.08-1.47) 0.002800 1.23 (1.11-1.37) < 2.1*10
-5
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With these results, no matter if the association results for the genetic risk factors were calculated 
with non-informative priors or informative priors, the most susceptible risk factors and the most 
protective risk factors for Glioma are the same as the results using Haplo.stats haplotypes and the 
best SNPs from the previous analysis.  The odds ratios with the more informative priors are not 
as extreme for the GTTTA haplotype on the SMAD 3 gene (OR = 0.20 with non-informative 
priors vs. OR = 0.24 with informative priors), and also for the AGCGG haplotype for the 
CRADD gene (OR = 3.43 with non-informative priors vs. OR = 3.30 with informative priors). 
 However, the more informative priors lead to much stronger associations in terms of smaller 
empirical p-values.  With the informative priors, 15 out of the 25 genetic risk factors had no 
iterations where the odds ratio was either below one for those associations with mean odds ratios 
greater than one, or the odds ratio was above one for those associations with mean odds ratios 
less than one.  The discriminatory power for models with BJLM inferred haplotypes and non-
informative priors is 0.654 (95% CI = 0.634-0.673), and this model is significantly better 
compared to the SNP only model (p-value = 0.0110), but not significantly better compared to the 
haplotype only model (p-value = 0.1283).  For models with BJLM inferred haplotypes plus SNPs 
and informative priors, the discriminatory power is 0.653 (95% CI = 0.633-0.673).  This model 
is significantly better compared to the SNP only model (p-value = 0.0143), but not significantly 
better compared to the haplotype only model (p-value = 0.1543).  
To further test the effectiveness of the full genetic model (with BJLM inferred 
haplotypes) compared to models with just haplotypes and SNPs only, the NRI will be calculated 
and examined for both BJLM based models.  The increase in overall NRI is higher and more 
significant when examining the full genetic model compared to the SNP only model with both 
non-informative (NRI = 0.1594, p-value = <0.0001) and informative (NRI = 0.1494, p-value = 
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<0.0001) priors, then examining the full genetic model compared to the haplotype only model 
with both non-informative (NRI = 0.0818, p-value = 0.0246) and informative (NRI = 0.0780, p-
value = 0.0320) priors.   
More improvement is shown for cases when SNPs are added to a haplotype only model 
with non-informative (NRI = 0.1625, p-value = <0.0001) and informative (NRI = 0.1558, p-
value = <0.0001) priors compared to when haplotypes are added to a SNP only model with either 
non-informative (NRI = 0.0486, p-value = 0.0932) or informative (NRI = 0.0532, p-value = 
0.0640) priors.  Finally, adding haplotypes to a SNP only model substantially improves the 
results for the controls with either non-informative (NRI = 0.1108, p-value = < 0.0001) or 
informative (NRI = 0.0958, p-value = < 0.0001) priors compared to adding SNPs to a Haplotype 
only model with either non-informative (NRI = -0.0807, p-value = 0.0003) or informative (NRI 
= -0.0778, p-value = 0.0004) priors. 
7.4. Discussion of Glioma Modeling 
The purpose of this study was to develop genetic risk modeled that incorporated 
haplotype analysis to elucidate associations in Glioma that could not be obtained solely with 
single SNP based strategies.  This study showed that haplotypes can increase the discriminatory 
power and the correct estimation of risk in cases and controls, and that even in the presence of 
very significant SNPs, 10 haplotypes did show signification association with Glioma 
development.  For instance, the SMAD3 and CD247 gene were well represented, with five out of 
10 haplotypes in the full genetic model.  The strongest genetic effect that showed susceptibility 
with Glioma development occurred with the inferred haplotype AGCGG from the CRADD gene 
on chromosome 12.  Also, the genetic effect of the AGCGG haplotype on the  CRADD gene 
jumped almost forty percent in the Bayesian model, from OR = 2.53 to OR = 3.43 when SNPs 
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were included in the analysis, which suggests that adding SNPs to haplotype only model may be 
very beneficial in finding strong, but rare associations with haplotypes. 
 Variant alleles on the CD247 gene have been shown to be important factors in 
designating risk for diseases such as lymphocytic leukemia and systemic sclerosis
230,231
.  CD247 
is known to interact with key chronic lymphocytic leukemia biomarker ZAP70, with an increase 
of activity of roughly 1.8 times that seen in normal individuals (p-value = 7.1*10
-8
)
230
.   
However, for systemic sclerosis, SNP rs2056626, a SNP on the CD247 gene, showed a slight 
protective effect against systemic sclerosis
231
.   CD247 encodes subunits of the T-cell receptor 
zeta complex, participates in immune response regulation, and has some local expression in the 
adult brain
231-233
.   Since the local expression of the gene occurs in the brain for adults, it could 
be hypothesized that altered expression of this gene could lead to increased risk for Glioma. 
 Another gene which showed multiple associations with Glioma was SMAD3, or mothers 
against decapentaplegic homolog 3 gene located on Chromosome 15.  However, unlike the 
CD247 gene, variants in this gene were highly protective against Glioma development.  SMAD3 
is involved with in modulating signals with the protein activin and transforming growth factor 
beta, and can limit expression the expression of human telomerase reverse transcription
234
.  
Depressed expression of this gene could be a risk factor for cancer, especially with gastric 
cancer, where 3/8
th
 of the cases have no detective levels of Gastric cancer
234
.  SMAD3 has 
shown decreased expression generally in stage 4 glioblastoma and other forms of Glioma
234-236
.  
In this analysis, the up-regulation of haplotypes along the SMAD3 strongly protect individuals 
from Glioma.  Haplotypes consisting of variant alleles from the SMAD3 gene could eventually 
be a great target for possible gene or drug therapy. 
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 Genomic risk factors with large effects on either Glioma development or protection 
against Glioma have been found on the death domain-containing protein (CRADD) gene located 
on chromosome 12, and the SNP rs10009998, which is located on chromosome 4.  First, the 
CRADD gene has been shown to interact with the caspase-2 pathway, which is a pathway that 
helps to regulate apoptosis via the mitochrondia
237-241
.  By initiating variants on this gene, the 
effect of the CRADD gene on apoptosis could be lessened, which will lead to increased cell 
growth, and this could be a reason for the increased risk of Glioma development.  In a separate 
SNP-SNP analysis in which the interactions of specific SNPs were examined, the number of 
interactions involving the CRADD gene was the third highest among all the inflammation genes, 
which suggests that no matter the analysis, whether single SNP based or haplotype based, the 
CRADD gene is a substantial target for possible Glioma treatment
224
.  Second, the SNP 
rs10009998 exists on the IL15 gene which is located on chromosome 4.  IL-15 is a cell death 
regulator that allows for creation of the natural killer 92 cells (NK-92)
242
.  Up-regulation of IL-
15 leads to a marked increase in expression of NK-92 cells which can increase the rate of 
apoptosis
242
.  With increased apoptosis rates, cell growth is substantially lessened, and this could 
be why variant alleles on the SNP rs10009998 could be crucial in dramatically reducing Glioma 
risk. 
 Despite showing very good results with the genetic risk models, there are some 
limitations with this study.  First, there are no covariates with the controls from CGEMS  that 
can be examined for further analysis, or to improve the risk models even more.  As stated earlier 
in this chapter, most of the potential non-genetic risk factors show weak and contradictory 
evidence for association with Glioma.  However, having age and sex as covariates would have 
allowed for potential absolute risk calculations that could have stated the risk of Glioma for a 
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determined time period.  Second, the CGEMS controls were used initially for prostate and breast 
cancer and not Glioma.  However, the CGEMS controls have been used successfully for previous 
analysis, including an earlier Glioma study
225
, so CGEMS controls have been shown to be viable 
in genetic research. 
 This study has shown the effectiveness of jointly using SNPs and haplotypes in a genetic 
risk model.  In a recent study, simulating 41 and 96 genetic variants for breast cancer with odds 
ratios of 1.3-1.5 are needed to for the discriminatory power to be 0.67 and 0.68 respectively
123
, 
and there are questions whether these values are valid, or have been discovered by chance
124
.  In 
this analysis, 25 genetic variants can lead to discriminatory power of 0.654 for Glioma, and also 
possibly find new areas of association for disease.  By using haplotypes and mixing traits of both 
SNPs and haplotypes, one can maximize the increase in discriminatory power and NRI, and 
begin to develop genetic risk models that can be crucial in discovering new areas of research for 
treatment of Glioma.  
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Chapter 8: Summary and Future Research Directions 
8.1. Summary 
 8.1.1. Summary of Spitz Lung Cancer Validation 
 In this dissertation thesis, the Spitz lung cancer model was validated with data from the 
NELSON group in the Netherlands (PI: Dr. Rob J van Klavaran).  Discriminatory power results 
from the NELSON dataset demonstrated that the Spitz model successfully predicted case/control 
status at 69% (95% CI = 64-75%), which is higher than the internal validation results
27
.  In the 
Harvard data set
67
, discriminatory power was superior for those who were former smokers 
compared to current smokers (0.70 vs. 0.68); however, the opposite is true in the NELSON data 
set (0.74 for current smokers vs. 0.61 for former smokers).  When compared to two other lung 
cancer risk models, the Spitz model’s discriminatory power was comparable to both the 
Liverpool Lung Project’s risk model and the Bach lung cancer risk model.   
In addition, the results of the calibration of the Spitz model, using the NELSON data, was 
good.  In the lowest risk group and the three highest risk groups, the observed rates of disease 
were within the bounds of the 95% CI, but in the higher end of the CI range.   There could be 
two reasons for the discrepancy between observed risk for cancer measured by the total numbers 
of cases divided by the total number of individuals and the 95% CI of the calculated 5 year 
absolute risk for lung cancer.  First, more stringent methods to measure some of the effects of the 
non-smoking variables, especially emphysema, may be needed.  Emphysema has been shown in 
numerous studies to be a statistically significant factor for lung cancer
27,93-95
, so if the risk of 
emphysema is being understated, if patient self-reported emphysema is not clinically validated, 
or if the discriminatory effect of emphysema is low within a data set, absolute risk values may be 
biased toward the null for these individuals, leading to less accurate validity results.  Second, the 
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matching of smoking status within the Spitz model could result in lower absolute risks, and 
hence, the full effect of smoking on lung cancer may not be measured for those with higher lung 
cancer risks despite the use of adjustment factors to account for smoking status.    
8.1.2.   Summary of Why We Need to Better Incorporate Haplotypes into Risk 
Models 
 In Chapter 3, the 1
st
 attempt to extend the Spitz lung cancer risk models using haplotypes 
was conducted using two areas of linkage disequilibrium which was reported by Amos et al
45
.  
These haplotypes were inferred from SNPs rs2736100 and rs401681 from chromosome 5, and 
SNPs rs1051730 and rs8034191 on chromosome 15.  However, models with inferred haplotypes 
did not improve the discriminatory power compared to models with top SNPs from the Texas 
Lung GWAS.  Therefore, the question was asked at the end of chapter three:  Can modeling and 
selection of haplotypes be improved such that increased discriminatory power will be achieved 
in risk models that could be use to select individuals for screening trials or to identify individuals 
at high-risk for incidence of disease?  This would lead to the creation of the BJLM in Chapter 4. 
 With the BJLM, data from HapMap was utilized to infer haplotypes.  The BJLM was 
designed to seamlessly incorporate the genetic information from all 11 populations in the 
HapMap data (Table 1.1).   Haplotypes were inferred with the use of a Bayesian MCMC model 
(section 4.2.2) for individuals with full genetic SNP data.  Individuals with missing SNP data had 
their haplotypes inferred using the set of haplotypes determined with full genetic SNP data by 
the incorporation of a modified forward-backward algorithm (section 4.2.3).  Then, these 
haplotype results were collected assuming additive, dominant, and recessive genetic effects, and 
were then automatically formatted into WINBUGS code from MATLAB so that the effect of 
each inferred haplotype (frequency > 0.01) can be estimated.  Finally, simulations with 
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haplotypes ranging from two to twelve SNPs were created with HapSim, a haplotype simulator 
program written in R
162
.  Genetic data for these simulations were extracted from both the CEU 
and TSI populations in HapMap from the base-pair region 11,754,200 and 11,774,700 in 
chromosome 1.  Also, in the simulation analysis, the missing data ranged from 1% to 5% for 
each SNP to test the robustness of the BJLM.  For all haplotype lengths, increasing amounts of 
missing data did not substantially increase the 95% Credible Intervals of each haplotype inferred, 
therefore the BJLM is stable for inferring haplotypes of length 2 to 12 SNPs. 
  8.1.3.   Summary of Developing Risk Models with BJLM Inferred Haplotypes 
 In Chapters 5, 6, and 7, risk models were constructed using haplotypes from the BJLM 
and haplo.stats with a Hodgkin disease dataset, a Texas Lung GWAS dataset, and a Glioma 
dataset, respectively.  For the Hodgkin data set, discriminatory power was increased for models 
with haplotypes inferred from the BJLM compared to haplo.stats assuming both additive (AUC 
= 0.634, 95% CI = 0.569-0.691 vs. AUC = 0.632, 95% CI = 0.567-0.690) and dominant genetic 
effects  (AUC = 0.644, 95% CI = 0.581-0.699 vs. AUC = 0.643, 95% CI = 0.580-0.699), but this 
increase was not significant for either genetic model (p-value = 0.1562, and p-value = 0.3477 for 
additive and dominant genetic models, respectively). 
 In Chapter six, models with haplotypes inferred from the BJLM had significantly 
increased discriminatory power compared to the original Spitz lung cancer risk model
27
, and also 
the model with haplotypes inferred from haplo.stats.  In fact, the BJLM classified cases 9% 
better than haplo.stats, and classified controls 29% better than haplo.stats according to the Net 
Reclassification Index.   
For the Glioma dataset discussed in Chapter 7, to attempt to improve the genetic models 
by incorporating more genetic information, models with both top SNPs and best Haplotypes 
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were developed.  It was imperative to make sure that there was no inclusion of a top 20 SNP that 
was also included in the same model as a haplotype containing the most significant SNPs.   In 
this case, all haplotypes that were not inferred with a top 20 significant SNP was added to the 
model consisting of single SNPs.  With models that included top SNPs and top haplotypes 
inferred from haplo.stats, there was significant improvement in terms of discriminatory power 
(0.654 vs. 0.637, p = 0.0112), and the NRI (NRI = 0.1541, p-value = < 0.0001) compared to 
models with just SNPs.   These results for discriminatory power (0.654 vs. 0.637, p = 0.0110) 
and NRI (NRI = 0.1594, p-value = < 0.0001) are similar for haplotypes inferred with the BJLM.   
 The improvement with the BJLM compared to other haplotype inferring methods like 
haplo.stats come from estimating more precise associations in terms of p-values from both 
haplotypes with frequencies < 5% and recessive modeled haplotypes.  For instance, with 
haplotype TC on the IL4 gene on Chromosome 5 for the Hodgkin dataset, the overall frequency 
of the haplotype was less than 5%, and the odds ratio as determined by haplo.stats is 9.24 (95% 
CI = 1.81-47.2, p-value = 0.006).  However, the odds ratio as estimated by the BJLM was 12.16 
(95% CI = 2.47-90.1, p-value = 0.00044).  For haplotypes inferred assuming recessive traits, p-
values were more significant with haplotypes inferred using BJLM compared to haplo.stats in all 
five instances where recessive genetic effects were modeled in the Texas Lung GWAS and 
Glioma datasets.  The better determination of haplotype associations assuming recessive genetic 
effects was especially important for extending the Spitz former smoker model using Texas Lung 
GWAS data as haplotype CGAC on the IREB2 gene from Chromosome 15 was significantly 
associated with lung cancer with the BJLM (OR = 9.85, 95% CI = 1.28-218.1, p = 0.0250), but 
not in haplo.stats (OR = 6.56, 95% CI = 0.787-54.66, p-value = 0.0857).  Improvement with 
estimating association with low-frequency haplotypes and recessive haplotypes in the BJLM is 
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due directly to the use of genetic information from HapMap.  With the genetic information from 
HapMap, the control haplotypes assessed in the population being studied are better inferred, so 
the differences in cases can be more precisely extracted compared to programs that use no 
outside information to infer their haplotypes, like haplo.stats.   
8.2. Future Research Directions 
 In this dissertation, a novel Bayesian method was constructed to incorporate genetic 
information from HapMap to estimate haplotypes to study any type of disease.  This involved a 
binary outcome of either disease or no disease as the dependent variable, and the inferred 
haplotypes and other covariates as the independent variables.  Data sets that were examined 
consisted of candidate genes (Hodgkin), inflammation pathways (Glioma), or a selected sub-set 
of SNPs acquired from a meta-analysis (Lung).  Therefore, three potential areas of future 
analysis would be to incorporate genetic information from sources other than HapMap, extend 
the dependent variable to examine non-binary outcomes, and to extend the analysis to full 
genome wide association studies. 
 8.2.1. Incorporate 1000 Genomes as External Data into the BJLM   
 The goal of the 1000 genomes project is to attempt to find more common variants that 
have minor allele frequency of 1% by the process of gene sequencing, which breaks a subject’s 
DNA into smaller sections.  In the 1000 genomes project, sequencing was first conducted four 
times each for each subject (4x).  Then, for 1000 specific regions of the genome, sequencing was 
conducted at a much higher rate (50x).  Data for the 1000 genome project is located on the 1000 
genome website (http://browser.1000genomes.org/index.html) and can be extracted into 
Haploview ready format consistently for a small base pair range (10000-25000 bp).  The 1000 
genome data has some advantages over HapMap data in that there are actually more SNPs 
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available for genetic analysis; however, it generally has less samples per population than 
HapMap data because of the expense that was involved with sequencing.   
 To incorporate 1000 genome data seamlessly into the BJLM, the genetic SNP data would 
have to be filtered similarly to the data from HapMap.  This process could be done in a 
spreadsheet relatively easily, but would need to be coded for use by the BJLM.  The process 
needed to extract the 1000 genomes data from the 1000 genomes website for a specific 
population is shown schematically (Figure 8.1). 
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Figure 8.1:  Process for Extracting 1000 Genomes Data for Future Analysis 
 
Figure 8.1:  With 1000 genome data, genetic information from all populations studied in the 
1000 genomes project is loaded as a genotype file for further examination.  Therefore, only those 
individuals that occur in the same population as the dataset to be examined would have to be 
extracted from the 1000 genome database.  For example, if studying the Texas Lung GWAS 
population from Chapter 6, only Caucasians from the 1000 genomes data can be used to make 
inferences on the genetic data, and this occurs in the 1000 genome data from those with id 
numbers NA06984 to NA12890.  Also, in the 1000 genome data, multiple sets of genotype 
information are available for the same individual, and this has to be filtered out so that only one 
set of genotypes exist for one individual.   
 
 
All of this was could be conducted with a spreadsheet program,, but for perfect integration into 
the BJLM, code would have to be developed in MATLAB, or a similar language, to perform this 
task automatically. 
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8.2.2. Incorporate Non-Binary Outcomes 
 In this dissertation, the dependent variable was disease status; however, there are many 
cases in which the dependent variable may be non-binary.  For example, one may want to test the 
association between genetic information like SNPs and haplotypes and inflammatory 
biomarkers.  For lung cancer, an important host susceptibility biomarker of increasing 
importance is the smokers’ sensitivity to the nicotine-derived nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanome (NNK), which is a strong pulmonary 
carcinogen
243-246
.   Identifying important genes involved in the metabolism and/or repair of 
damage induced by such a potent carcinogen may allow better identification of high risk 
individuals.  With programs like WINBUGS, models can be constructed that can examine the 
association between important areas of the genome for lung cancer susceptibility and 
protectively and the mechanism of NNK carcinogenicity.  Better elucidation of the relationship 
between haplotypes and the NNK could lead to better drug targets to treat lung damage.   
 8.2.3. Extend Analysis to Full GWAS studies and Final Conclusion 
 In two of the three analyses conducted with the BJLM, genetic data was obtained from 
sub-sections of large GWAS studies, whether that was for the extension of the Spitz lung cancer 
risk models with haplotypes or for the creation of a Glioma risk model.  The Spitz lung cancer 
risk model was extended with haplotypes, and this led to higher discriminatory power increases 
than with previously published extension of the Spitz lung cancer risk model with just SNPs
30
.  
Also, with just 15 SNPs and 10 haplotypes, a purely genetic Glioma model was created from 
genetic information in the inflammation pathway, and discriminatory power was 65.4%. 
Furthermore, this model had significantly increased discriminatory power compared to a model 
with just top SNPs from the inflammation pathway (0.654 vs. 0.637, p = 0.0110).  These 
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promising results suggest that genetic models that incorporate the information from a full GWAS 
analysis will lead to even better modeling of disease.  Therefore, I propose conducting analysis 
throughout the genome to find the absolute best haplotype and SNP associations with lung 
cancer and Glioma (p-value of 10
-7 
or less only), and developing risk models that could be used 
in cancer prevention studies, screening trials, personalized medicine clinics, or even drug 
development.  Finding the genetic associations that lead to better modeling of disease causation 
will lead to better treatment of disease, and the BJLM may become a vital instrument in finding 
these important genetic associations with disease. 
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Appendix 1:  Incidence rates and mortality rates used to calculate absolute risk in the 
validation of the Spitz lung cancer risk model in Chapter 2 
 
Table 1: Lung cancer and mortality rates per 100,000 (excluding lung cancer) by age and 
sex for residents of the Netherlands 
Age 
(years) 
Men Women 
Incidence Mortality Incidence Mortality 
50–54 61.4 43.9 75.0 49.4 
55–59 115.8 87.0 90.6 69.3 
60–64 192.4 151.7 129.9 104.8 
65–69 325.1 258.4 142.3 114.9 
70–74 474.2 432.8 174.4 166.7 
 
 
Table 2:  Adjustment constants* (acji) to estimate smoking status–specific incidence rates in 
the NELSON Data Set 
Sex Never Smokers Former Smokers Current Smokers 
Male 0.12 2.55 2.99† 
Female 0.42 3.08 3.17 
 
* Adjustment constants (acji, j = 1 male, j = 2 female; i = 1 never smoker, i = 2 former smoker,  
i = 3 current smoker) computed based on the following prevalence estimates: According to data 
from the Netherlands Cohort Study on Diet and Cancer, 96.4% of all male lung cancer cases and 
79.3% of all female lung cancer cases occur in ever smokers
1a
; 32.2% of men (aged 15+) and 
25.0% of women (aged 15+) were current smokers
2a
, 30.0% of men and 49.7% of women were 
never smokers
3a
, and therefore 37.8% of men and 25.7% of women were former smokers
3a
. 
† Therefore, for a male current smoker, the constant is derived from the ratio of the proportion of 
all lung cancer cases in ever-smoking men (0.964) to the proportion of male current smokers in 
the population at risk (0.322), i.e., ac13 = 0.964/0.322 = 2.99 
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Appendix 2: Simulating Missing Data Results for all Haplotypes > 5% Frequency in the 
BJLM Simulation Study for Haplotypes of Length 4 to 11 
Table 1: Haplotype Frequencies for 4 SNP Haplotypes.  CI = Credible Interval 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGAC 0.307 0.284 0.334 
11 CAAC 0.156 0.137 0.181 
4 TGGT 0.140 0.118 0.161 
3 TGGC 0.102 0.086 0.122 
14 CAGT 0.081 0.061 0.098 
5 TAAC 0.075 0.057 0.089 
2% Missing SNP Data 
1 TGAC 0.306 0.281 0.331 
11 CAAC 0.161 0.141 0.181 
4 TGGT 0.142 0.124 0.159 
3 TGGC 0.102 0.084 0.121 
14 CAGT 0.083 0.065 0.104 
5 TAAC 0.075 0.059 0.089 
3% Missing SNP Data 
1 TGAC 0.309 0.286 0.335 
11 CAAC 0.159 0.138 0.184 
4 TGGT 0.141 0.122 0.161 
3 TGGC 0.101 0.080 0.122 
14 CAGT 0.085 0.069 0.102 
5 TAAC 0.078 0.058 0.092 
4% Missing SNP Data 
1 TGAC 0.314 0.283 0.338 
11 CAAC 0.164 0.137 0.189 
4 TGGT 0.144 0.125 0.167 
3 TGGC 0.098 0.084 0.115 
14 CAGT 0.084 0.068 0.104 
5 TAAC 0.075 0.063 0.091 
5% Missing SNP Data 
1 TGAC 0.304 0.271 0.327 
11 CAAC 0.167 0.145 0.187 
4 TGGT 0.152 0.135 0.175 
3 TGGC 0.104 0.077 0.127 
14 CAGT 0.084 0.067 0.104 
5 TAAC 0.071 0.054 0.088 
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Figure 1: Graphical Representations for 4 SNP Haplotypes 
A) 1% Missing Data     B) 2% Missing Data 
           
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 1:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGAC, Red Line = CAAC, Green Line = TGGT, Purple Line = 
TGGC, Light Blue Line = CAGT, and Orange Line = TAAC. 
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Table 2: Haplotype Frequencies for 5 SNP Haplotypes.  CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACC 0.305 0.274 0.329 
13 CAACC 0.157 0.129 0.178 
6 TGGTT 0.140 0.122 0.161 
4 TGGCC 0.102 0.089 0.121 
18 CAGTT 0.079 0.062 0.093 
7 TAACC 0.074 0.060 0.088 
2% Missing SNP Data 
1 TGACC 0.304 0.283 0.327 
13 CAACC 0.162 0.131 0.180 
6 TGGTT 0.143 0.122 0.160 
4 TGGCC 0.100 0.084 0.119 
18 CAGTT 0.081 0.061 0.098 
7 TAACC 0.075 0.060 0.094 
3% Missing SNP Data 
1 TGACC 0.306 0.284 0.332 
13 CAACC 0.161 0.138 0.179 
6 TGGTT 0.141 0.120 0.163 
4 TGGCC 0.100 0.078 0.117 
18 CAGTT 0.083 0.064 0.103 
7 TAACC 0.080 0.063 0.097 
4% Missing SNP Data 
1 TGACC 0.297 0.268 0.328 
13 CAACC 0.161 0.137 0.184 
6 TGGTT 0.147 0.132 0.168 
4 TGGCC 0.102 0.083 0.121 
18 CAGTT 0.086 0.068 0.105 
7 TAACC 0.077 0.059 0.091 
5% Missing SNP Data 
1 TGACC 0.298 0.269 0.330 
13 CAACC 0.165 0.139 0.190 
6 TGGTT 0.151 0.124 0.167 
4 TGGCC 0.097 0.077 0.117 
18 CAGTT 0.084 0.061 0.100 
7 TAACC 0.079 0.062 0.098 
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Figure 2: Graphical Representations for 5 SNP Haplotypes 
A) 1% Missing Data     B) 2% Missing Data 
 
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 2:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACC, Red Line = CAACC, Green Line = TGGTT, Purple Line = 
TGGCC, Light Blue Line = CAGTT, and Orange Line = TAACC. 
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Table 3: Haplotype Frequencies for 6 SNP Haplotypes.  CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCT 0.303 0.281 0.327 
13 CAACCC 0.156 0.135 0.175 
6 TGGTTT 0.141 0.123 0.162 
4 TGGCCT 0.099 0.082 0.118 
18 CAGTTC 0.081 0.059 0.101 
7 TAACCC 0.075 0.057 0.087 
2% Missing SNP Data 
1 TGACCT 0.300 0.274 0.323 
13 CAACCC 0.158 0.137 0.183 
6 TGGTTT 0.142 0.120 0.165 
4 TGGCCT 0.101 0.085 0.123 
18 CAGTTC 0.082 0.064 0.100 
7 TAACCC 0.079 0.065 0.093 
3% Missing SNP Data 
1 TGACCT 0.299 0.272 0.322 
13 CAACCC 0.162 0.138 0.181 
6 TGGTTT 0.145 0.126 0.164 
4 TGGCCT 0.101 0.083 0.120 
18 CAGTTC 0.083 0.067 0.100 
7 TAACCC 0.079 0.060 0.101 
4% Missing SNP Data 
1 TGACCT 0.293 0.264 0.318 
13 CAACCC 0.159 0.138 0.189 
6 TGGTTT 0.148 0.124 0.167 
4 TGGCCT 0.100 0.082 0.117 
18 CAGTTC 0.084 0.071 0.103 
7 TAACCC 0.084 0.066 0.102 
5% Missing SNP Data 
1 TGACCT 0.291 0.265 0.324 
13 CAACCC 0.164 0.139 0.188 
6 TGGTTT 0.146 0.126 0.173 
4 TGGCCT 0.100 0.084 0.120 
18 CAGTTC 0.085 0.067 0.104 
7 TAACCC 0.082 0.059 0.100 
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Figure 3: Graphical Representations for 6 SNP Haplotypes 
A) 1% Missing Data     B) 2% Missing Data 
       
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 3:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACCT, Red Line = CAACCC, Green Line = TGGTTT, Purple 
Line = TGGCCT, Light Blue Line = CAGTTC, and Orange Line = TAACCC. 
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Table 4: Haplotype Frequencies for 7 SNP Haplotypes.  CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCTC 0.292 0.258 0.315 
19 CAACCCC 0.153 0.129 0.175 
8 TGGTTTC 0.113 0.088 0.128 
24 CAGTTCC 0.081 0.065 0.104 
10 TAACCCC 0.072 0.058 0.086 
5 TGGCCTC 0.061 0.046 0.073 
2% Missing SNP Data 
1 TGACCTC 0.288 0.261 0.311 
19 CAACCCC 0.159 0.137 0.181 
8 TGGTTTC 0.112 0.089 0.132 
24 CAGTTCC 0.084 0.067 0.101 
10 TAACCCC 0.072 0.055 0.087 
5 TGGCCTC 0.059 0.044 0.074 
3% Missing SNP Data 
1 TGACCTC 0.281 0.256 0.308 
19 CAACCCC 0.161 0.137 0.180 
8 TGGTTTC 0.116 0.098 0.132 
24 CAGTTCC 0.084 0.068 0.100 
10 TAACCCC 0.073 0.060 0.094 
5 TGGCCTC 0.060 0.045 0.076 
4% Missing SNP Data 
1 TGACCTC 0.281 0.251 0.313 
19 CAACCCC 0.162 0.140 0.184 
8 TGGTTTC 0.115 0.098 0.133 
24 CAGTTCC 0.085 0.068 0.104 
10 TAACCCC 0.076 0.060 0.091 
5 TGGCCTC 0.057 0.044 0.078 
5% Missing SNP Data 
1 TGACCTC 0.284 0.259 0.306 
19 CAACCCC 0.165 0.141 0.189 
8 TGGTTTC 0.115 0.094 0.130 
24 CAGTTCC 0.086 0.067 0.101 
10 TAACCCC 0.076 0.057 0.093 
5 TGGCCTC 0.059 0.043 0.075 
 
 
 
 
 
 
187 
 
 
Figure 4: Graphical Representation for 7 SNP Examinations 
 
A) 1% Missing Data     B) 2% Missing Data 
         
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 4:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACCTC, Red Line = CAACCCC, Green Line = TGGTTTC, 
Purple Line = CAGTTCC, Light Blue Line = TAACCCC, and Orange Line = TGGCCTC. 
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Table 5: Haplotype Frequencies for 8 SNP Haplotypes.  CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCTCC 0.288 0.263 0.319 
19 CAACCCCC 0.160 0.132 0.180 
8 TGGTTTCT 0.110 0.091 0.126 
24 CAGTTCCT 0.081 0.063 0.101 
10 TAACCCCC 0.071 0.056 0.082 
5 TGGCCTCC 0.061 0.049 0.075 
2% Missing SNP Data 
1 TGACCTCC 0.287 0.268 0.309 
19 CAACCCCC 0.159 0.140 0.182 
8 TGGTTTCT 0.115 0.095 0.137 
24 CAGTTCCT 0.082 0.067 0.097 
10 TAACCCCC 0.075 0.057 0.094 
5 TGGCCTCC 0.059 0.045 0.073 
3% Missing SNP Data 
1 TGACCTCC 0.278 0.254 0.304 
19 CAACCCCC 0.167 0.143 0.191 
8 TGGTTTCT 0.121 0.098 0.139 
24 CAGTTCCT 0.077 0.059 0.094 
10 TAACCCCC 0.074 0.061 0.090 
5 TGGCCTCC 0.058 0.046 0.073 
4% Missing SNP Data 
1 TGACCTCC 0.279 0.251 0.308 
19 CAACCCCC 0.166 0.142 0.188 
8 TGGTTTCT 0.119 0.097 0.139 
24 CAGTTCCT 0.084 0.064 0.102 
10 TAACCCCC 0.075 0.058 0.092 
5 TGGCCTCC 0.060 0.045 0.077 
5% Missing SNP Data 
1 TGACCTCC 0.278 0.250 0.301 
19 CAACCCCC 0.171 0.145 0.195 
8 TGGTTTCT 0.123 0.100 0.150 
24 CAGTTCCT 0.080 0.060 0.097 
10 TAACCCCC 0.079 0.062 0.095 
5 TGGCCTCC 0.058 0.045 0.074 
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Figure 5: Graphical Representation for 8 SNP Examinations  
 
A) 1% Missing Data     B) 2% Missing Data 
     
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 5:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACCTCC, Red Line = CAACCCCC, Green Line = TGGTTTCT, 
Purple Line = CAGTTCCT, Light Blue Line = TAACCCCC, and Orange Line = TGGCCTCC. 
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Table 6: Haplotype Frequencies for 9 SNP Haplotypes. CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCTCCA 0.285 0.257 0.310 
22 CAACCCCCA 0.158 0.137 0.178 
9 TGGTTTCTG 0.112 0.097 0.128 
28 CAGTTCCTG 0.079 0.063 0.094 
11 TAACCCCCA 0.074 0.059 0.093 
6 TGGCCTCCA 0.060 0.046 0.072 
2% Missing SNP Data 
1 TGACCTCCA 0.286 0.261 0.318 
22 CAACCCCCA 0.157 0.133 0.186 
9 TGGTTTCTG 0.116 0.094 0.134 
28 CAGTTCCTG 0.084 0.065 0.101 
11 TAACCCCCA 0.074 0.057 0.090 
6 TGGCCTCCA 0.059 0.044 0.076 
3% Missing SNP Data 
1 TGACCTCCA 0.281 0.255 0.311 
22 CAACCCCCA 0.160 0.138 0.182 
9 TGGTTTCTG 0.117 0.092 0.140 
28 CAGTTCCTG 0.085 0.071 0.101 
11 TAACCCCCA 0.076 0.057 0.093 
6 TGGCCTCCA 0.061 0.046 0.078 
4% Missing SNP Data 
1 TGACCTCCA 0.277 0.250 0.303 
22 CAACCCCCA 0.161 0.137 0.191 
9 TGGTTTCTG 0.120 0.103 0.139 
28 CAGTTCCTG 0.083 0.068 0.103 
11 TAACCCCCA 0.078 0.064 0.094 
6 TGGCCTCCA 0.059 0.043 0.072 
5% Missing SNP Data 
1 TGACCTCCA 0.285 0.254 0.312 
22 CAACCCCCA 0.165 0.143 0.187 
9 TGGTTTCTG 0.115 0.099 0.139 
28 CAGTTCCTG 0.084 0.065 0.099 
11 TAACCCCCA 0.079 0.058 0.098 
6 TGGCCTCCA 0.056 0.041 0.072 
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Figure 6: Graphical Representation for 9 SNP Examinations 
 
A) 1% Missing Data     B) 2% Missing Data 
         
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 6:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACCTCCA, Red Line = CAACCCCCA, Green Line = 
TGGTTTCTG, Purple Line = CAGTTCCTG, Light Blue Line = TAACCCCCA, and Orange 
Line = TGGCCTCCA. 
 
 
 
 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
1 9 
17
 
25
 
33
 
41
 
49
 
57
 
65
 
73
 
81
 
89
 
97
 0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
1 9 
17
 
25
 
33
 
41
 
49
 
57
 
65
 
73
 
81
 
89
 
97
 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
1 13
 
25
 
37
 
49
 
61
 
73
 
85
 
97
 0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
1 13
 
25
 
37
 
49
 
61
 
73
 
85
 
97
 0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
0.35 
1 13
 
25
 
37
 
49
 
61
 
73
 
85
 
97
 
192 
 
Table 7: Haplotype Frequencies for 10 SNP Haplotypes. CI = Credible Interval 
 
Haplotype # 
 
Haplotype Median 
Frequency  
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCTCCAT 0.286 0.258 0.315 
9 TGGTTTCTGT 0.112 0.092 0.130 
24 CAACCCCCAT 0.103 0.079 0.122 
11 TAACCCCCAT 0.076 0.058 0.094 
34 CAGTTCCTGT 0.066 0.050 0.084 
6 TGGCCTCCAT 0.059 0.047 0.074 
2% Missing SNP Data 
1 TGACCTCCAT 0.281 0.251 0.308 
9 TGGTTTCTGT 0.113 0.090 0.134 
24 CAACCCCCAT 0.105 0.084 0.121 
11 TAACCCCCAT 0.074 0.061 0.089 
34 CAGTTCCTGT 0.073 0.054 0.090 
6 TGGCCTCCAT 0.061 0.044 0.073 
3% Missing SNP Data 
1 TGACCTCCAT 0.275 0.249 0.302 
9 TGGTTTCTGT 0.116 0.093 0.136 
24 CAACCCCCAT 0.104 0.087 0.125 
11 TAACCCCCAT 0.076 0.056 0.094 
34 CAGTTCCTGT 0.073 0.057 0.090 
6 TGGCCTCCAT 0.062 0.046 0.076 
4% Missing SNP Data 
1 TGACCTCCAT 0.278 0.241 0.306 
9 TGGTTTCTGT 0.120 0.099 0.139 
24 CAACCCCCAT 0.107 0.084 0.128 
11 TAACCCCCAT 0.081 0.061 0.102 
34 CAGTTCCTGT 0.069 0.051 0.081 
6 TGGCCTCCAT 0.059 0.043 0.075 
5% Missing SNP Data 
1 TGACCTCCAT 0.281 0.253 0.308 
9 TGGTTTCTGT 0.123 0.098 0.147 
24 CAACCCCCAT 0.109 0.090 0.129 
11 TAACCCCCAT 0.077 0.057 0.093 
34 CAGTTCCTGT 0.071 0.051 0.093 
6 TGGCCTCCAT 0.060 0.045 0.077 
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Figure 7: Graphical Representation for 10 SNP Examinations 
 
A) 1% Missing Data     B) 2% Missing Data 
          
C) 3% Missing Data  D) 4 % Missing Data  E) 5 % Missing Data 
 
Figure 7:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = TGACCTCCAT, Red Line = TGGTTTCTGT, Green Line = 
CAACCCCCAT, Purple Line = TAACCCCCAT, Light Blue Line = CAGTTCCTGT, and 
Orange Line = TGGCCTCCAT. 
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Table 8: Haplotype Frequencies for 11 SNP Haplotypes.  CI = Credible Interval 
Haplotype # Haplotype Median 
Frequency 
2.5% 
CI 
97.5% 
CI 
1% Missing SNP Data 
1 TGACCTCCATG 0.273 0.249 0.296 
12 TGGTTTCTGTG 0.114 0.095 0.131 
29 CAACCCCCATG 0.079 0.061 0.097 
42 CAGTTCCTGTG 0.068 0.052 0.086 
8 TGGCCTCCATG 0.061 0.047 0.075 
14 TAACCCCCATG 0.055 0.044 0.070 
2 % Missing SNP Data 
1 TGACCTCCATG 0.270 0.244 0.292 
12 TGGTTTCTGTG 0.117 0.098 0.138 
29 CAACCCCCATG 0.076 0.058 0.095 
42 CAGTTCCTGTG 0.071 0.056 0.092 
8 TGGCCTCCATG 0.060 0.046 0.077 
14 TAACCCCCATG 0.053 0.040 0.069 
3% Missing SNP Data 
1 TGACCTCCATG 0.267 0.230 0.300 
12 TGGTTTCTGTG 0.116 0.097 0.138 
29 CAACCCCCATG 0.078 0.059 0.096 
42 CAGTTCCTGTG 0.073 0.052 0.091 
8 TGGCCTCCATG 0.060 0.048 0.075 
14 TAACCCCCATG 0.055 0.040 0.068 
4% Missing SNP Data 
1 TGACCTCCATG 0.273 0.243 0.298 
12 TGGTTTCTGTG 0.117 0.098 0.135 
29 CAACCCCCATG 0.082 0.062 0.096 
42 CAGTTCCTGTG 0.069 0.052 0.085 
8 TGGCCTCCATG 0.059 0.041 0.072 
14 TAACCCCCATG 0.053 0.038 0.075 
5% Missing SNP Data 
1 TGACCTCCATG 0.269 0.237 0.305 
12 TGGTTTCTGTG 0.123 0.098 0.146 
29 CAACCCCCATG 0.081 0.059 0.100 
42 CAGTTCCTGTG 0.064 0.046 0.080 
8 TGGCCTCCATG 0.061 0.043 0.074 
14 TAACCCCCATG 0.052 0.034 0.066 
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Figure 8: Graphical Representations for 11 SNP Haplotypes 
A) 1% Missing Data    B) 2% Missing Data 
       
C) 3% Missing Data  D)  4% Missing Data E)  5% Missing Data  
 
Figure 8:  The X axis is the simulation run, and the Y axis is the haplotype frequency.  The lines 
are as follows:  Blue Line = Haplotype TGACCTCCATG, Red Line = Haplotype 
TGGTTTCTGTG, Green Line = Haplotype CAACCCCCATG, Purple Line = Haplotype 
TGGCCTCCATG, and the Light Blue Line = Haplotype CAGTTCCTGTG. 
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Appendix 3: Chapter 7 (Glioma Development) 
Figure 1: Sample WINBUGS Code for Analysis with Informative Priors  
model 
{ 
for( i in 1 : N ) { 
 casecntl[i] ~ dbin(p[i],1) 
 logit(p[i]) <- alpha + (beta[1]*rs4761533[i]) + (beta[2]*rs8079544[i]) 
 + (beta[3]*rs10009998[i]) + (beta[4]*rs314253[i]) + (beta[5]*rs16833157[i])  
 + (beta[6]*rs10484796[i]) + (beta[7]*rs11265608[i]) + (beta[8]*rs1319868[i])  
 + (beta[9]*rs791589[i]) + (beta[10]*rs10857092[i]) + (beta[11]*rs6879021[i])  
 + (beta[12]*rs693293[i]) + (beta[13]*rs959382[i]) + (beta[14]*rs2061450[i])  
 + (beta[15]*rs276467[i]) + (beta[16]*Haplo2CD247[i]) 
+ (beta[17]*Haplo2HLADRA[i]) + (beta[18]*Haplo8CRADD2[i])  
+ (beta[19]*Haplo8SMAD3[i]) + (beta[20]*Haplo5SMAD3[i])  
+ (beta[21]*Haplo5ITGAX[i]) + (beta[22]*Haplo2CD2472[i]) 
+(beta[23]*Haplo3CD2472[i]) + inprod(d[],Genetics[i,]) 
}     
#  Inprod functions represents a matrix of the final two Haplotypes to be examined  
# (PRF1 and GNAI1) 
 # Priors for logit model 
 alpha ~ dnorm(0.0,1.0E-2) 
beta[1] ~ dnorm(0.341,138.4083) 
 beta[2] ~ dnorm(0.405,84.168) 
 beta[3] ~ dnorm(-2.219,2.815189) 
 beta[4] ~ dnorm(0.173,355.9986) 
 beta[5] ~ dnorm(-0.414,60.09254) 
 beta[6] ~ dnorm(-0.165,384.4675) 
 beta[7] ~ dnorm(0.265,152.4158) 
 beta[8] ~ dnorm(0.296,145.1589) 
 beta[9] ~ dnorm(0.230,182.615) 
 beta[10] ~ dnorm(0.319,94.25959) 
 beta[11] ~ dnorm(0.157,384.4675) 
 beta[12] ~ dnorm(-0.311,113.1734) 
beta[13] ~ dnorm(0.270,173.1302) 
 beta[14] ~ dnorm(-0.178,277.7778) 
 beta[15] ~ dnorm(0.237,192.9012) 
 beta[16] ~ dnorm(0.7401,20.03704) 
 beta[17] ~ dnorm(-0.23413,180.1721) 
 beta[18] ~ dnorm(1.1938,5.07264) 
 beta[19] ~ dnorm(-0.1866,191.834) 
 beta[20] ~ dnorm(-1.3624,2.614936) 
 beta[21] ~ dnorm(0.2366,183.6062) 
 beta[22] ~ dnorm(0.144,313.2587) 
 beta[23] ~ dnorm(0.172,203.4998) 
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 d[1]~dnorm(0.1568,309.9583) 
 d[2]~dnorm(0.1897,172.6755) 
 # Determine Empirical p-value in Bayesian Context (P = 23, K = 2) 
 for (o in 1:P) { 
  betapabove[o] <- step(beta[o]-0) 
  betapbelow[o] <- 1-step(beta[o]-0) 
   } 
 for (l in 1:K)  
   { 
   dpabove[l] <- step(d[l]-0) 
dpbelow[l] <- 1-step(d[l]-0) 
      } 
} 
   
 #INSERT DATA HERE 
  
Inits1  list(alpha = 0, beta = c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0), d = c(0,0)) 
 
 
Table 1: Location of Haplotypes that do not overlap with each other 
Haplotypes  Chromosome Genes 
AGG 1 CD247 
ATT 6 HLA-DRA 
AAT 12 IGF1 
AGCGG 12 CRADD 
GCTCA 15 SMAD3 
GTTTA 15 SMAD3 
AGG 16 ITGAX 
TG 1  CD247 
GA 1  CD247 
AGA 2 
 
STAT 
TGC 10  PRF1 
TTTCA 7  GNAI1 
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Table 2: Most Significant SNPs for the Glioma Inflammation Set 
SNP (rs Number) Chromosome Base-Pair P-Value 
rs4761533 12 92826085 0.000179 
rs8079544 17 7520777 0.000325 
rs10009998 4 142981726 0.000607 
rs7963343 12 92819753 0.000669 
rs865926 12 101469341 0.000696 
rs314253 17 7032374 0.001055 
rs16833157 2 191570643 0.001073 
rs10484796 6 137477360 0.001151 
rs11265608 1 152630764 0.001218 
rs1319868 15 97004502 0.001469 
rs2840191 6 91543934 0.001611 
rs791589 10 6129577 0.00176 
rs10857092 4 123608669 0.001864 
rs6879021 5 86530513 0.001916 
rs693293 3 139891866 0.00205 
rs2395175 6 32513004 0.002267 
rs959382 2 181915047 0.002414 
rs2061450 18 58911792 0.002572 
rs7341365 6 91537489 0.002641 
rs276467 6 137505911 0.002712 
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Table 3: Associations between Best SNPs and Glioma assuming best genetic model for each 
SNP 
Chromosome SNP  Base-Pair Genetic Model OR (95% CI) P-Value 
12 rs4761533 92826085 Dominant 1.406 (1.191-1.660) < 0.001 
17 rs8079544 7520777 Dominant 1.499 (1.212-1.854) < 0.001 
4 rs10009998 142981726 Recessive 0.109 (0.034-0.350) < 0.001 
12 rs7963343 92819753 Dominant 1.326 (1.141-1.540) < 0.001 
12 rs865926 101469341 Dominant 1.523 (1.197-1.938) 0.001 
17 rs314253 7032374 Additive 1.189 (1.072-1.318) 0.001 
2 rs16833157 191570643 Additive 0.661 (0.513-0.851) 0.001 
6 rs10484796 137477360 Additive 0.848 (0.768-0.937) 0.001 
1 rs11265608 152630764 Additive 1.303 (1.111-1.529) 0.001 
15 rs1319868 97004502 Dominant 1.344 (1.141-1.583) < 0.001 
6 rs2840191 91543934 Dominant 1.341 (1.166-1.542) < 0.001 
10 rs791589 6129577 Additive 1.259 (1.089-1.455) 0.002 
4 rs10857092 123608669 Dominant 1.376 (1.125-1.683) 0.002 
5 rs6879021 86530513 Additive 1.170 (1.059-1.292) 0.002 
3 rs693293 139891866 Dominant 0.733 (0.610-0.880) 0.001 
6 rs2395175 32513004 Additive 1.231 (1.077-1.407) 0.002 
2 rs959382 181915047 Dominant 1.310 (1.129-1.521) < 0.001 
18 rs2061450 58911792 Additive 0.837 (0.744-0.941) 0.003 
6 rs7341365 91537489 Dominant 1.325 (1.152-1.524) < 0.001 
6 rs276467 137505911 Dominant 1.268 (1.100-1.461) 0.001 
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Table 4: Best association results from the 18 unique haplotypes blocks, and the best genetic 
model for which the results were determined, are listed below: 
 
 Haplo.stats results BJLM results 
Chm.  
(Gene) 
Haplotype Genetic 
Model 
OR  
(95% CI) 
P-value OR  
(95% CI) 
P-value
1 
12 
(CRADD) 
GCAGA Dominant 1.45(1.22-1.71) 0.000021 1.44(1.22-1.71) 0.000044 
1 (IL6R) GGAA Additive 1.37(1.15-1.62) 0.000303 1.36(1.15-1.62) 0.000178 
1 (CD247) AGG Dominant 2.10(1.35-3.25) 0.000932 2.11(1.36-3.27) 0.000756 
17 (DLG4) AG Additive 1.16(1.04-1.30) 0.00841 1.16(1.04-1.30) 0.009022 
6 
(HLA-DRA) 
ATT Additive 0.79(0.68-0.92) 0.00170 0.79(0.68-0.91) 0.00187 
12 (IGF1) AAT Dominant 1.45(1.16-1.82) 0.00112 1.45(1.16-1.81) 0.00111 
15 (IGF1R) AG Dominant 1.27(1.09-1.48) 0.00243 1.27(1.09-1.48) 0.00218 
15 (IGF1R) AT Dominant 1.42(1.20-1.69) 0.00038 1.42(1.20-1.69) 0.000133 
6 (IL22RA2) TCGGG Additive 0.85(0.75-0.97) 0.0121 0.85(0.75-0.96) 0.0106 
6 (IL22RA2) TTGAA Dominant 0.75(0.61-0.91) 0.00359 0.75(0.61-0.91) 0.00267 
3 (PIK3CB) TGCGAC
C 
Dominant 0.72(0.60-0.87) 0.000704 0.72(0.60-0.87) 0.000444 
6 
(MAP3K7) 
GT Dominant 1.34(1.16-1.54) 0.000048 1.34(1.17-1.54) 0.000088 
12 
(CRADD) 
AGCGG Additive 1.35(1.13-1.61) 0.000889 1.36(1.14-1.62) 0.000978 
15 
(SMAD3) 
GCTCA Recessive 0.26(0.08-0.86) 0.0277 0.22(0.05-0.70) 0.00671 
15 
(SMAD3) 
GTTTA Additive 0.83(0.72-0.96) 0.00982 0.83(0.72-0.96) 0.00947 
16 (ITGAX) AGG Dominant 1.27(1.10-1.46) 0.00136 1.30(1.12-1.51) 0.000578 
6 
(HLA-DRA) 
GCGACC
AGTAC 
Additive 1.25(1.07-1.49) 0.00575 1.25(1.07-1.47) 0.00538 
6 
(HLA-DRA) 
ACGACC
GGGGC 
Recessive 0.52(0.27-0.99) 0.0461 0.51(0.25-0.95) 0.0336 
1 (CD247) TG Additive 1.15(1.03-1.29) 0.0111 1.14(1.02-1.27) 0.0241 
1 (CD247) GA Additive 1.18(1.04-1.36) 0.0142 1.16(1.01-1.33) 0.0359 
2 (STAT)
2 
AGA Additive 0.86(0.76-0.96) 0.0116 0.85(0.76-0.96) 0.0115 
10 (PRF1) TGC Additive 1.17(1.05-1.31) 0.00602 1.17(1.05-1.30) 0.00644 
7 (GNAI1) TTTCA Dominant 1.21(1.04-1.40) 0.0127 1.21(1.05-1.41) 0.0112 
1 
 P-Value in this case is 2*min(freq(coefficient above zero), freq(coefficient below zero)) for 
each non burn-in run of the Bayesian Logistic model 
 
2
 Actually is a haplotype that begins on the STAT1 gene and ends on the STAT4 gene 
 
 
201 
 
Vita 
 Anthony M. D’Amelio Jr. was born in Philadelphia, PA, on May 12, 1982.  He received a 
Bachelor of Science of Engineering in the field of Biomedical Engineering from Duke 
University in May of 2004.  Anthony worked as a youth fellow and research assistant with the 
Hepatitis B Foundation in Doylestown, PA, for a year from August 2004 to August 2005.  
During his time at the Hepatitis B Foundation, Anthony’s contributions helped to publish two 
manuscripts in which he was a contributor.  They are, “GP73, a resident Golgi glycoprotein, is a 
novel serum marker for hepatocellular carcinoma” in the Journal of Hepatology, and “N-linked 
glycosylation of the liver cancer biomarker GP73” in the Journal of Cell Biochemistry.  Anthony 
also worked as a research assistant in the Quality Control department at Discovery Laboratories 
in Doylestown, PA, from October 2005 to April 2006.  After deciding that Quality Control was 
not his life calling, he entered the Graduate School of Biomedical Sciences at University of 
Texas-Houston as a PhD student in August 2006.  He entered the laboratory of Dr. Carol J. Etzel 
as a rotational student (20 hours a week for 10 weeks) from September 2006 to November 2006.  
After two more laboratory rotations, Anthony joined Dr. Carol J. Etzel’s lab full time in June 
2007.  His research interest includes risk model development and validation, genetic analysis, 
and mathematical methods to improve discriminatory power.  His research topic for his 
dissertation was the development of a Bayesian mathematical model to examine the associations 
between haplotypes (a linked set of single nucleotide polymorphisms) and disease. 
